University Of Iowa Health Care | |
200 Hawkins Dr Iowa City IA 52242 | |
(319) 356-1616 | |
(319) 384-5164 |
Full Name | University Of Iowa Health Care |
---|---|
Speciality | Family Medicine |
Location | 200 Hawkins Dr, Iowa City, Iowa |
Authorized Official Name and Position | Douglas J Vandaele (ASSOCIATE DEAN) |
Authorized Official Contact | 3193538162 |
Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
Mailing Address | Practice Location Address |
---|---|
University Of Iowa Health Care 200 Hawkins Dr Iowa City IA 52242-1009 Ph: (319) 356-1616 | University Of Iowa Health Care 200 Hawkins Dr Iowa City IA 52242 Ph: (319) 356-1616 |
NPI Number | 1477554814 |
---|---|
Provider Enumeration Date | 08/09/2005 |
Last Update Date | 04/30/2024 |
Medicare PECOS PAC ID | 7618884230 |
---|---|
Medicare Enrollment ID | O20031107000060 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Identifier | Type | State | Issuer |
---|---|---|---|
1477554814 | NPI | - | NPPES |
33537 | Other | IA | WELLMARK BCBS OF IA |
004246 | Medicaid | IA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | (Iowa) | Primary |
207R00000X | Internal Medicine | (Iowa) | Secondary |
208000000X | Pediatrics | (Iowa) | Secondary |
208600000X | Surgery | (Iowa) | Secondary |
Provider Name | Douglas Jerry Vandaele |
---|---|
Provider Type | Practitioner - Otolaryngology |
Provider Identifiers | NPI Number: 1821082587 PECOS PAC ID: 0941105324 Enrollment ID: I20031201000128 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | David A Stoltz |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1962425785 PECOS PAC ID: 9931004298 Enrollment ID: I20031201000546 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alison C Lynch |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1528055886 PECOS PAC ID: 5799682969 Enrollment ID: I20031216000423 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amy L Lukas |
---|---|
Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
Provider Identifiers | NPI Number: 1083601744 PECOS PAC ID: 5597663831 Enrollment ID: I20031223000796 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael L Nosbisch |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1295779627 PECOS PAC ID: 7214835289 Enrollment ID: I20031229000677 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mary S Dirks |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1326021387 PECOS PAC ID: 7517868821 Enrollment ID: I20040120000136 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael R Muellerleile |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1255316444 PECOS PAC ID: 7517852908 Enrollment ID: I20040216000771 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Robert A Beck |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1568561710 PECOS PAC ID: 9537054770 Enrollment ID: I20040217001040 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Scott J Sheets |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1982699260 PECOS PAC ID: 9032005566 Enrollment ID: I20040223000995 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Stuart L Weinstein |
---|---|
Provider Type | Practitioner - Orthopedic Surgery |
Provider Identifiers | NPI Number: 1952393332 PECOS PAC ID: 0244126209 Enrollment ID: I20040225001209 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Aliye Uc |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1215923925 PECOS PAC ID: 5395632459 Enrollment ID: I20040303000112 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jean T Hogan |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1962561456 PECOS PAC ID: 8325930076 Enrollment ID: I20040326001049 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Thomas D Scholz |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1588650246 PECOS PAC ID: 3274425947 Enrollment ID: I20040326001148 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mark C Wilson |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1356323786 PECOS PAC ID: 1850288044 Enrollment ID: I20040402001138 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sergei I Syrbu |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1043208846 PECOS PAC ID: 0547253254 Enrollment ID: I20040407001128 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Donald E Macfarlane |
---|---|
Provider Type | Practitioner - Hematology |
Provider Identifiers | NPI Number: 1013905181 PECOS PAC ID: 7012901499 Enrollment ID: I20040408001509 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Dionne Allison Skeete |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1952393787 PECOS PAC ID: 6608860549 Enrollment ID: I20040413000802 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Geeta Lal |
---|---|
Provider Type | Practitioner - Surgical Oncology |
Provider Identifiers | NPI Number: 1073514147 PECOS PAC ID: 4981699519 Enrollment ID: I20040414001869 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Thomas H Haugen |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1164410965 PECOS PAC ID: 0042205056 Enrollment ID: I20040419001031 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Anita J Moonjely |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1649255035 PECOS PAC ID: 3173510963 Enrollment ID: I20040426000808 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michelle T Weckmann |
---|---|
Provider Type | Practitioner - Hospice/palliative Care |
Provider Identifiers | NPI Number: 1134196025 PECOS PAC ID: 8224025044 Enrollment ID: I20040426001075 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jerilyn S Lundberg |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1447245493 PECOS PAC ID: 6204824006 Enrollment ID: I20040503000023 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jeffrey K Powers |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1801992888 PECOS PAC ID: 3375538176 Enrollment ID: I20040503001492 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Clark J Obr |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1003885971 PECOS PAC ID: 3173511425 Enrollment ID: I20040504001635 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nidal H Harb |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1871572677 PECOS PAC ID: 4082603725 Enrollment ID: I20040508000287 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Natalie L Lanternier |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1205823556 PECOS PAC ID: 0143210047 Enrollment ID: I20040513000774 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Vanessa A Kimm |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1013969435 PECOS PAC ID: 5799776522 Enrollment ID: I20040520001009 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Edward F Bell |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1548255326 PECOS PAC ID: 0446241095 Enrollment ID: I20040521000425 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brenda L Hoskins-mein |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1336121755 PECOS PAC ID: 3072594951 Enrollment ID: I20040526001227 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mark Charles Smith |
---|---|
Provider Type | Practitioner - Radiation Oncology |
Provider Identifiers | NPI Number: 1487656971 PECOS PAC ID: 5395727754 Enrollment ID: I20040601001238 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Anjana Aggarwal |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1467436899 PECOS PAC ID: 4789666405 Enrollment ID: I20040604000790 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Melinda S Brokaw |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1659593572 PECOS PAC ID: 7416930854 Enrollment ID: I20040608000965 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jill L Liesveld |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1134114804 PECOS PAC ID: 3870576978 Enrollment ID: I20040610000278 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jonathan S Simmons |
---|---|
Provider Type | Practitioner - Critical Care (intensivists) |
Provider Identifiers | NPI Number: 1154317857 PECOS PAC ID: 3375527732 Enrollment ID: I20040615000521 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Philip M Polgreen |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1710975750 PECOS PAC ID: 7315921004 Enrollment ID: I20040618000213 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Tracy L Shaw |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1306868526 PECOS PAC ID: 7618952490 Enrollment ID: I20040624000377 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jeremy D Greenlee |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1053304170 PECOS PAC ID: 8224016464 Enrollment ID: I20040713000661 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kelly K Ward |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1790774818 PECOS PAC ID: 1557349727 Enrollment ID: I20040713000879 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | John H Fingert |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1306847454 PECOS PAC ID: 3779561881 Enrollment ID: I20040713001205 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kristen M Brown |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1518952720 PECOS PAC ID: 4183603160 Enrollment ID: I20040714000859 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Enrique C Leira |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1619960085 PECOS PAC ID: 6507845443 Enrollment ID: I20040715000346 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael P Miller |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1447240874 PECOS PAC ID: 9931188273 Enrollment ID: I20040719001317 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rebecca G Chackalackal |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1609863323 PECOS PAC ID: 6406826429 Enrollment ID: I20040728000357 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Barbara J Freyenberger |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1891780748 PECOS PAC ID: 0042281586 Enrollment ID: I20040805001347 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Henning Gerke |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1588644207 PECOS PAC ID: 5395716849 Enrollment ID: I20040805001356 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ronda K Dennis Smithart |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1316926785 PECOS PAC ID: 6901878529 Enrollment ID: I20040817000685 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brian Phillip Daniel |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1609864271 PECOS PAC ID: 1557334497 Enrollment ID: I20040818000344 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jose V G Angel |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1255449070 PECOS PAC ID: 2163327859 Enrollment ID: I20040825000333 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kokila N Thenuwara |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1447239777 PECOS PAC ID: 2163498304 Enrollment ID: I20040908001294 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Tarah Colaizy |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1386639227 PECOS PAC ID: 3072573377 Enrollment ID: I20041012000712 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Timothy J Holton |
---|---|
Provider Type | Practitioner - Maxillofacial Surgery |
Provider Identifiers | NPI Number: 1942278551 PECOS PAC ID: 5395706766 Enrollment ID: I20041020000480 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Moshe Wald |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1205808433 PECOS PAC ID: 7719948488 Enrollment ID: I20041026000196 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Hiroyuki Oya |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1689667701 PECOS PAC ID: 7416910179 Enrollment ID: I20041104000640 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael D Abramoff |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1578564639 PECOS PAC ID: 0446213755 Enrollment ID: I20041108001010 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Benjamin E Reinking |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1972579233 PECOS PAC ID: 5496718736 Enrollment ID: I20041124000395 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Gagan D Kamal |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1124090980 PECOS PAC ID: 6507814878 Enrollment ID: I20050104000680 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Larry E Lenth |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1528173838 PECOS PAC ID: 3274582192 Enrollment ID: I20050118001023 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Christina C Charis-donelson |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1053388686 PECOS PAC ID: 8325098064 Enrollment ID: I20050131000159 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jack Charles Kademian |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1407832140 PECOS PAC ID: 4082667746 Enrollment ID: I20050223000278 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Natalie R Vanwaning |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1013903368 PECOS PAC ID: 6709831449 Enrollment ID: I20050316000260 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Srinivasan Rajagopal |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1457347163 PECOS PAC ID: 1153377585 Enrollment ID: I20050329000307 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Erwei Gao |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1245276245 PECOS PAC ID: 9335195791 Enrollment ID: I20050329000611 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ann K Mindock |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1346220431 PECOS PAC ID: 6709826894 Enrollment ID: I20050509000369 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jason H Barker |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1730161050 PECOS PAC ID: 9537105382 Enrollment ID: I20050630001150 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Samuel E Kinzer |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1417942350 PECOS PAC ID: 2961448345 Enrollment ID: I20050707000565 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Dawn R Ebach |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1457346231 PECOS PAC ID: 4284670662 Enrollment ID: I20050707000602 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Heather Lucy Bair |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1992795694 PECOS PAC ID: 5395771653 Enrollment ID: I20050709000040 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brad Heithoff |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1437137239 PECOS PAC ID: 6406838424 Enrollment ID: I20050725000320 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | William J Sharp |
---|---|
Provider Type | Practitioner - Vascular Surgery |
Provider Identifiers | NPI Number: 1497756050 PECOS PAC ID: 7618904152 Enrollment ID: I20050726000844 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Robert D Roghair |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1497740104 PECOS PAC ID: 3971531476 Enrollment ID: I20050727000030 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Scott M Eberly |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1013982347 PECOS PAC ID: 2466353636 Enrollment ID: I20050812000528 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Wendy W Shen |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1902896707 PECOS PAC ID: 2163452814 Enrollment ID: I20050812000899 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jeanenne M Suneja |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1922072958 PECOS PAC ID: 9739111865 Enrollment ID: I20050908001140 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | James J Schuh |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1487713533 PECOS PAC ID: 7214998475 Enrollment ID: I20050915000976 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Vincent Liu |
---|---|
Provider Type | Practitioner - Dermatology |
Provider Identifiers | NPI Number: 1871574814 PECOS PAC ID: 1557358546 Enrollment ID: I20050915000996 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Andrew Norris |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1922080134 PECOS PAC ID: 0042243255 Enrollment ID: I20050916000649 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Azeemuddin Ahmed |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1609850148 PECOS PAC ID: 6204860067 Enrollment ID: I20050921000407 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brian K Link |
---|---|
Provider Type | Practitioner - Hematology/oncology |
Provider Identifiers | NPI Number: 1487635793 PECOS PAC ID: 0042244790 Enrollment ID: I20050921001095 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ronald J Weigel |
---|---|
Provider Type | Practitioner - Surgical Oncology |
Provider Identifiers | NPI Number: 1265416705 PECOS PAC ID: 8628027927 Enrollment ID: I20051010000955 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Gayle M Wallace |
---|---|
Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
Provider Identifiers | NPI Number: 1679552871 PECOS PAC ID: 7416973342 Enrollment ID: I20051024000113 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Thad E Abrams |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1326022385 PECOS PAC ID: 1951328657 Enrollment ID: I20051101000971 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Abdullah Thayyil |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1922088582 PECOS PAC ID: 1850384314 Enrollment ID: I20051121000119 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kilee Dunham |
---|---|
Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
Provider Identifiers | NPI Number: 1730166166 PECOS PAC ID: 6103846910 Enrollment ID: I20051122000832 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rebecca J Boscaljon |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1023095379 PECOS PAC ID: 3971524471 Enrollment ID: I20051213000161 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Tess M Judge Ellis |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1902996382 PECOS PAC ID: 2062433170 Enrollment ID: I20051215000730 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Tina L Davenport |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1952363624 PECOS PAC ID: 1850315771 Enrollment ID: I20060118000920 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Tammy Lynn Wilgenbusch |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1770532558 PECOS PAC ID: 5991729998 Enrollment ID: I20060118001015 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | John E Femino |
---|---|
Provider Type | Practitioner - Orthopedic Surgery |
Provider Identifiers | NPI Number: 1467421487 PECOS PAC ID: 5698789691 Enrollment ID: I20060130000305 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Gregory A Schmidt |
---|---|
Provider Type | Practitioner - Critical Care (intensivists) |
Provider Identifiers | NPI Number: 1073582102 PECOS PAC ID: 9830127364 Enrollment ID: I20060130000688 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jodi J Bloxham |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1790737880 PECOS PAC ID: 1759396534 Enrollment ID: I20060215000501 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nancy Ellen Beyer |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1831274547 PECOS PAC ID: 2264447705 Enrollment ID: I20060220000519 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Robert S Rossi |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1518918317 PECOS PAC ID: 0840244430 Enrollment ID: I20060313000255 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mario B Sy |
---|---|
Provider Type | Practitioner - Hematology/oncology |
Provider Identifiers | NPI Number: 1447210638 PECOS PAC ID: 2860409893 Enrollment ID: I20060315000467 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bradley J Vanvoorhis |
---|---|
Provider Type | Practitioner - Endocrinology |
Provider Identifiers | NPI Number: 1144214339 PECOS PAC ID: 2860409562 Enrollment ID: I20060321000089 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Paula A Giudici |
---|---|
Provider Type | Practitioner - Dermatology |
Provider Identifiers | NPI Number: 1679538086 PECOS PAC ID: 3779591458 Enrollment ID: I20060323000109 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Karen M Gehrs |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1669473732 PECOS PAC ID: 4183632672 Enrollment ID: I20060324000230 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Britt L Marcussen |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1205824000 PECOS PAC ID: 8224046693 Enrollment ID: I20060327000324 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Scott Alan Larson |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1992757991 PECOS PAC ID: 5890758346 Enrollment ID: I20060425000648 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lynda A Green |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1104878958 PECOS PAC ID: 2961412622 Enrollment ID: I20060426000477 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Frederick M Frank |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1396707733 PECOS PAC ID: 5092725283 Enrollment ID: I20060503000074 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Selden E Spencer |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1275514606 PECOS PAC ID: 5890705099 Enrollment ID: I20060503000182 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael J Goodheart |
---|---|
Provider Type | Practitioner - Gynecological Oncology |
Provider Identifiers | NPI Number: 1811985666 PECOS PAC ID: 3072526250 Enrollment ID: I20060712000008 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | James R Hopson |
---|---|
Provider Type | Practitioner - Cardiac Electrophysiology |
Provider Identifiers | NPI Number: 1699755777 PECOS PAC ID: 1951341056 Enrollment ID: I20060717000130 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Linda M Lee |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1649250267 PECOS PAC ID: 5597705699 Enrollment ID: I20060717000161 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | John P Mehegan |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1114907292 PECOS PAC ID: 2860432952 Enrollment ID: I20060717000172 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amy Marie Stier |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1447290770 PECOS PAC ID: 5890708127 Enrollment ID: I20060803000015 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bridget M Watters |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1144260480 PECOS PAC ID: 5698778850 Enrollment ID: I20060809000185 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael E Takacs |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1427029529 PECOS PAC ID: 1557330834 Enrollment ID: I20060809000230 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Melissa A Gambrall |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1346291267 PECOS PAC ID: 7618980939 Enrollment ID: I20060811000375 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Shawn T Simmons |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1033105168 PECOS PAC ID: 4385647312 Enrollment ID: I20060814000046 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael E Ohl |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1518903509 PECOS PAC ID: 0648239681 Enrollment ID: I20060818000041 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Visweswara Tatini |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1578500401 PECOS PAC ID: 6608857289 Enrollment ID: I20060823000255 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Archana T Laroia |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1588600548 PECOS PAC ID: 9436153616 Enrollment ID: I20060830000273 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Patricia Beth Espe Pfeifer |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1205887882 PECOS PAC ID: 7517961733 Enrollment ID: I20060831000044 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rachel A Maassen |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1770535593 PECOS PAC ID: 4688678816 Enrollment ID: I20060831000072 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amani Abdall Bashir |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1063448686 PECOS PAC ID: 5294739421 Enrollment ID: I20060831000096 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Manish Suneja |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1558396655 PECOS PAC ID: 7315941325 Enrollment ID: I20060906000233 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Isabella M Grumbach |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1730108879 PECOS PAC ID: 7113921628 Enrollment ID: I20060913000667 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bruno A Policeni |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1306879069 PECOS PAC ID: 2961407705 Enrollment ID: I20060928000547 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nancy A Williams |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1093701625 PECOS PAC ID: 9335145341 Enrollment ID: I20061016000218 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Umashankar Subramaniam |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1487768032 PECOS PAC ID: 6608872627 Enrollment ID: I20061016000312 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kathleen Sue Wittich |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1538100508 PECOS PAC ID: 3173567815 Enrollment ID: I20061018000172 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Laura M Dellos |
---|---|
Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
Provider Identifiers | NPI Number: 1609871649 PECOS PAC ID: 5799704763 Enrollment ID: I20061018000219 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Debra K Schnoor |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1194735167 PECOS PAC ID: 7416954128 Enrollment ID: I20061021000038 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amal A Shibli Rahhal |
---|---|
Provider Type | Practitioner - Endocrinology |
Provider Identifiers | NPI Number: 1760596357 PECOS PAC ID: 8426055146 Enrollment ID: I20061023000097 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Andrea L Greiner |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1427016716 PECOS PAC ID: 0648222109 Enrollment ID: I20061025000196 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kalpaj R Parekh |
---|---|
Provider Type | Practitioner - Thoracic Surgery |
Provider Identifiers | NPI Number: 1396849675 PECOS PAC ID: 3173520517 Enrollment ID: I20061027000453 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Renee C Meade |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1376536581 PECOS PAC ID: 8921007105 Enrollment ID: I20061218000029 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lori Beireis |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1275568875 PECOS PAC ID: 3476553330 Enrollment ID: I20061228000232 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Steven W Anderson |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1184790560 PECOS PAC ID: 8628078482 Enrollment ID: I20070102000268 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Denice M Hodgson Zingman |
---|---|
Provider Type | Practitioner - Cardiac Electrophysiology |
Provider Identifiers | NPI Number: 1497729271 PECOS PAC ID: 2163422841 Enrollment ID: I20070102000453 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Antonio J Sanchez |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1467441238 PECOS PAC ID: 9335155852 Enrollment ID: I20070104000066 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Robert D Jones |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1740351485 PECOS PAC ID: 9638179104 Enrollment ID: I20070105000477 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jeannett T Wu |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1497705594 PECOS PAC ID: 3274563952 Enrollment ID: I20070116000124 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Soe Nyunt |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1457301640 PECOS PAC ID: 3173524279 Enrollment ID: I20070116000128 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ann M Aschoff |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1578632154 PECOS PAC ID: 5698776755 Enrollment ID: I20070117000019 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | John S Chase |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1487642013 PECOS PAC ID: 7416958582 Enrollment ID: I20070117000102 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael A Odonnell |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1124029582 PECOS PAC ID: 9234130303 Enrollment ID: I20070117000104 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | David P Bender |
---|---|
Provider Type | Practitioner - Gynecological Oncology |
Provider Identifiers | NPI Number: 1487641247 PECOS PAC ID: 6406857572 Enrollment ID: I20070117000111 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Janet A Fairley |
---|---|
Provider Type | Practitioner - Dermatology |
Provider Identifiers | NPI Number: 1023069929 PECOS PAC ID: 9931119773 Enrollment ID: I20070129000420 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Vickie Diamandakis Pyevich |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1003882374 PECOS PAC ID: 6002717436 Enrollment ID: I20070130000715 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Julia A Klesney Tait |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1679631204 PECOS PAC ID: 7214939289 Enrollment ID: I20070203000036 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Daniel T Tranel |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1528147774 PECOS PAC ID: 0648272617 Enrollment ID: I20070203000067 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Donna M D Alessandro |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1396730248 PECOS PAC ID: 0042212029 Enrollment ID: I20070203000124 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amy M Yoder Dowden |
---|---|
Provider Type | Practitioner - Allergy/immunology |
Provider Identifiers | NPI Number: 1235204496 PECOS PAC ID: 2668474644 Enrollment ID: I20070203000146 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Leonid V Zingman |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1285709899 PECOS PAC ID: 2264534411 Enrollment ID: I20070219000802 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sherry R Timmons |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1427152420 PECOS PAC ID: 8325140312 Enrollment ID: I20070221000639 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lucy A Wibbenmeyer |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1346242906 PECOS PAC ID: 3274535372 Enrollment ID: I20070223000006 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Theresa M Brennan |
---|---|
Provider Type | Practitioner - Interventional Cardiology |
Provider Identifiers | NPI Number: 1063400620 PECOS PAC ID: 1052413564 Enrollment ID: I20070301000000 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Agustin Aguilar |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1649252503 PECOS PAC ID: 8921100439 Enrollment ID: I20070301000025 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Asif Ahmed |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1881673499 PECOS PAC ID: 3870695307 Enrollment ID: I20070301000168 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Vera M Howe |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1437124989 PECOS PAC ID: 8527161934 Enrollment ID: I20070305000585 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Hisakazu Hoshi |
---|---|
Provider Type | Practitioner - Surgical Oncology |
Provider Identifiers | NPI Number: 1841355096 PECOS PAC ID: 6204939325 Enrollment ID: I20070310000045 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joel Shilyansky |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1942251368 PECOS PAC ID: 6204939994 Enrollment ID: I20070319000227 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mohammed M Milhem |
---|---|
Provider Type | Practitioner - Hematology/oncology |
Provider Identifiers | NPI Number: 1558429100 PECOS PAC ID: 2466556402 Enrollment ID: I20070330000199 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lisa M Antes |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1174511026 PECOS PAC ID: 6709981137 Enrollment ID: I20070413000306 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | John A Bertolatus |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1720075831 PECOS PAC ID: 1557466760 Enrollment ID: I20070417000547 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Haroon R Afridi |
---|---|
Provider Type | Practitioner - Interventional Radiology |
Provider Identifiers | NPI Number: 1033154620 PECOS PAC ID: 7911002639 Enrollment ID: I20070424000680 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Francois M Abboud |
---|---|
Provider Type | Practitioner - Cardiac Surgery |
Provider Identifiers | NPI Number: 1598753113 PECOS PAC ID: 2466559463 Enrollment ID: I20070529000187 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nicholas E Walker |
---|---|
Provider Type | Practitioner - Interventional Cardiology |
Provider Identifiers | NPI Number: 1437241221 PECOS PAC ID: 6709986672 Enrollment ID: I20070705000665 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Judy Streit |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1124141528 PECOS PAC ID: 9739167495 Enrollment ID: I20070719000452 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kimberly S Staffey |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1184634099 PECOS PAC ID: 6507967213 Enrollment ID: I20070725000378 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amy N Vahrenwald |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1518179001 PECOS PAC ID: 1355442617 Enrollment ID: I20070731000276 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sandy D Hong |
---|---|
Provider Type | Practitioner - Rheumatology |
Provider Identifiers | NPI Number: 1245353242 PECOS PAC ID: 3779674064 Enrollment ID: I20070731000573 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Olivia E Bailey |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1558563163 PECOS PAC ID: 6103917497 Enrollment ID: I20070731000609 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Carla M Nester |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1538387873 PECOS PAC ID: 8729179973 Enrollment ID: I20070802000424 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Gretchen E Vigil |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1407842735 PECOS PAC ID: 6608967625 Enrollment ID: I20070806000615 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mark K Santillan |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1114137668 PECOS PAC ID: 0547351397 Enrollment ID: I20070808000145 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Cynthia M Burr |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1669519377 PECOS PAC ID: 3375634074 Enrollment ID: I20070810000401 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rebecca S Davis |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1508823105 PECOS PAC ID: 6901998301 Enrollment ID: I20070815000136 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Eric A Epping |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1447468343 PECOS PAC ID: 8820180946 Enrollment ID: I20070822000160 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Eyad M Hanna |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1306041660 PECOS PAC ID: 5890887913 Enrollment ID: I20070822000184 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nicolas O Noiseux |
---|---|
Provider Type | Practitioner - Orthopedic Surgery |
Provider Identifiers | NPI Number: 1124127865 PECOS PAC ID: 5890792550 Enrollment ID: I20070822000218 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Riad M Rahhal |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1073722112 PECOS PAC ID: 6103918164 Enrollment ID: I20070822000647 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | James S Klutts |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1124112719 PECOS PAC ID: 6901999432 Enrollment ID: I20070829000606 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alexander G Bassuk |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1679549737 PECOS PAC ID: 7012986292 Enrollment ID: I20070829000976 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brian Lester Swick |
---|---|
Provider Type | Practitioner - Dermatology |
Provider Identifiers | NPI Number: 1811942840 PECOS PAC ID: 7416989181 Enrollment ID: I20070905000108 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mirac N Ince |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1285844217 PECOS PAC ID: 4880787787 Enrollment ID: I20070910000218 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Julie K Osterhaus |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1235124942 PECOS PAC ID: 4284728320 Enrollment ID: I20070919000818 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ingrid M Lizarraga |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1750590907 PECOS PAC ID: 3476647348 Enrollment ID: I20070922000114 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sandeep T Laroia |
---|---|
Provider Type | Practitioner - Interventional Radiology |
Provider Identifiers | NPI Number: 1154403632 PECOS PAC ID: 6608960497 Enrollment ID: I20070925000076 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alan I Reed |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1174623599 PECOS PAC ID: 6800981242 Enrollment ID: I20071001000567 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amy L Newton |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1376639914 PECOS PAC ID: 1759381486 Enrollment ID: I20071002000621 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jeffrey J Nichols |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1710910559 PECOS PAC ID: 2860587649 Enrollment ID: I20071009000553 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Margaret S Guither |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1881747897 PECOS PAC ID: 5890881403 Enrollment ID: I20071012000160 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Danielle J Wendel |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1437345857 PECOS PAC ID: 5991892234 Enrollment ID: I20071102000053 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mary M Drury |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1174677074 PECOS PAC ID: 3971690918 Enrollment ID: I20071107000511 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Margarida M Silverman |
---|---|
Provider Type | Practitioner - Hematopoietic Cell Transplantation And Cellular Therapy |
Provider Identifiers | NPI Number: 1295724821 PECOS PAC ID: 5597853689 Enrollment ID: I20071127000362 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Angela Jo Schadler |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1356326581 PECOS PAC ID: 4981601366 Enrollment ID: I20071213000445 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Gregory Bell |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1841305042 PECOS PAC ID: 9638077159 Enrollment ID: I20071228000376 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Julie E Lindower |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1669435145 PECOS PAC ID: 8628158847 Enrollment ID: I20071231000092 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Melhem J Sharafuddin |
---|---|
Provider Type | Practitioner - Vascular Surgery |
Provider Identifiers | NPI Number: 1326118332 PECOS PAC ID: 8921189432 Enrollment ID: I20080122000543 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Merle H Muller |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1891770350 PECOS PAC ID: 2163505983 Enrollment ID: I20080215000578 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Richard G Burton |
---|---|
Provider Type | Practitioner - Maxillofacial Surgery |
Provider Identifiers | NPI Number: 1083699920 PECOS PAC ID: 1456434281 Enrollment ID: I20080215000647 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Maheen Rajput |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1316064637 PECOS PAC ID: 7416031893 Enrollment ID: I20080223000082 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mishelle L Paullus |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1528247368 PECOS PAC ID: 4688758014 Enrollment ID: I20080225000354 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Todd G Kopelman |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1063699668 PECOS PAC ID: 3476637513 Enrollment ID: I20080227000562 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | John M Buatti |
---|---|
Provider Type | Practitioner - Radiation Oncology |
Provider Identifiers | NPI Number: 1205829058 PECOS PAC ID: 5395848246 Enrollment ID: I20080404000831 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Susan R Scott |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1013049691 PECOS PAC ID: 3678650314 Enrollment ID: I20080404000847 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Edward J Melcher |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1831368935 PECOS PAC ID: 3072690122 Enrollment ID: I20080414000442 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Charles F Grose |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1184610206 PECOS PAC ID: 8820177074 Enrollment ID: I20080430000085 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Barbara L Patrick |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1538153457 PECOS PAC ID: 9234218629 Enrollment ID: I20080509000671 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Daniel Fick |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1457347049 PECOS PAC ID: 3779662168 Enrollment ID: I20080509000674 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jean M Ryan |
---|---|
Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
Provider Identifiers | NPI Number: 1538335930 PECOS PAC ID: 2567532971 Enrollment ID: I20080528000255 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michele L Jones Mcleod |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1255316923 PECOS PAC ID: 4789754854 Enrollment ID: I20080602000016 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kristine M Bonnett |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1184897001 PECOS PAC ID: 6901977891 Enrollment ID: I20080620000134 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amy Rebecca Ulring Larson Calhoun |
---|---|
Provider Type | Practitioner - Medical Genetics And Genomics |
Provider Identifiers | NPI Number: 1477761328 PECOS PAC ID: 4688745581 Enrollment ID: I20080620000173 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Martin Mueller |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1205036282 PECOS PAC ID: 4880782911 Enrollment ID: I20080627000129 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mudassir Ilyas Malik |
---|---|
Provider Type | Practitioner - Advanced Heart Failure And Transplant Cardiology |
Provider Identifiers | NPI Number: 1457553653 PECOS PAC ID: 0840362984 Enrollment ID: I20080707000075 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Arlene V Drack |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1598855264 PECOS PAC ID: 5395722003 Enrollment ID: I20080707000192 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Elizabeth A Newell |
---|---|
Provider Type | Practitioner - Critical Care (intensivists) |
Provider Identifiers | NPI Number: 1467661124 PECOS PAC ID: 9739251885 Enrollment ID: I20080707000201 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Liuska Maria Pesce |
---|---|
Provider Type | Practitioner - Endocrinology |
Provider Identifiers | NPI Number: 1972638864 PECOS PAC ID: 4981776069 Enrollment ID: I20080707000410 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alejandro P Comellas |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1104926617 PECOS PAC ID: 8729057039 Enrollment ID: I20080710000238 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Byron Ford Vandenberg |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1386614170 PECOS PAC ID: 1759283708 Enrollment ID: I20080710000268 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Andrea J Swenson |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1164630216 PECOS PAC ID: 7618040445 Enrollment ID: I20080725000754 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kimberly M Baker-el Abiad |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1033275052 PECOS PAC ID: 8527131358 Enrollment ID: I20080725000755 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Viktor Hanak |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1114905999 PECOS PAC ID: 4981684776 Enrollment ID: I20080726000100 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rashmi N Mueller |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1336209121 PECOS PAC ID: 8022182260 Enrollment ID: I20080805000901 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Savita Vishny Hegde |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1932239332 PECOS PAC ID: 8224043872 Enrollment ID: I20080806000758 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Susan L Roeder |
---|---|
Provider Type | Practitioner - Medical Oncology |
Provider Identifiers | NPI Number: 1487615340 PECOS PAC ID: 7416021548 Enrollment ID: I20080807000091 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Anil A Marian |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1760609846 PECOS PAC ID: 1456445824 Enrollment ID: I20080807000169 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Carryn M Anderson |
---|---|
Provider Type | Practitioner - Radiation Oncology |
Provider Identifiers | NPI Number: 1891987392 PECOS PAC ID: 3072688977 Enrollment ID: I20080812000240 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Evgeny V Arshava |
---|---|
Provider Type | Practitioner - Thoracic Surgery |
Provider Identifiers | NPI Number: 1326257585 PECOS PAC ID: 9931274123 Enrollment ID: I20080822000428 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Aimee F Foster |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1720279086 PECOS PAC ID: 3870669328 Enrollment ID: I20080905000636 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nitin A Pagedar |
---|---|
Provider Type | Practitioner - Otolaryngology |
Provider Identifiers | NPI Number: 1144433962 PECOS PAC ID: 6406922723 Enrollment ID: I20080910000036 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Emily J Griffin |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1952566390 PECOS PAC ID: 9931113701 Enrollment ID: I20080918000601 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kate D Hanrahan |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1134338965 PECOS PAC ID: 4284701681 Enrollment ID: I20080926000622 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Shauna L Lafleur |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1285834408 PECOS PAC ID: 6800963208 Enrollment ID: I20080926000642 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sailesh Chandur Harwani |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1669682407 PECOS PAC ID: 8628145992 Enrollment ID: I20080929000426 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Heather L Bingham |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1588644983 PECOS PAC ID: 2264469246 Enrollment ID: I20081001000317 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Maya J Mathews |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1750539334 PECOS PAC ID: 0749358679 Enrollment ID: I20081006000425 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kathryn J Allen |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1376574954 PECOS PAC ID: 1456454891 Enrollment ID: I20081103000208 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael J Tansey |
---|---|
Provider Type | Practitioner - Endocrinology |
Provider Identifiers | NPI Number: 1285620583 PECOS PAC ID: 4688733868 Enrollment ID: I20081103000238 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sharon L Marguglio |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1033360284 PECOS PAC ID: 9436218153 Enrollment ID: I20081110000212 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mark T Haas |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1942241138 PECOS PAC ID: 5597739128 Enrollment ID: I20081112000345 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Holly N Maas |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1033159660 PECOS PAC ID: 4981764487 Enrollment ID: I20081113000300 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kristin E Marsh |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1831307701 PECOS PAC ID: 1355401605 Enrollment ID: I20081117000822 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Cynthia A Haas |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1790802957 PECOS PAC ID: 1052378122 Enrollment ID: I20081120000605 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Karin Weber Gasparoni |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1003915679 PECOS PAC ID: 2769544154 Enrollment ID: I20081218000487 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brenda M Shafer |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1689819500 PECOS PAC ID: 2062574148 Enrollment ID: I20081224000321 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alicia K Gerke |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1053520759 PECOS PAC ID: 2163586314 Enrollment ID: I20090203000129 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bruce E Headings |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1982890406 PECOS PAC ID: 5799867941 Enrollment ID: I20090204000029 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sarah S Titler |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1881805562 PECOS PAC ID: 8022174911 Enrollment ID: I20090302000086 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Graeme J Pitcher |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1831338755 PECOS PAC ID: 1658437298 Enrollment ID: I20090305000263 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Erica S Brown |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1922247808 PECOS PAC ID: 6406912039 Enrollment ID: I20090306000250 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Christoph Oskar Randak |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1407065469 PECOS PAC ID: 8921164153 Enrollment ID: I20090312000528 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nicola Jane Stickney |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1942445937 PECOS PAC ID: 3476610585 Enrollment ID: I20090317000217 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | James F Carillo |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1366426678 PECOS PAC ID: 0143219873 Enrollment ID: I20090423000070 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mony Fraer |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1497845960 PECOS PAC ID: 4284674821 Enrollment ID: I20090423000652 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Deborah S Kacmarynski |
---|---|
Provider Type | Practitioner - Otolaryngology |
Provider Identifiers | NPI Number: 1457557704 PECOS PAC ID: 9537217849 Enrollment ID: I20090424000296 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joseph J Ehle |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1457337453 PECOS PAC ID: 1951459403 Enrollment ID: I20090511000467 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Daniel E Wesemann |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1366435125 PECOS PAC ID: 5193707172 Enrollment ID: I20090512000425 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Denisa M Haret |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1740370212 PECOS PAC ID: 3274682331 Enrollment ID: I20090519000621 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jody Jones |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1851421853 PECOS PAC ID: 0840244307 Enrollment ID: I20090521000066 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joseph Francis Szot |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1881682441 PECOS PAC ID: 4587713524 Enrollment ID: I20090521000130 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mark W Karwal |
---|---|
Provider Type | Practitioner - Hematology |
Provider Identifiers | NPI Number: 1891770616 PECOS PAC ID: 3375693641 Enrollment ID: I20090608000307 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brent A Hadder |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1245449016 PECOS PAC ID: 6608927132 Enrollment ID: I20090624000100 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jon N Vanheukelom |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1467547604 PECOS PAC ID: 3971654419 Enrollment ID: I20090624000201 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Matthew David Krasowski |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1003880436 PECOS PAC ID: 2365481249 Enrollment ID: I20090625000118 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rami G El Abiad |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1003025032 PECOS PAC ID: 9032260450 Enrollment ID: I20090625000136 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rachael Michelle Nicholson |
---|---|
Provider Type | Practitioner - Vascular Surgery |
Provider Identifiers | NPI Number: 1376746354 PECOS PAC ID: 6800948514 Enrollment ID: I20090710000042 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Chad R Tracy |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1710191408 PECOS PAC ID: 5294898524 Enrollment ID: I20090710000057 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | D Lowell Yoder |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1881689545 PECOS PAC ID: 4789736679 Enrollment ID: I20090724000028 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Hussain Banu |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1063622637 PECOS PAC ID: 9032262811 Enrollment ID: I20090727000245 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Colleen K Stockdale |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1841287604 PECOS PAC ID: 1153475041 Enrollment ID: I20090811000678 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lina M Moreno Uribe |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1770734873 PECOS PAC ID: 2668526575 Enrollment ID: I20090812000152 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Dilek Ince |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1336358019 PECOS PAC ID: 4587718077 Enrollment ID: I20090818000588 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Boulos S Nassar |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1043420730 PECOS PAC ID: 4486709409 Enrollment ID: I20090827000098 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jason M Powers |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1467440263 PECOS PAC ID: 5698820918 Enrollment ID: I20090909000597 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nicole Elizabeth Peterson |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1932343001 PECOS PAC ID: 8426103706 Enrollment ID: I20090910000373 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sharon Kay Cozad |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1396776308 PECOS PAC ID: 1951457126 Enrollment ID: I20090914000571 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Melinda Suoboda Seering |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1275631970 PECOS PAC ID: 0941208011 Enrollment ID: I20090923000026 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Steven J Bailin |
---|---|
Provider Type | Practitioner - Cardiac Electrophysiology |
Provider Identifiers | NPI Number: 1689656258 PECOS PAC ID: 4789720665 Enrollment ID: I20091007000037 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Dawn M Flynn |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1962498659 PECOS PAC ID: 4688710460 Enrollment ID: I20091008000193 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Molly M Bauer |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1902139363 PECOS PAC ID: 6305982190 Enrollment ID: I20091008000210 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Teresa A Morgan |
---|---|
Provider Type | Practitioner - Maxillofacial Surgery |
Provider Identifiers | NPI Number: 1356327712 PECOS PAC ID: 0143366674 Enrollment ID: I20091014000015 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kirk Fridrich |
---|---|
Provider Type | Practitioner - Maxillofacial Surgery |
Provider Identifiers | NPI Number: 1174508022 PECOS PAC ID: 8729181607 Enrollment ID: I20091014000056 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | William J Synan |
---|---|
Provider Type | Practitioner - Maxillofacial Surgery |
Provider Identifiers | NPI Number: 1518061514 PECOS PAC ID: 9830235381 Enrollment ID: I20091014000123 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kevin A Glenn |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1972591402 PECOS PAC ID: 9537205943 Enrollment ID: I20091014000740 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joy A Hesse |
---|---|
Provider Type | Practitioner - Qualified Speech Language Pathologist |
Provider Identifiers | NPI Number: 1306001037 PECOS PAC ID: 1850438193 Enrollment ID: I20091020000066 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jessica Kyle Smith |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1154460160 PECOS PAC ID: 7911065693 Enrollment ID: I20091028000282 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kellen A Kraber |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1174666721 PECOS PAC ID: 0244335784 Enrollment ID: I20091029000100 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kevin Doerschug |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1134109846 PECOS PAC ID: 9436297884 Enrollment ID: I20091105000365 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Gerald H Clamon |
---|---|
Provider Type | Practitioner - Medical Oncology |
Provider Identifiers | NPI Number: 1114902913 PECOS PAC ID: 3870631237 Enrollment ID: I20091105000389 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jill J Endres |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1356338610 PECOS PAC ID: 6103964499 Enrollment ID: I20091106000074 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Thoru Yamada |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1154313070 PECOS PAC ID: 3870631112 Enrollment ID: I20091106000401 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joseph A. Buckwalter |
---|---|
Provider Type | Practitioner - Orthopedic Surgery |
Provider Identifiers | NPI Number: 1790777167 PECOS PAC ID: 7113020066 Enrollment ID: I20091109000167 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bobby X Peters |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1467434324 PECOS PAC ID: 7113065384 Enrollment ID: I20091109000200 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | William D Clark |
---|---|
Provider Type | Practitioner - Hospice/palliative Care |
Provider Identifiers | NPI Number: 1083639140 PECOS PAC ID: 8426196643 Enrollment ID: I20091109000640 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael K Maharry |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1073509436 PECOS PAC ID: 2062550189 Enrollment ID: I20091111000084 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | George R Bergus |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1811983414 PECOS PAC ID: 2860530821 Enrollment ID: I20091111000478 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joseph J Cullen |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1396746616 PECOS PAC ID: 0547308520 Enrollment ID: I20091111000631 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Richard C Dobyns |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1912993387 PECOS PAC ID: 2163560038 Enrollment ID: I20091113000133 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | David A Bedell |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1588650956 PECOS PAC ID: 7012055999 Enrollment ID: I20091113000187 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mark E Dyken |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1699768440 PECOS PAC ID: 3072651819 Enrollment ID: I20091116000118 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Marcus B Nashelsky |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1629066485 PECOS PAC ID: 1658419437 Enrollment ID: I20091116000491 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bryan Dean Hested |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1942536057 PECOS PAC ID: 7810035581 Enrollment ID: I20091118000054 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Matthew L Lanternier |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1437148285 PECOS PAC ID: 2961540653 Enrollment ID: I20091118000209 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Carlyn M Christensen-szalanski |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1639151509 PECOS PAC ID: 8022157569 Enrollment ID: I20091123000473 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Dana M King |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1255316303 PECOS PAC ID: 8527107069 Enrollment ID: I20091123000512 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Daniel J Berg |
---|---|
Provider Type | Practitioner - Medical Oncology |
Provider Identifiers | NPI Number: 1841289790 PECOS PAC ID: 0143369686 Enrollment ID: I20091123000532 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Larisa A Sharp |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1346397619 PECOS PAC ID: 2163561234 Enrollment ID: I20091202000579 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jose A Morcuende |
---|---|
Provider Type | Practitioner - Orthopedic Surgery |
Provider Identifiers | NPI Number: 1790777985 PECOS PAC ID: 3274672969 Enrollment ID: I20091210000093 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | James V Nepola |
---|---|
Provider Type | Practitioner - Orthopedic Surgery |
Provider Identifiers | NPI Number: 1972597037 PECOS PAC ID: 7416097001 Enrollment ID: I20091211000361 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Catherine S Bradley |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1225022486 PECOS PAC ID: 7113968470 Enrollment ID: I20091211000381 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bruce J. Gantz |
---|---|
Provider Type | Practitioner - Otolaryngology |
Provider Identifiers | NPI Number: 1730173592 PECOS PAC ID: 3173626058 Enrollment ID: I20091211000385 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kristi E Chang |
---|---|
Provider Type | Practitioner - Otolaryngology |
Provider Identifiers | NPI Number: 1639160781 PECOS PAC ID: 6103966676 Enrollment ID: I20091214000374 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Henry T Hoffman |
---|---|
Provider Type | Practitioner - Otolaryngology |
Provider Identifiers | NPI Number: 1326031709 PECOS PAC ID: 6709926124 Enrollment ID: I20091216000229 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Stephen K Hunter |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1790779866 PECOS PAC ID: 5799825139 Enrollment ID: I20091216000341 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jason K Wilbur |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1265428858 PECOS PAC ID: 6103967864 Enrollment ID: I20100104000503 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Barcey T Levy |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1588650402 PECOS PAC ID: 5294876652 Enrollment ID: I20100107000106 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kelly S Skelly |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1194711770 PECOS PAC ID: 2860533239 Enrollment ID: I20100107000180 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lakshmi Durairaj |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1447232871 PECOS PAC ID: 6204977606 Enrollment ID: I20100107000380 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Charles A Jennissen |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1033194188 PECOS PAC ID: 8921149329 Enrollment ID: I20100107000401 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Thomas A Oetting |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1144221599 PECOS PAC ID: 6406997824 Enrollment ID: I20100107000522 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kenjirou Ohashi |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1932197894 PECOS PAC ID: 4981745213 Enrollment ID: I20100108000777 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joan E Maley |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1689662579 PECOS PAC ID: 4789725011 Enrollment ID: I20100108000803 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Richard J Smith |
---|---|
Provider Type | Practitioner - Otolaryngology |
Provider Identifiers | NPI Number: 1194718213 PECOS PAC ID: 3476694704 Enrollment ID: I20100108000852 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael Wall |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1538152665 PECOS PAC ID: 6103967435 Enrollment ID: I20100108000857 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Andrew S Nugent |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1679567648 PECOS PAC ID: 0446353320 Enrollment ID: I20100114000832 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Katherine Dianne Mathews |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1326034984 PECOS PAC ID: 9032251970 Enrollment ID: I20100115000151 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Margo L Schilling |
---|---|
Provider Type | Practitioner - Geriatric Medicine |
Provider Identifiers | NPI Number: 1255314563 PECOS PAC ID: 2860534708 Enrollment ID: I20100115000252 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | James R Howe |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1336140409 PECOS PAC ID: 6709928518 Enrollment ID: I20100116000038 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Deborah C Lin Dyken |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1932196698 PECOS PAC ID: 3678615481 Enrollment ID: I20100116000073 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Dianne M Mcbrien |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1063407757 PECOS PAC ID: 0941342752 Enrollment ID: I20100116000082 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brian P Wayson |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1467449579 PECOS PAC ID: 8022150846 Enrollment ID: I20100116000105 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Elizabeth A Faine |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1043545080 PECOS PAC ID: 3173665908 Enrollment ID: I20100116000283 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | William I Sivitz |
---|---|
Provider Type | Practitioner - Endocrinology |
Provider Identifiers | NPI Number: 1891783445 PECOS PAC ID: 7315089158 Enrollment ID: I20100116000345 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Paul B Mccray |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1417943747 PECOS PAC ID: 9830231679 Enrollment ID: I20100116000374 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Robert L. Rodnitzky |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1801889936 PECOS PAC ID: 3072616952 Enrollment ID: I20100116000410 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mark E Wilkinson |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1568463826 PECOS PAC ID: 5496897241 Enrollment ID: I20100118000027 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Thomas J Gross |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1861489973 PECOS PAC ID: 8123160975 Enrollment ID: I20100118000030 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Young Ha Kwon |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1891788915 PECOS PAC ID: 1850433608 Enrollment ID: I20100118000034 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jack Thomas Stapleton |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1083603773 PECOS PAC ID: 9830231604 Enrollment ID: I20100118000219 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Louis V Kirchhoff |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1174510283 PECOS PAC ID: 5193867885 Enrollment ID: I20100119000156 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Zuhair K Ballas |
---|---|
Provider Type | Practitioner - Allergy/immunology |
Provider Identifiers | NPI Number: 1316935943 PECOS PAC ID: 3476695172 Enrollment ID: I20100119000237 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Darus Lee Bennett |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1952399800 PECOS PAC ID: 3072655711 Enrollment ID: I20100119000653 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Thomas J Barloon |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1811985799 PECOS PAC ID: 8426190174 Enrollment ID: I20100119000668 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Scott M Graham |
---|---|
Provider Type | Practitioner - Otolaryngology |
Provider Identifiers | NPI Number: 1508850678 PECOS PAC ID: 2961544614 Enrollment ID: I20100119000679 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | John L Marsh |
---|---|
Provider Type | Practitioner - Orthopedic Surgery |
Provider Identifiers | NPI Number: 1871585273 PECOS PAC ID: 1658413307 Enrollment ID: I20100119000708 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Georges Y El Khoury |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1861480717 PECOS PAC ID: 3072655729 Enrollment ID: I20100119000733 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Marta J Hemmingson-vanbeek |
---|---|
Provider Type | Practitioner - Dermatology |
Provider Identifiers | NPI Number: 1467446765 PECOS PAC ID: 7416099031 Enrollment ID: I20100120000670 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Raymond T Wiblin |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1609858034 PECOS PAC ID: 5698817229 Enrollment ID: I20100120000681 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joel N Kline |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1871584201 PECOS PAC ID: 6103968730 Enrollment ID: I20100120000731 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Steven R Lentz |
---|---|
Provider Type | Practitioner - Hematology |
Provider Identifiers | NPI Number: 1316934318 PECOS PAC ID: 4284776816 Enrollment ID: I20100120000742 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Douglas B Hornick |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1437147386 PECOS PAC ID: 5092857623 Enrollment ID: I20100120000754 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Emily S Herzig |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1578891958 PECOS PAC ID: 1456493840 Enrollment ID: I20100122000704 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ian H Law |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1093700783 PECOS PAC ID: 2163492448 Enrollment ID: I20100123000112 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael M Graham |
---|---|
Provider Type | Practitioner - Nuclear Medicine |
Provider Identifiers | NPI Number: 1205824174 PECOS PAC ID: 1254473663 Enrollment ID: I20100123000125 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Arnold H Menezes |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1881687903 PECOS PAC ID: 8921140344 Enrollment ID: I20100123000201 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Christie P Thomas |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1760470611 PECOS PAC ID: 2567504988 Enrollment ID: I20100123000203 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Melinda J Johnson |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1497739403 PECOS PAC ID: 8820130248 Enrollment ID: I20100123000214 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rebecca S Tuetken |
---|---|
Provider Type | Practitioner - Rheumatology |
Provider Identifiers | NPI Number: 1174512859 PECOS PAC ID: 2466594882 Enrollment ID: I20100123000218 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | David A Katz |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1023090321 PECOS PAC ID: 6901948322 Enrollment ID: I20100123000221 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Douglas L Somers |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1609858919 PECOS PAC ID: 1456493873 Enrollment ID: I20100123000227 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Arlan T Johnson |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1134111339 PECOS PAC ID: 7012059280 Enrollment ID: I20100126000755 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | James D Rossen |
---|---|
Provider Type | Practitioner - Interventional Cardiology |
Provider Identifiers | NPI Number: 1134100514 PECOS PAC ID: 4981746187 Enrollment ID: I20100127000227 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Edward A Aul |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1538151105 PECOS PAC ID: 5991847030 Enrollment ID: I20100127000604 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brian R Wolf |
---|---|
Provider Type | Practitioner - Sports Medicine |
Provider Identifiers | NPI Number: 1255326732 PECOS PAC ID: 8820130909 Enrollment ID: I20100128000016 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Patrick W Hitchon |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1043203177 PECOS PAC ID: 9537201611 Enrollment ID: I20100128000034 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Matthew A. Howard |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1770576803 PECOS PAC ID: 6800999780 Enrollment ID: I20100128000042 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Christopher J Benson |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1225026859 PECOS PAC ID: 7416099502 Enrollment ID: I20100128000074 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Donald D Heistad |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1982692505 PECOS PAC ID: 9133261225 Enrollment ID: I20100128000085 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Peter M Snyder |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1073501698 PECOS PAC ID: 8729121777 Enrollment ID: I20100130000066 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jeffrey S Wilson |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1962485326 PECOS PAC ID: 7416090485 Enrollment ID: I20100130000230 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bradley S Dixon |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1053393363 PECOS PAC ID: 1759424724 Enrollment ID: I20100130000268 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Hans R House |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1760464622 PECOS PAC ID: 3375686348 Enrollment ID: I20100130000279 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ann E Smith |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1437146990 PECOS PAC ID: 5294878047 Enrollment ID: I20100202000935 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Christine W Sindt |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1346241916 PECOS PAC ID: 9830232685 Enrollment ID: I20100202000939 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | James A Brown |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1467562181 PECOS PAC ID: 2264584440 Enrollment ID: I20100206000166 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Loreen A Herwaldt |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1811979131 PECOS PAC ID: 9436292836 Enrollment ID: I20100208000430 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Javier H Campos Torres |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1861488991 PECOS PAC ID: 8729121876 Enrollment ID: I20100211000416 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mary S Stone |
---|---|
Provider Type | Practitioner - Dermatology |
Provider Identifiers | NPI Number: 1194719401 PECOS PAC ID: 7618011404 Enrollment ID: I20100217000346 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | David E Swanson |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1962490581 PECOS PAC ID: 0749324564 Enrollment ID: I20100217000624 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Margery J Amelon |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1427045186 PECOS PAC ID: 4587708227 Enrollment ID: I20100219000143 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Steven A Moore |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1174511935 PECOS PAC ID: 2860536406 Enrollment ID: I20100219000253 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Petar S Lenert |
---|---|
Provider Type | Practitioner - Rheumatology |
Provider Identifiers | NPI Number: 1790772846 PECOS PAC ID: 8628112299 Enrollment ID: I20100219000573 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael G Kienzle |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1407830888 PECOS PAC ID: 2264576834 Enrollment ID: I20100219000576 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Herbert A Berger |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1366439473 PECOS PAC ID: 4789728353 Enrollment ID: I20100219000596 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Shawna J Westermann |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1114909413 PECOS PAC ID: 2961546536 Enrollment ID: I20100219000604 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | David E Elliott |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1881668689 PECOS PAC ID: 3678617248 Enrollment ID: I20100219000611 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | William B Silverman |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1811971849 PECOS PAC ID: 8123162799 Enrollment ID: I20100219000621 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lauris C Kaldjian |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1790772051 PECOS PAC ID: 6406990092 Enrollment ID: I20100220000075 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joseph S Dillon |
---|---|
Provider Type | Practitioner - Endocrinology |
Provider Identifiers | NPI Number: 1710960026 PECOS PAC ID: 3779627377 Enrollment ID: I20100220000082 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joseph L Zabner |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1689658692 PECOS PAC ID: 0042354649 Enrollment ID: I20100220000090 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | John T Kelley |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1871567131 PECOS PAC ID: 7517948631 Enrollment ID: I20100220000304 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Randy Herbert Kardon |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1134120371 PECOS PAC ID: 7719021252 Enrollment ID: I20100222000156 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Keith D. Carter |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1942201082 PECOS PAC ID: 1759484603 Enrollment ID: I20100222000204 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Karl J Kreder |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1487655700 PECOS PAC ID: 1153466263 Enrollment ID: I20100301000492 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mary Gwen Zmolek Beck |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1174597116 PECOS PAC ID: 4789729898 Enrollment ID: I20100301000495 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Margaret A Smollen |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1255325189 PECOS PAC ID: 3375605256 Enrollment ID: I20100303001048 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lori S Wenzel |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1144214073 PECOS PAC ID: 5193887073 Enrollment ID: I20100303001066 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Simon C Kao |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1710975669 PECOS PAC ID: 0840335600 Enrollment ID: I20100304000100 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael Patrick D Alessandro |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1871582718 PECOS PAC ID: 2466597224 Enrollment ID: I20100304000126 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Christopher Scott Cooper |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1982606547 PECOS PAC ID: 8820133697 Enrollment ID: I20100304000132 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | John W Cromwell |
---|---|
Provider Type | Practitioner - Colorectal Surgery (proctology) |
Provider Identifiers | NPI Number: 1174535504 PECOS PAC ID: 7719089705 Enrollment ID: I20100304000226 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Robert A Robinson |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1184612988 PECOS PAC ID: 1153466990 Enrollment ID: I20100304000830 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Annette Jean Schlueter |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1497743686 PECOS PAC ID: 2567507304 Enrollment ID: I20100304000873 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Steven F Polyak |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1932141660 PECOS PAC ID: 8820051394 Enrollment ID: I20100306000292 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Merete Ibsen |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1174510416 PECOS PAC ID: 1254476856 Enrollment ID: I20100308000367 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Yasser M El Hattab |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1922094630 PECOS PAC ID: 5799820304 Enrollment ID: I20100308000379 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | David P Papworth |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1740260363 PECOS PAC ID: 9234274846 Enrollment ID: I20100308000392 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Yasser M Karim |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1275520611 PECOS PAC ID: 7214072826 Enrollment ID: I20100308000413 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mark A Granner |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1528051653 PECOS PAC ID: 4284779794 Enrollment ID: I20100309000464 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Laila Dahmoush |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1861480667 PECOS PAC ID: 9234274648 Enrollment ID: I20100309000533 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Daniel Kahn |
---|---|
Provider Type | Practitioner - Nuclear Medicine |
Provider Identifiers | NPI Number: 1568450419 PECOS PAC ID: 3779628037 Enrollment ID: I20100311000137 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mahmoud H Abou Alaiwa |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1609860006 PECOS PAC ID: 9537105192 Enrollment ID: I20100312000495 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Paul D Lindower |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1609863752 PECOS PAC ID: 1153456355 Enrollment ID: I20100312000593 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Samuel Kuperman |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1336137298 PECOS PAC ID: 2567597776 Enrollment ID: I20100312000645 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | James H Beeghly |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1710954813 PECOS PAC ID: 4880729003 Enrollment ID: I20100312000793 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jennifer Lynn Noeller |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1730172867 PECOS PAC ID: 8325173917 Enrollment ID: I20100322000426 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Cormac T Osullivan |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1427044577 PECOS PAC ID: 1951436542 Enrollment ID: I20100322000438 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Patrick G Hartley |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1003893702 PECOS PAC ID: 2567597156 Enrollment ID: I20100322000464 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Robert M Weiss |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1063494870 PECOS PAC ID: 3870629025 Enrollment ID: I20100327000119 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kathleen M Fear |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1346237799 PECOS PAC ID: 2365578515 Enrollment ID: I20100327000194 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Yutaka Sato |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1063400919 PECOS PAC ID: 6709989684 Enrollment ID: I20100330000349 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Tyrone B Whitter |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1942297056 PECOS PAC ID: 7618003294 Enrollment ID: I20100408000025 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Tad R Mabry |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1558424051 PECOS PAC ID: 3072649656 Enrollment ID: I20100408000033 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Robert P From |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1194711218 PECOS PAC ID: 9335275916 Enrollment ID: I20100408000038 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Yusuf Menda |
---|---|
Provider Type | Practitioner - Nuclear Medicine |
Provider Identifiers | NPI Number: 1538157425 PECOS PAC ID: 0042346637 Enrollment ID: I20100408000068 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Deema A Fattal |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1982696803 PECOS PAC ID: 5395871982 Enrollment ID: I20100408000096 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | James Grant Mccoy |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1417958638 PECOS PAC ID: 6608977939 Enrollment ID: I20100421000452 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | George J. Weiner |
---|---|
Provider Type | Practitioner - Hematology/oncology |
Provider Identifiers | NPI Number: 1407826456 PECOS PAC ID: 2163525049 Enrollment ID: I20100421000465 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jeffery L Meier |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1760470678 PECOS PAC ID: 7911034095 Enrollment ID: I20100421000502 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kyle E Brown |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1851388904 PECOS PAC ID: 2365579448 Enrollment ID: I20100421000521 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Patricia L Winokur |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1568444883 PECOS PAC ID: 1951438035 Enrollment ID: I20100421000608 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Edwin M Stone |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1831182237 PECOS PAC ID: 9638206725 Enrollment ID: I20100421000673 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nasreen A Syed |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1427059872 PECOS PAC ID: 3678600764 Enrollment ID: I20100421000726 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Herbert Boldt |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1558362871 PECOS PAC ID: 0749317840 Enrollment ID: I20100421000745 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Molly R Burma |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1134115488 PECOS PAC ID: 6204963242 Enrollment ID: I20100422000424 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Warren N Schmidt |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1760464143 PECOS PAC ID: 4385771336 Enrollment ID: I20100422000570 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | William L Iverson |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1346238904 PECOS PAC ID: 6901933969 Enrollment ID: I20100422000610 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jose M Manaligod |
---|---|
Provider Type | Practitioner - Otolaryngology |
Provider Identifiers | NPI Number: 1265429609 PECOS PAC ID: 3476680448 Enrollment ID: I20100422000723 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ergun Yassar Uc |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1609851054 PECOS PAC ID: 7113054107 Enrollment ID: I20100422000968 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Isaac Samuel |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1447244413 PECOS PAC ID: 5890822886 Enrollment ID: I20100422001045 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Paul A Leonard |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1528056371 PECOS PAC ID: 6406983410 Enrollment ID: I20100423000049 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | William M Nauseef |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1992793848 PECOS PAC ID: 0840327599 Enrollment ID: I20100428000782 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Megan S Davis Degeus |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1093043580 PECOS PAC ID: 5799812442 Enrollment ID: I20100428000846 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Diane E Elas |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1447247200 PECOS PAC ID: 4082741665 Enrollment ID: I20100430000335 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Minako Hayakawa |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1891784674 PECOS PAC ID: 1850428442 Enrollment ID: I20100430000404 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Noelle C Bowdler |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1396732160 PECOS PAC ID: 7113054701 Enrollment ID: I20100430000413 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ann Struve |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1134455702 PECOS PAC ID: 0143358564 Enrollment ID: I20100505000955 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lana Jane Goldsmith |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1487643235 PECOS PAC ID: 6800924234 Enrollment ID: I20100505001047 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Cassim M Igram |
---|---|
Provider Type | Practitioner - Orthopedic Surgery |
Provider Identifiers | NPI Number: 1700846615 PECOS PAC ID: 6406925957 Enrollment ID: I20100506000983 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Phillip A Horwitz |
---|---|
Provider Type | Practitioner - Interventional Cardiology |
Provider Identifiers | NPI Number: 1124016787 PECOS PAC ID: 6103954383 Enrollment ID: I20100507000770 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Eva Tsalikian |
---|---|
Provider Type | Practitioner - Endocrinology |
Provider Identifiers | NPI Number: 1619963949 PECOS PAC ID: 9335242213 Enrollment ID: I20100512000080 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Marlan R Hansen |
---|---|
Provider Type | Practitioner - Otolaryngology |
Provider Identifiers | NPI Number: 1326031733 PECOS PAC ID: 8022146984 Enrollment ID: I20100513000509 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | James Yuknam Choi |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1144216805 PECOS PAC ID: 0345378204 Enrollment ID: I20100513000554 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Stephen R Russell |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1235130584 PECOS PAC ID: 9739217605 Enrollment ID: I20100513000648 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Val Cowley Sheffield |
---|---|
Provider Type | Practitioner - Medical Genetics And Genomics |
Provider Identifiers | NPI Number: 1437146909 PECOS PAC ID: 0042348930 Enrollment ID: I20100513000878 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Hiroto Kawasaki |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1982697009 PECOS PAC ID: 4486782372 Enrollment ID: I20100513000907 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mary K Obrien |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1982692711 PECOS PAC ID: 2365570272 Enrollment ID: I20100514000040 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Delwyn Deon Miller |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1285620815 PECOS PAC ID: 9436287133 Enrollment ID: I20100517000131 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | David L Bushnell |
---|---|
Provider Type | Practitioner - Nuclear Medicine |
Provider Identifiers | NPI Number: 1104814094 PECOS PAC ID: 9830228519 Enrollment ID: I20100519000529 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Curtis T Poor |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1942260732 PECOS PAC ID: 3072693555 Enrollment ID: I20100520000145 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Judith H W Crossett |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1639164320 PECOS PAC ID: 4284763780 Enrollment ID: I20100521000042 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alan F Ross |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1518947175 PECOS PAC ID: 0143359695 Enrollment ID: I20100521000663 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Thomas H Wassink |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1760470637 PECOS PAC ID: 1850420274 Enrollment ID: I20100524000571 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael A Flaum |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1700872348 PECOS PAC ID: 2567591985 Enrollment ID: I20100524000601 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rebecca J Winnike |
---|---|
Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
Provider Identifiers | NPI Number: 1205003928 PECOS PAC ID: 7214066562 Enrollment ID: I20100525000140 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jessica Stevens |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1295728400 PECOS PAC ID: 4981733219 Enrollment ID: I20100526000045 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Molly J Bock |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1962483909 PECOS PAC ID: 1456480631 Enrollment ID: I20100526000637 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Charles Michael Knudson |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1144218926 PECOS PAC ID: 3476682352 Enrollment ID: I20100602000847 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mary E Johnson |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1518953629 PECOS PAC ID: 7214066018 Enrollment ID: I20100603000100 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Eileen Frances Yeisley |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1477882439 PECOS PAC ID: 9234269333 Enrollment ID: I20100616000812 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Beng Choon Ho |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1407841174 PECOS PAC ID: 9537299649 Enrollment ID: I20100617000038 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Robert Alan Philibert |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1023003787 PECOS PAC ID: 7618007626 Enrollment ID: I20100617000054 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Donald Wayne Black |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1528053220 PECOS PAC ID: 3072643089 Enrollment ID: I20100617000063 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jodi T Tate |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1225023971 PECOS PAC ID: 0042340051 Enrollment ID: I20100617000090 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Shobha Chitneni |
---|---|
Provider Type | Practitioner - Hematology/oncology |
Provider Identifiers | NPI Number: 1184684987 PECOS PAC ID: 9234154386 Enrollment ID: I20100618000637 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Janice Marie Rose Staber |
---|---|
Provider Type | Practitioner - Hematology/oncology |
Provider Identifiers | NPI Number: 1013126705 PECOS PAC ID: 1850421710 Enrollment ID: I20100621000004 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Hristina K Koleva |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1962607358 PECOS PAC ID: 1557491412 Enrollment ID: I20100621000036 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lynn R Fitzpatrick |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1891783155 PECOS PAC ID: 0648301580 Enrollment ID: I20100622000101 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Dawn Annette Allen |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1588650832 PECOS PAC ID: 4587795125 Enrollment ID: I20100626000129 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Marion Lee Sanders |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1932305331 PECOS PAC ID: 4789715939 Enrollment ID: I20100701000617 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Justin Wade Smock |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1720284128 PECOS PAC ID: 0749311710 Enrollment ID: I20100708000689 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kathy L Kyser |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1740266329 PECOS PAC ID: 8729119714 Enrollment ID: I20100708001000 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael John Jung |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1023093580 PECOS PAC ID: 2365573359 Enrollment ID: I20100708001006 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | David Michael Kuehn |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1922096874 PECOS PAC ID: 3375675309 Enrollment ID: I20100709000492 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rebecca Joy Timmer Benson |
---|---|
Provider Type | Practitioner - Hospice/palliative Care |
Provider Identifiers | NPI Number: 1023213030 PECOS PAC ID: 8224160833 Enrollment ID: I20100717000077 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Daniel A Katz |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1023019676 PECOS PAC ID: 8123150513 Enrollment ID: I20100721000087 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jennifer J Smith Gordon |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1568672988 PECOS PAC ID: 7810020690 Enrollment ID: I20100730000097 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Abbey Joy Hardy Fairbanks |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1619073988 PECOS PAC ID: 6901939784 Enrollment ID: I20100730000112 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Matthew J Bollier |
---|---|
Provider Type | Practitioner - Orthopedic Surgery |
Provider Identifiers | NPI Number: 1881897676 PECOS PAC ID: 5890828677 Enrollment ID: I20100730000133 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kelly Elizabeth Wood |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1407901283 PECOS PAC ID: 0042343824 Enrollment ID: I20100730000160 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Peggy C Nopoulos |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1326033002 PECOS PAC ID: 6507999117 Enrollment ID: I20100803000999 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Vicki J Kijewski |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1417942178 PECOS PAC ID: 5496888000 Enrollment ID: I20100803001024 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | David J Moser |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1164417820 PECOS PAC ID: 3476686080 Enrollment ID: I20100803001050 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Adrian N Holm |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1093794844 PECOS PAC ID: 5890725105 Enrollment ID: I20100804000722 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Malcolm H Yeh |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1407848336 PECOS PAC ID: 1557494929 Enrollment ID: I20100805000468 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Steven Lloyd Fletcher |
---|---|
Provider Type | Practitioner - Maxillofacial Surgery |
Provider Identifiers | NPI Number: 1841407756 PECOS PAC ID: 8820121189 Enrollment ID: I20100806000415 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Aaron C Smith |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1871614149 PECOS PAC ID: 5496889388 Enrollment ID: I20100813000690 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Veeratrishul Allareddy |
---|---|
Provider Type | Practitioner - Maxillofacial Surgery |
Provider Identifiers | NPI Number: 1023268430 PECOS PAC ID: 0244364156 Enrollment ID: I20100813000911 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kristen F Walker |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1760687628 PECOS PAC ID: 1951435874 Enrollment ID: I20100813000940 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Cynthia Darlene Waters |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1194043190 PECOS PAC ID: 9335273259 Enrollment ID: I20100813001036 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Christine M Mcnair |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1811151103 PECOS PAC ID: 5698809515 Enrollment ID: I20100813001059 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Douglas E Laux |
---|---|
Provider Type | Practitioner - Medical Oncology |
Provider Identifiers | NPI Number: 1295946218 PECOS PAC ID: 1759415409 Enrollment ID: I20100817000336 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Douglas M Kinscherff |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1770603086 PECOS PAC ID: 8123152840 Enrollment ID: I20100817001179 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Thomas D Striegel |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1578898615 PECOS PAC ID: 9739221649 Enrollment ID: I20100817001314 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Carolyn Louise Turvey |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1487640751 PECOS PAC ID: 4486788023 Enrollment ID: I20100817001668 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Benjamin James Miller |
---|---|
Provider Type | Practitioner - Orthopedic Surgery |
Provider Identifiers | NPI Number: 1427284512 PECOS PAC ID: 8729112396 Enrollment ID: I20100818000290 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kenneth G Nepple |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1659580678 PECOS PAC ID: 2264566835 Enrollment ID: I20100818000320 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rodrigo Bayon |
---|---|
Provider Type | Practitioner - Otolaryngology |
Provider Identifiers | NPI Number: 1700079480 PECOS PAC ID: 9032261672 Enrollment ID: I20100818000930 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sarah E Polk |
---|---|
Provider Type | Practitioner - Podiatry |
Provider Identifiers | NPI Number: 1063666089 PECOS PAC ID: 4880728369 Enrollment ID: I20100819000491 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Daniel J Leary |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1083819742 PECOS PAC ID: 0345374831 Enrollment ID: I20100819000617 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jessica D Kresowik |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1801006242 PECOS PAC ID: 5890829253 Enrollment ID: I20100820000294 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Chris S Jensen |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1841288552 PECOS PAC ID: 4981738366 Enrollment ID: I20100820000588 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | George B Richerson |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1164404802 PECOS PAC ID: 1557485604 Enrollment ID: I20100826000840 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mandy L Harris |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1720277692 PECOS PAC ID: 7618091760 Enrollment ID: I20100826000859 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Katherine I Harris |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1306040472 PECOS PAC ID: 6507934791 Enrollment ID: I20100826000868 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Paramesh B Ramadugu |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1871563858 PECOS PAC ID: 6507888252 Enrollment ID: I20100831000020 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bradley A Erickson |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1164679262 PECOS PAC ID: 9032265855 Enrollment ID: I20100831000683 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jennifer R Doyle |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1679560171 PECOS PAC ID: 3870617384 Enrollment ID: I20100903000537 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Eyup Hakan Duran |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1780846287 PECOS PAC ID: 6204951510 Enrollment ID: I20100909001137 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Frederick C Johlin |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1821085960 PECOS PAC ID: 3971628207 Enrollment ID: I20100910000059 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Dennis J Firchau |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1437236429 PECOS PAC ID: 6305913591 Enrollment ID: I20100910000170 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | John W Hellstein |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1396837050 PECOS PAC ID: 3476678566 Enrollment ID: I20100913000889 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Tameem A Shoukih |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1992790273 PECOS PAC ID: 0244355717 Enrollment ID: I20100921000907 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sarah R Kluesner |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1679889661 PECOS PAC ID: 5395861868 Enrollment ID: I20100922000617 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jodi Beth Stedman |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1447416011 PECOS PAC ID: 9436275765 Enrollment ID: I20100923001516 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Tamara J Crawford |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1639490600 PECOS PAC ID: 0749472140 Enrollment ID: I20101004000983 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Andrew R Peterson |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1528023504 PECOS PAC ID: 8022118173 Enrollment ID: I20101007000007 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Elliott H Sohn |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1467563312 PECOS PAC ID: 9830246370 Enrollment ID: I20101011000786 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | John M Dagle |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1942299060 PECOS PAC ID: 1759574387 Enrollment ID: I20101014001464 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joy E Moel |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1518106509 PECOS PAC ID: 4688867088 Enrollment ID: I20101019000652 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Dean A Abramson |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1275517658 PECOS PAC ID: 6103018775 Enrollment ID: I20101020001198 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Gregory L Gullickson |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1023120276 PECOS PAC ID: 3072706191 Enrollment ID: I20101021001011 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Luong M Banh |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1457560609 PECOS PAC ID: 1557416179 Enrollment ID: I20101103001005 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joe Moonjely |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1215021753 PECOS PAC ID: 0042405607 Enrollment ID: I20101109001409 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Christopher Paul Hogrefe |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1184881401 PECOS PAC ID: 7214122456 Enrollment ID: I20101112000653 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Steven R Armstrong |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1598869505 PECOS PAC ID: 4183810716 Enrollment ID: I20101122001220 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Georgia K Johnson |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1932203627 PECOS PAC ID: 1153517610 Enrollment ID: I20101123000229 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Andrea A Timmerman |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1174824205 PECOS PAC ID: 7618163007 Enrollment ID: I20101124000665 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sarah Thomas |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1225071772 PECOS PAC ID: 4587851852 Enrollment ID: I20101213000534 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Matthew James Thurtell |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1194904169 PECOS PAC ID: 2668660754 Enrollment ID: I20101215000966 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Milena A Gebska |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1780850313 PECOS PAC ID: 2961690128 Enrollment ID: I20110103000950 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ron O Abrons |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1104874742 PECOS PAC ID: 7214095363 Enrollment ID: I20110210000755 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Melissa Erin Tvedte |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1336444140 PECOS PAC ID: 2567642200 Enrollment ID: I20110211000727 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Marina Y Usacheva |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1821085549 PECOS PAC ID: 0143401448 Enrollment ID: I20110218000986 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael M Hummel |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1891757225 PECOS PAC ID: 4587554571 Enrollment ID: I20110304000305 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Carla J Pies |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1326297359 PECOS PAC ID: 0648453456 Enrollment ID: I20110331000340 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Yulia N Matveeva |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1114101201 PECOS PAC ID: 0345424768 Enrollment ID: I20110411000013 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Parren Scott Mcneely |
---|---|
Provider Type | Practitioner - Nuclear Medicine |
Provider Identifiers | NPI Number: 1841369022 PECOS PAC ID: 1850576497 Enrollment ID: I20110426000536 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Tricia Eileen Michna |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1568761849 PECOS PAC ID: 3173708716 Enrollment ID: I20110426000591 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kara R Dierikx |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1407149891 PECOS PAC ID: 6608053509 Enrollment ID: I20110601000673 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Manuel R Gomez |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1417051418 PECOS PAC ID: 5092992826 Enrollment ID: I20110603000575 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Carol Holman |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1023042595 PECOS PAC ID: 1254368632 Enrollment ID: I20110606000307 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Holly-marie Bolger |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1972709814 PECOS PAC ID: 0547447294 Enrollment ID: I20110606000339 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sarah E Haskell |
---|---|
Provider Type | Practitioner - Critical Care (intensivists) |
Provider Identifiers | NPI Number: 1780893503 PECOS PAC ID: 9537346291 Enrollment ID: I20110606000366 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Katie M U Larson Ode |
---|---|
Provider Type | Practitioner - Endocrinology |
Provider Identifiers | NPI Number: 1104029008 PECOS PAC ID: 0547447211 Enrollment ID: I20110606000465 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Satoshi Hanada |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1134329345 PECOS PAC ID: 4284811837 Enrollment ID: I20110607000731 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mederic Hall |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1093836728 PECOS PAC ID: 6901999648 Enrollment ID: I20110620000094 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael Akwantsin Kwofie |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1669633608 PECOS PAC ID: 1557549573 Enrollment ID: I20110622000328 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Padmalatha K Collappakkam |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1790983989 PECOS PAC ID: 4981882925 Enrollment ID: I20110622000601 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Millicent V Oracion |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1891902235 PECOS PAC ID: 7517145469 Enrollment ID: I20110624000317 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Melissa D Gonzalez |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1760623391 PECOS PAC ID: 3971781824 Enrollment ID: I20110624000325 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lindsay N Boyum |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1801037494 PECOS PAC ID: 7416135363 Enrollment ID: I20110624000332 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Eugenia Mazur |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1407147911 PECOS PAC ID: 1052599909 Enrollment ID: I20110624000337 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Andrea L Porter |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1760774608 PECOS PAC ID: 4880872621 Enrollment ID: I20110627000783 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nicholas Matthew Mohr |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1467654566 PECOS PAC ID: 2769536572 Enrollment ID: I20110628000169 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Dmitriy Acherkan |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1952565368 PECOS PAC ID: 4082892450 Enrollment ID: I20110707000446 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Vanessa A Curtis |
---|---|
Provider Type | Practitioner - Endocrinology |
Provider Identifiers | NPI Number: 1750348496 PECOS PAC ID: 6103004460 Enrollment ID: I20110711000263 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Praveen Vikas |
---|---|
Provider Type | Practitioner - Medical Oncology |
Provider Identifiers | NPI Number: 1619162435 PECOS PAC ID: 7214003037 Enrollment ID: I20110711000446 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jami L Shepard |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1730386582 PECOS PAC ID: 8527236827 Enrollment ID: I20110712000227 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Wenqing Sun |
---|---|
Provider Type | Practitioner - Radiation Oncology |
Provider Identifiers | NPI Number: 1619187036 PECOS PAC ID: 6305015710 Enrollment ID: I20110801000582 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | April D Hubbard |
---|---|
Provider Type | Practitioner - Qualified Audiologist |
Provider Identifiers | NPI Number: 1407134349 PECOS PAC ID: 9830368208 Enrollment ID: I20110802000269 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Benjamin W Darbro |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1669671814 PECOS PAC ID: 3971772948 Enrollment ID: I20110808000741 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brian Kent Gehlbach |
---|---|
Provider Type | Practitioner - Critical Care (intensivists) |
Provider Identifiers | NPI Number: 1285797704 PECOS PAC ID: 0446432926 Enrollment ID: I20110815000114 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Matthew D Karam |
---|---|
Provider Type | Practitioner - Orthopedic Surgery |
Provider Identifiers | NPI Number: 1790993160 PECOS PAC ID: 8022141571 Enrollment ID: I20110815000937 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ravinder K Dervesh |
---|---|
Provider Type | Practitioner - Interventional Cardiology |
Provider Identifiers | NPI Number: 1013107291 PECOS PAC ID: 5890964464 Enrollment ID: I20110816000790 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rhonda Jean Dunn |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1013205657 PECOS PAC ID: 9436329588 Enrollment ID: I20110826000444 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rami Adnan Boutros |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1063477024 PECOS PAC ID: 8022020338 Enrollment ID: I20110909002674 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Erin Marianne Crocker |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1609075944 PECOS PAC ID: 5698828754 Enrollment ID: I20110919000055 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Changhyun Lee |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1407137193 PECOS PAC ID: 0648441956 Enrollment ID: I20110919000074 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Danielle Mr Kelsay |
---|---|
Provider Type | Practitioner - Qualified Audiologist |
Provider Identifiers | NPI Number: 1558513127 PECOS PAC ID: 5294906434 Enrollment ID: I20110920000902 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Anne M Wallace |
---|---|
Provider Type | Practitioner - Qualified Speech Language Pathologist |
Provider Identifiers | NPI Number: 1982849634 PECOS PAC ID: 2163693243 Enrollment ID: I20110921000475 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Matthew K Geneser |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1205006061 PECOS PAC ID: 2163693912 Enrollment ID: I20110927000692 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Stephanie M Fleckenstein |
---|---|
Provider Type | Practitioner - Qualified Audiologist |
Provider Identifiers | NPI Number: 1285886853 PECOS PAC ID: 8123290830 Enrollment ID: I20110930000237 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Katherine L Imborek |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1902069875 PECOS PAC ID: 6406028877 Enrollment ID: I20111006000406 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Khadija Shahid |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1710929526 PECOS PAC ID: 8325021405 Enrollment ID: I20111006000575 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jaclyn Roman |
---|---|
Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
Provider Identifiers | NPI Number: 1639459902 PECOS PAC ID: 9335311638 Enrollment ID: I20111011000025 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Randi J Key |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1295016210 PECOS PAC ID: 5092987305 Enrollment ID: I20111011000134 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Deqin Ma |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1407175359 PECOS PAC ID: 4183896095 Enrollment ID: I20111018000495 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brianne M Foulker |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1689954489 PECOS PAC ID: 3274705041 Enrollment ID: I20111020000776 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sarat C Kuppachi |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1093983629 PECOS PAC ID: 0749356798 Enrollment ID: I20111026000781 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Elizabeth R Cullen |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1316221708 PECOS PAC ID: 7315111903 Enrollment ID: I20111116000668 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lindsay R Shedek |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1871877316 PECOS PAC ID: 8325212939 Enrollment ID: I20111116000937 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michelle L Schnack |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1972812097 PECOS PAC ID: 1557536554 Enrollment ID: I20111202000075 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Krista M Ford |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1225311012 PECOS PAC ID: 3274708748 Enrollment ID: I20111212000455 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Daniel G Miller |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1538324819 PECOS PAC ID: 4981772522 Enrollment ID: I20111219000562 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kimberly K Sprague |
---|---|
Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
Provider Identifiers | NPI Number: 1629044755 PECOS PAC ID: 6002083821 Enrollment ID: I20120119000509 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Allison E Wynes |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1952678161 PECOS PAC ID: 8022285501 Enrollment ID: I20120124000769 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Unyime S Ituk |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1871809616 PECOS PAC ID: 4981729944 Enrollment ID: I20120206000678 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brynna L Vanwyk |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1679841142 PECOS PAC ID: 4587821152 Enrollment ID: I20120209000227 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Andrew M Bellizzi |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1215159199 PECOS PAC ID: 7113079922 Enrollment ID: I20120210000279 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Adisa Tokaca |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1659654028 PECOS PAC ID: 6002074234 Enrollment ID: I20120220000811 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Dina N Al-zubeidi |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1245448232 PECOS PAC ID: 3971761008 Enrollment ID: I20120221000837 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Barbara Coffman |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1912284258 PECOS PAC ID: 5294993234 Enrollment ID: I20120222000959 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Courtney E Kremer |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1669740957 PECOS PAC ID: 3678731593 Enrollment ID: I20120223000697 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Elizabeth M Giedt |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1023380755 PECOS PAC ID: 2860650553 Enrollment ID: I20120227000677 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Matthew Thomas Spragg |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1164425963 PECOS PAC ID: 1759351190 Enrollment ID: I20120227000773 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Krista M Johnson |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1457412280 PECOS PAC ID: 4789714304 Enrollment ID: I20120321000820 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael E Shy |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1982642617 PECOS PAC ID: 1951313170 Enrollment ID: I20120405000421 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jessica B Upah |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1104190057 PECOS PAC ID: 2466613625 Enrollment ID: I20120416000013 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Gretchen M Kass |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1376809251 PECOS PAC ID: 0941461933 Enrollment ID: I20120418000807 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jennifer E Hrabe |
---|---|
Provider Type | Practitioner - Colorectal Surgery (proctology) |
Provider Identifiers | NPI Number: 1619139839 PECOS PAC ID: 9931361409 Enrollment ID: I20120427000673 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jade L Runge |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1174880744 PECOS PAC ID: 6204098171 Enrollment ID: I20120510000516 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lisa Renee Kongable |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1336158666 PECOS PAC ID: 9335301209 Enrollment ID: I20120510000561 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Cheryl A Conrad |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1568647303 PECOS PAC ID: 1052574498 Enrollment ID: I20120522000782 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ramzi N El Accaoui |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1316157241 PECOS PAC ID: 1658534664 Enrollment ID: I20120531000118 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Megan I Samuelson |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1316157902 PECOS PAC ID: 1456515105 Enrollment ID: I20120611000273 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | William M Rockey |
---|---|
Provider Type | Practitioner - Radiation Oncology |
Provider Identifiers | NPI Number: 1043416548 PECOS PAC ID: 7012171499 Enrollment ID: I20120614000721 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Douglas W Storm |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1720257678 PECOS PAC ID: 3870774680 Enrollment ID: I20120620000247 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nkanyezi Ngwenyama Ferguson |
---|---|
Provider Type | Practitioner - Micrographic Dermatologic Surgery (mds) |
Provider Identifiers | NPI Number: 1366755530 PECOS PAC ID: 8628232733 Enrollment ID: I20120620000606 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kathryn A Steffen |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1891052445 PECOS PAC ID: 3779748652 Enrollment ID: I20120626000760 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kristin J Foster |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1982962619 PECOS PAC ID: 8123283009 Enrollment ID: I20120626000764 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Eilene M Swartz |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1689933731 PECOS PAC ID: 6406011246 Enrollment ID: I20120629000299 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Barry London |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1356315501 PECOS PAC ID: 6507758430 Enrollment ID: I20120629000391 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Howard O Rourke |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1194915413 PECOS PAC ID: 1951587468 Enrollment ID: I20120717000389 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Eric W Aschenbrenner |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1811960230 PECOS PAC ID: 8921035999 Enrollment ID: I20120725000446 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Elizabeth S Cramer |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1386870483 PECOS PAC ID: 6608032198 Enrollment ID: I20120727000620 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jessie E Marks |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1912134339 PECOS PAC ID: 6204092711 Enrollment ID: I20120727000777 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | James J Kellen |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1619906336 PECOS PAC ID: 3072610567 Enrollment ID: I20120727000780 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sudhakar Subramani |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1558641241 PECOS PAC ID: 5597921817 Enrollment ID: I20120731000528 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sathvika Velur |
---|---|
Provider Type | Practitioner - Endocrinology |
Provider Identifiers | NPI Number: 1932339413 PECOS PAC ID: 0042476335 Enrollment ID: I20120801000419 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rebecca L Zwanziger |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1609121748 PECOS PAC ID: 3577719111 Enrollment ID: I20120814000257 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Breanna C Herring |
---|---|
Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
Provider Identifiers | NPI Number: 1578828406 PECOS PAC ID: 3870740046 Enrollment ID: I20120822000505 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Linda M Cadaret |
---|---|
Provider Type | Practitioner - Advanced Heart Failure And Transplant Cardiology |
Provider Identifiers | NPI Number: 1437121407 PECOS PAC ID: 2668666587 Enrollment ID: I20120827000503 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Himena V Harris |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1801157854 PECOS PAC ID: 4789832163 Enrollment ID: I20120910000055 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jerrod N Keith |
---|---|
Provider Type | Practitioner - Plastic And Reconstructive Surgery |
Provider Identifiers | NPI Number: 1528105889 PECOS PAC ID: 3577711951 Enrollment ID: I20120910000093 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bradley A Ford |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1942490156 PECOS PAC ID: 1850549981 Enrollment ID: I20120914000655 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ivy R Burns |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1104149392 PECOS PAC ID: 1254589385 Enrollment ID: I20120914000725 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rachel R Butler |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1043449689 PECOS PAC ID: 5294984951 Enrollment ID: I20121012000645 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Natalie L Denburg |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1336440031 PECOS PAC ID: 1153570817 Enrollment ID: I20121012000681 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Katherine M White |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1518903731 PECOS PAC ID: 8123164803 Enrollment ID: I20121018000546 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | David C Jensen |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1902152176 PECOS PAC ID: 5991955130 Enrollment ID: I20121023000785 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Hyung-sub Shim |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1407064785 PECOS PAC ID: 3476742982 Enrollment ID: I20121023000799 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Stacie A Kasper |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1124389176 PECOS PAC ID: 8820248800 Enrollment ID: I20121029000447 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nathan A Shaw |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1053604868 PECOS PAC ID: 8628228533 Enrollment ID: I20121030000017 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sarah L Miller |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1346443306 PECOS PAC ID: 4981854833 Enrollment ID: I20121030000466 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Tiffany K Rickertsen |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1699024497 PECOS PAC ID: 2860643392 Enrollment ID: I20121109000625 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Laura L Fuller |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1982813150 PECOS PAC ID: 8921037722 Enrollment ID: I20121109000630 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nandakumar Narayanan |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1831349620 PECOS PAC ID: 8921259359 Enrollment ID: I20121113000379 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mark A Greiner |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1194992958 PECOS PAC ID: 2961680848 Enrollment ID: I20121113000403 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Dacia Nicole Watts |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1467747782 PECOS PAC ID: 8325299613 Enrollment ID: I20121114000424 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lori A Christensen |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1639165285 PECOS PAC ID: 5193978625 Enrollment ID: I20130114000282 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jill M Kain |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1780933440 PECOS PAC ID: 8527212042 Enrollment ID: I20130211000335 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Erin M Shriver |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1750325932 PECOS PAC ID: 6002811700 Enrollment ID: I20130221000327 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kendra K Struck |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1124364948 PECOS PAC ID: 0547415689 Enrollment ID: I20130221000356 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Melissa M Collier |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1356692131 PECOS PAC ID: 9638324502 Enrollment ID: I20130226000043 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Abbie L Volz |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1528304763 PECOS PAC ID: 3072768613 Enrollment ID: I20130305000014 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | David G Gratton |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1962506667 PECOS PAC ID: 3476798612 Enrollment ID: I20130318000362 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Natasha L Clark |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1609120815 PECOS PAC ID: 2264678218 Enrollment ID: I20130417000163 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Paul G Vanheukelom |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1700044849 PECOS PAC ID: 7517137219 Enrollment ID: I20130423000017 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Regina M Randall |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1366783805 PECOS PAC ID: 1850538349 Enrollment ID: I20130430000236 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nitin J Karandikar |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1679542138 PECOS PAC ID: 4385717933 Enrollment ID: I20130506000326 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Karin F Hoth |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1578754784 PECOS PAC ID: 9234223660 Enrollment ID: I20130522000674 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bruce Cary Justman |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1639273329 PECOS PAC ID: 4981843141 Enrollment ID: I20130619000114 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Polly J Ferguson |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1154316842 PECOS PAC ID: 0547400426 Enrollment ID: I20130717000867 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Christopher Callahan Schuster |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1437479771 PECOS PAC ID: 0446491336 Enrollment ID: I20130718000086 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lastascia N Coleman |
---|---|
Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
Provider Identifiers | NPI Number: 1205173440 PECOS PAC ID: 4587805338 Enrollment ID: I20130722000129 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bryan Golden Allen |
---|---|
Provider Type | Practitioner - Radiation Oncology |
Provider Identifiers | NPI Number: 1689832081 PECOS PAC ID: 6204077662 Enrollment ID: I20130726000569 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amy Lynn Conrad |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1942646195 PECOS PAC ID: 7315188562 Enrollment ID: I20130730000905 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jeffrey E Senasu |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1962718007 PECOS PAC ID: 8729229851 Enrollment ID: I20130731000840 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Tejinder Singh Swaran Singh |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1215197660 PECOS PAC ID: 3274774310 Enrollment ID: I20130801000116 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael A Ciliberto |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1043418809 PECOS PAC ID: 4183801491 Enrollment ID: I20130805000023 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Catherine D Degeeter |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1982860185 PECOS PAC ID: 1850533811 Enrollment ID: I20130805000416 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kaikobad Irani |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1699748335 PECOS PAC ID: 3779521695 Enrollment ID: I20130805000516 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Scott M Lieberman |
---|---|
Provider Type | Practitioner - Rheumatology |
Provider Identifiers | NPI Number: 1447440698 PECOS PAC ID: 8921137803 Enrollment ID: I20130805000568 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rachel Beth Mejia Sounhein |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1336374768 PECOS PAC ID: 8022257153 Enrollment ID: I20130813000238 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sandra D Abramoff |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1952519993 PECOS PAC ID: 3779725916 Enrollment ID: I20130816000797 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Satsuki Matsumoto |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1609072818 PECOS PAC ID: 4183867955 Enrollment ID: I20130826000877 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nicholas R Butler |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1427285071 PECOS PAC ID: 6800035155 Enrollment ID: I20130827000408 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ethan F Kuperman |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1528225042 PECOS PAC ID: 2769650993 Enrollment ID: I20130827000769 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brian James Dlouhy |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1619175148 PECOS PAC ID: 0345480505 Enrollment ID: I20130829000509 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Arwa Aburizik |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1356559298 PECOS PAC ID: 2466691670 Enrollment ID: I20130829000557 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Katherine G Keech |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1811001274 PECOS PAC ID: 9436204179 Enrollment ID: I20130829000644 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Osamah T Aldoss |
---|---|
Provider Type | Practitioner - Interventional Cardiology |
Provider Identifiers | NPI Number: 1104043710 PECOS PAC ID: 2062655590 Enrollment ID: I20130830000263 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Eiyu Matsumoto |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1366606162 PECOS PAC ID: 4789821265 Enrollment ID: I20130830000346 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Erin P Martin |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1780846790 PECOS PAC ID: 9436399961 Enrollment ID: I20130904000483 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | John C Keech |
---|---|
Provider Type | Practitioner - Thoracic Surgery |
Provider Identifiers | NPI Number: 1770685604 PECOS PAC ID: 0648413021 Enrollment ID: I20130904000529 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kiran Annam |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1477993830 PECOS PAC ID: 7618110958 Enrollment ID: I20130905000388 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Janet H Pollard |
---|---|
Provider Type | Practitioner - Nuclear Medicine |
Provider Identifiers | NPI Number: 1780842450 PECOS PAC ID: 1850530304 Enrollment ID: I20130906000743 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Luis J Garcia |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1386858751 PECOS PAC ID: 4183880016 Enrollment ID: I20130911000675 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Heather A Hoffman |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1518308121 PECOS PAC ID: 6709020621 Enrollment ID: I20130916000556 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lauren Elizabeth Graham |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1780820860 PECOS PAC ID: 6800045691 Enrollment ID: I20130917000094 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Peter N Nau |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1073727087 PECOS PAC ID: 7719143924 Enrollment ID: I20130918000257 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Catherine Melissa Metz |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1942462437 PECOS PAC ID: 6507005949 Enrollment ID: I20130918000362 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Peter Densen |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1518949825 PECOS PAC ID: 0446494801 Enrollment ID: I20130925000298 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Meghan A Connett |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1215258538 PECOS PAC ID: 0547494510 Enrollment ID: I20131004000344 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Angela T Farrell |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1871814194 PECOS PAC ID: 4385881028 Enrollment ID: I20131009001956 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Vicki C Jensen |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1548601610 PECOS PAC ID: 3678707205 Enrollment ID: I20131014001188 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael J Herzig |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1487950671 PECOS PAC ID: 0042445074 Enrollment ID: I20131029001975 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sara J Kraus |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1851725238 PECOS PAC ID: 8921233834 Enrollment ID: I20131031000972 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jenna K Herrig |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1861831265 PECOS PAC ID: 4880829670 Enrollment ID: I20131104000239 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jennifer A Johnson |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1699744045 PECOS PAC ID: 1658399373 Enrollment ID: I20131107000744 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amanda J Pitts |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1407280654 PECOS PAC ID: 4486881810 Enrollment ID: I20131210002086 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nidhi Handoo |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1093150658 PECOS PAC ID: 3678700820 Enrollment ID: I20131213000070 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amanda J Grafft |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1427482850 PECOS PAC ID: 1456588631 Enrollment ID: I20131213000928 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Melissa Anne Bognar |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1679870661 PECOS PAC ID: 1153558333 Enrollment ID: I20131213001013 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Anne C Gentil Archer |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1356774798 PECOS PAC ID: 7810124849 Enrollment ID: I20131218000658 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Eri Shinozaki |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1841467115 PECOS PAC ID: 9739340720 Enrollment ID: I20131220001443 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mohammad A Bashir |
---|---|
Provider Type | Practitioner - Cardiac Surgery |
Provider Identifiers | NPI Number: 1790994960 PECOS PAC ID: 0244468908 Enrollment ID: I20140102001435 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ferhaan Ahmad |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1699747881 PECOS PAC ID: 1254399686 Enrollment ID: I20140108001862 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Claudia L Corwin |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1164717989 PECOS PAC ID: 9335158799 Enrollment ID: I20140115000670 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kang Yu K Lee Son |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1487083911 PECOS PAC ID: 8820226780 Enrollment ID: I20140122001881 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sarah M Cisco |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1063840320 PECOS PAC ID: 7517195381 Enrollment ID: I20140124001766 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lance A Lalonde |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1336446913 PECOS PAC ID: 0648409862 Enrollment ID: I20140211001849 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Christina M Shutters |
---|---|
Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
Provider Identifiers | NPI Number: 1396172862 PECOS PAC ID: 9931338985 Enrollment ID: I20140214001370 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Megan M Vanotterloo |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1720401961 PECOS PAC ID: 8022248020 Enrollment ID: I20140312001316 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bailey J Noble |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1871915710 PECOS PAC ID: 9739310632 Enrollment ID: I20140318000193 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Monika R Jindal |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1598050023 PECOS PAC ID: 4385884493 Enrollment ID: I20140325001695 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Samantha B Lee |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1326375551 PECOS PAC ID: 6305980681 Enrollment ID: I20140327001599 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Laura J Ramsey |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1255393997 PECOS PAC ID: 6901038165 Enrollment ID: I20140422002271 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | David W Kaczka |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1760423396 PECOS PAC ID: 0446225742 Enrollment ID: I20140429001031 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Stacey A Appenheimer |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1225357585 PECOS PAC ID: 2769626142 Enrollment ID: I20140508001295 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Umar Farooq |
---|---|
Provider Type | Practitioner - Hematopoietic Cell Transplantation And Cellular Therapy |
Provider Identifiers | NPI Number: 1336333673 PECOS PAC ID: 2860625258 Enrollment ID: I20140509001555 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michihiko Goto |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1578703898 PECOS PAC ID: 4284871765 Enrollment ID: I20140509001960 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | John C Selby |
---|---|
Provider Type | Practitioner - Dermatology |
Provider Identifiers | NPI Number: 1356662621 PECOS PAC ID: 5496994790 Enrollment ID: I20140512000830 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Aaron J Kauer |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1811123318 PECOS PAC ID: 1951541507 Enrollment ID: I20140522001781 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Fabiana C Policeni |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1033372149 PECOS PAC ID: 9234370727 Enrollment ID: I20140527001871 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Muhammad Furqan |
---|---|
Provider Type | Practitioner - Medical Oncology |
Provider Identifiers | NPI Number: 1306090220 PECOS PAC ID: 3678796281 Enrollment ID: I20140529002082 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | David J Gordon |
---|---|
Provider Type | Practitioner - Hematology/oncology |
Provider Identifiers | NPI Number: 1336321330 PECOS PAC ID: 6507999323 Enrollment ID: I20140606001036 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Derek J Zhorne |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1134428451 PECOS PAC ID: 9436323821 Enrollment ID: I20140606001808 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Thomas W Woodward |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1932137353 PECOS PAC ID: 0648337758 Enrollment ID: I20140617002108 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Leah M Zhorne |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1639483407 PECOS PAC ID: 9830331552 Enrollment ID: I20140618001178 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Naomi H Rodgers |
---|---|
Provider Type | Practitioner - Qualified Speech Language Pathologist |
Provider Identifiers | NPI Number: 1336406537 PECOS PAC ID: 9830313592 Enrollment ID: I20140619000879 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sara Nesler |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1467460238 PECOS PAC ID: 8123025749 Enrollment ID: I20140625000350 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amanda C Elliott |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1972739894 PECOS PAC ID: 3072753524 Enrollment ID: I20140626000136 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jesus Gonzalez Bosquet |
---|---|
Provider Type | Practitioner - Gynecological Oncology |
Provider Identifiers | NPI Number: 1427023175 PECOS PAC ID: 5294707147 Enrollment ID: I20140627001722 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Samantha M Schutt |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1700207008 PECOS PAC ID: 3971728346 Enrollment ID: I20140627001876 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Erin R Howe |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1104118892 PECOS PAC ID: 4183864283 Enrollment ID: I20140630000228 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Yousef N Zakharia |
---|---|
Provider Type | Practitioner - Hematology/oncology |
Provider Identifiers | NPI Number: 1871756163 PECOS PAC ID: 1557509254 Enrollment ID: I20140708000927 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brigit E Ray |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1396038261 PECOS PAC ID: 8224279468 Enrollment ID: I20140709001094 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Meredith L Fishbane-gordon |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1417165614 PECOS PAC ID: 4284859836 Enrollment ID: I20140715002110 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Daniel P Runde |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1255567095 PECOS PAC ID: 1052561149 Enrollment ID: I20140716000807 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Anthony N Snow |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1891958245 PECOS PAC ID: 2062638695 Enrollment ID: I20140717000258 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Erik C Milbrandt |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1437565793 PECOS PAC ID: 7618193145 Enrollment ID: I20140718001339 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Susan M Duffy |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1851509749 PECOS PAC ID: 6507904927 Enrollment ID: I20140724001166 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Diana K Bayer-bowstead |
---|---|
Provider Type | Practitioner - Allergy/immunology |
Provider Identifiers | NPI Number: 1730318205 PECOS PAC ID: 5193941995 Enrollment ID: I20140731001950 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Spas V Kotev |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1881879971 PECOS PAC ID: 7012134588 Enrollment ID: I20140806001339 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jacob H Shields |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1336450279 PECOS PAC ID: 6103040886 Enrollment ID: I20140811002719 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lauren M Ringe |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1285041871 PECOS PAC ID: 4284851213 Enrollment ID: I20140814001187 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jessie R Alex |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1801200530 PECOS PAC ID: 2961629944 Enrollment ID: I20140814002786 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Munir-zakary R Tanas |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1891805842 PECOS PAC ID: 2365589306 Enrollment ID: I20140815000335 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Carissa B Gunderson |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1760616437 PECOS PAC ID: 8921222316 Enrollment ID: I20140815000389 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lynn R Nelson |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1982019063 PECOS PAC ID: 2365669363 Enrollment ID: I20140815000553 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | John L Blau |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1871757690 PECOS PAC ID: 9133346141 Enrollment ID: I20140815000745 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael D Colburn |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1720370810 PECOS PAC ID: 6103066204 Enrollment ID: I20140818002502 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lillian M Erdahl |
---|---|
Provider Type | Practitioner - Surgical Oncology |
Provider Identifiers | NPI Number: 1336353705 PECOS PAC ID: 1557501749 Enrollment ID: I20140819000106 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kimberly S Delcour |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1932201597 PECOS PAC ID: 0648498329 Enrollment ID: I20140821000290 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alan E Gunderson |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1942404785 PECOS PAC ID: 4789870254 Enrollment ID: I20140825001025 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael C Willey |
---|---|
Provider Type | Practitioner - Orthopedic Surgery |
Provider Identifiers | NPI Number: 1598991085 PECOS PAC ID: 2860632163 Enrollment ID: I20140828001730 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jamie L Elizalde |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1104171511 PECOS PAC ID: 3779701099 Enrollment ID: I20140828001777 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael G Pomeroy |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1215202122 PECOS PAC ID: 0446478762 Enrollment ID: I20140828001938 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Katherine L Browne |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1609282862 PECOS PAC ID: 3577781731 Enrollment ID: I20140829001085 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mohamad Mokadem |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1386803187 PECOS PAC ID: 5496974305 Enrollment ID: I20140908001912 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Andrea E Achenbach |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1881975910 PECOS PAC ID: 5698994523 Enrollment ID: I20140908002460 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Patrick O Oben |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1255617700 PECOS PAC ID: 4082833769 Enrollment ID: I20140910002449 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jamison D Prickett |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1861808602 PECOS PAC ID: 7012136500 Enrollment ID: I20140916000312 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Abbey S Merryman |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1487972451 PECOS PAC ID: 9638398134 Enrollment ID: I20140916000757 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Shilpa C Balikai |
---|---|
Provider Type | Practitioner - Critical Care (intensivists) |
Provider Identifiers | NPI Number: 1720265044 PECOS PAC ID: 8022237338 Enrollment ID: I20140918002550 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Heather R Elmore |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1265832323 PECOS PAC ID: 1355560400 Enrollment ID: I20140922002756 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amy L Wilson |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1629486592 PECOS PAC ID: 8123248051 Enrollment ID: I20140927000328 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael Mural |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1346675477 PECOS PAC ID: 7012149495 Enrollment ID: I20141002001459 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Howard Jeffrey Cowen |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1073617072 PECOS PAC ID: 5597985929 Enrollment ID: I20141006001995 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Santiago Ortega Gutierrez |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1629148010 PECOS PAC ID: 4082746482 Enrollment ID: I20141007001188 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Poorani Sekar |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1740441807 PECOS PAC ID: 8820222391 Enrollment ID: I20141014002424 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Heather Kowalski |
---|---|
Provider Type | Practitioner - Orthopedic Surgery |
Provider Identifiers | NPI Number: 1386809374 PECOS PAC ID: 8123249281 Enrollment ID: I20141015000981 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jennifer Elizabeth Hartshorn |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1912252420 PECOS PAC ID: 4385865179 Enrollment ID: I20141020002025 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kevin M Mcgrane |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1316355985 PECOS PAC ID: 1759502354 Enrollment ID: I20141023002570 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Daniel Caplan |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1205840287 PECOS PAC ID: 6406077015 Enrollment ID: I20141024000215 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amy L Bradley |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1427450378 PECOS PAC ID: 1456572981 Enrollment ID: I20141024001728 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rolando Sanchez Sanchez |
---|---|
Provider Type | Practitioner - Critical Care (intensivists) |
Provider Identifiers | NPI Number: 1043455215 PECOS PAC ID: 5395966733 Enrollment ID: I20141028001202 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lovkesh Arora |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1700029857 PECOS PAC ID: 3476774811 Enrollment ID: I20141028001242 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kristin J Carne |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1710244652 PECOS PAC ID: 2567684723 Enrollment ID: I20141104001410 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rachel Beiler-funmilayo |
---|---|
Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
Provider Identifiers | NPI Number: 1467854018 PECOS PAC ID: 7012139041 Enrollment ID: I20141106002242 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Annalisa M Cochran |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1144623422 PECOS PAC ID: 3072735927 Enrollment ID: I20141110002189 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rahul Rastogi |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1811913031 PECOS PAC ID: 7618008160 Enrollment ID: I20141119000899 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nicole H Goff |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1912345844 PECOS PAC ID: 2365664711 Enrollment ID: I20141119001478 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | April Np Schmitz |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1558764449 PECOS PAC ID: 6002038478 Enrollment ID: I20141119002204 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Surangama Sharma |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1124349857 PECOS PAC ID: 5597987974 Enrollment ID: I20141119002485 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rebecca L Mccann |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1417350257 PECOS PAC ID: 5698097632 Enrollment ID: I20141203000166 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Prerna Rastogi |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1205064748 PECOS PAC ID: 7618299348 Enrollment ID: I20141208000111 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jennifer J Becker |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1679977482 PECOS PAC ID: 3476875121 Enrollment ID: I20141208001133 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Tassie A Carter |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1023399011 PECOS PAC ID: 3072836485 Enrollment ID: I20141216000281 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lori D Winborn |
---|---|
Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
Provider Identifiers | NPI Number: 1992846489 PECOS PAC ID: 0244553493 Enrollment ID: I20141219001703 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Andrea Nicole Weber |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1205194370 PECOS PAC ID: 9830339969 Enrollment ID: I20150105000741 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Gordon Buchanan |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1558543595 PECOS PAC ID: 8820275613 Enrollment ID: I20150106002087 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Samuel L Johnston |
---|---|
Provider Type | Practitioner - Cardiac Electrophysiology |
Provider Identifiers | NPI Number: 1184832271 PECOS PAC ID: 8527182245 Enrollment ID: I20150115000660 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lama Noureddine |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1013176817 PECOS PAC ID: 8527382654 Enrollment ID: I20150121001152 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alyaman Saeed |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1609820158 PECOS PAC ID: 1456333772 Enrollment ID: I20150121002045 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sindhura Allareddy |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1801190657 PECOS PAC ID: 6507180155 Enrollment ID: I20150130001342 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Molly E Heitman |
---|---|
Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
Provider Identifiers | NPI Number: 1043616691 PECOS PAC ID: 3173848314 Enrollment ID: I20150211001464 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Julia N Freel |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1053718437 PECOS PAC ID: 8628394319 Enrollment ID: I20150223000944 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jaime E Bonner |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1649669698 PECOS PAC ID: 7719203025 Enrollment ID: I20150304001476 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Elizabeth J Miller |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1982005096 PECOS PAC ID: 8628394863 Enrollment ID: I20150305000229 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jennifer J Coreas |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1780072678 PECOS PAC ID: 6507182755 Enrollment ID: I20150305000559 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Anjali A Sharathkumar |
---|---|
Provider Type | Practitioner - Hematology/oncology |
Provider Identifiers | NPI Number: 1194945691 PECOS PAC ID: 4385668805 Enrollment ID: I20150421000506 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rup K Sainju |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1033362504 PECOS PAC ID: 8820317712 Enrollment ID: I20150427001277 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amer El Sayed |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1457745937 PECOS PAC ID: 2466771142 Enrollment ID: I20150430001024 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ali S Nasr |
---|---|
Provider Type | Practitioner - Cardiac Surgery |
Provider Identifiers | NPI Number: 1417221524 PECOS PAC ID: 1355660036 Enrollment ID: I20150430001092 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Tahuanty A Pena |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1790986925 PECOS PAC ID: 5698953404 Enrollment ID: I20150513000958 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Charles A Rappaport |
---|---|
Provider Type | Practitioner - Critical Care (intensivists) |
Provider Identifiers | NPI Number: 1528326089 PECOS PAC ID: 7416277538 Enrollment ID: I20150513001100 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Temitope M Awelewa |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1194012815 PECOS PAC ID: 2769702885 Enrollment ID: I20150513001161 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Hanna Stevens |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1255528196 PECOS PAC ID: 1254409584 Enrollment ID: I20150513001245 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Spyridon Fortis |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1831329630 PECOS PAC ID: 4981924016 Enrollment ID: I20150513001447 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | John A Bernat |
---|---|
Provider Type | Practitioner - Medical Genetics And Genomics |
Provider Identifiers | NPI Number: 1609003011 PECOS PAC ID: 3779803762 Enrollment ID: I20150514001076 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Daniel J Livorsi |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1720240237 PECOS PAC ID: 6305024225 Enrollment ID: I20150518001403 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Elaine Michele Binkley |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1114219078 PECOS PAC ID: 8325289143 Enrollment ID: I20150520001385 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Anthony J Fischer |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1952539447 PECOS PAC ID: 2567783327 Enrollment ID: I20150604001735 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Raul A Villacreses Rada |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1386901817 PECOS PAC ID: 2466773221 Enrollment ID: I20150604001757 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jeydith Traeger Gutierrez |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1982968830 PECOS PAC ID: 4183945777 Enrollment ID: I20150608002461 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Stephanie J Chen |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1891080032 PECOS PAC ID: 0648591131 Enrollment ID: I20150609002552 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Shona S Lenss |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1497728240 PECOS PAC ID: 3072702414 Enrollment ID: I20150611002516 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ilonka D Molano De Pena |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1407051030 PECOS PAC ID: 4587893060 Enrollment ID: I20150616001568 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Wendy L Fiordellisi |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1982962122 PECOS PAC ID: 1951612761 Enrollment ID: I20150622000053 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jeniece M Nott |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1093941460 PECOS PAC ID: 1557501053 Enrollment ID: I20150624000413 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lindsey G Behrens |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1568843910 PECOS PAC ID: 8729399100 Enrollment ID: I20150626000202 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Emily Lanzel |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1497002620 PECOS PAC ID: 7911219167 Enrollment ID: I20150701001289 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Caryn M Berkowitz |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1780625301 PECOS PAC ID: 6002900669 Enrollment ID: I20150702001541 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Douglas Edward Kendrick |
---|---|
Provider Type | Practitioner - Maxillofacial Surgery |
Provider Identifiers | NPI Number: 1245550003 PECOS PAC ID: 4082926704 Enrollment ID: I20150708001991 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Emily K Hill |
---|---|
Provider Type | Practitioner - Gynecological Oncology |
Provider Identifiers | NPI Number: 1487984589 PECOS PAC ID: 4486966173 Enrollment ID: I20150709000928 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bradley L Manning |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1881642049 PECOS PAC ID: 1052495801 Enrollment ID: I20150709001098 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jason M Misurac |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1205061900 PECOS PAC ID: 9739326141 Enrollment ID: I20150710000604 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sarah A Shaffer |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1336312560 PECOS PAC ID: 3375708217 Enrollment ID: I20150714002201 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lauren M Partyka |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1750692976 PECOS PAC ID: 8426361627 Enrollment ID: I20150716002827 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Pavlina S Kemp |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1780900597 PECOS PAC ID: 4082854211 Enrollment ID: I20150723007138 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Julia S Shelton |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1871640698 PECOS PAC ID: 2961715628 Enrollment ID: I20150723009039 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Karen N Bryant |
---|---|
Provider Type | Practitioner - Qualified Speech Language Pathologist |
Provider Identifiers | NPI Number: 1962656710 PECOS PAC ID: 6507170172 Enrollment ID: I20150728003640 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Wesley R Benn |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1174905772 PECOS PAC ID: 5496069619 Enrollment ID: I20150731016975 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Allan Michael Andersen |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1457524332 PECOS PAC ID: 3870743438 Enrollment ID: I20150803001455 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Anu Subramanian |
---|---|
Provider Type | Practitioner - Qualified Speech Language Pathologist |
Provider Identifiers | NPI Number: 1265612626 PECOS PAC ID: 2769797448 Enrollment ID: I20150811004308 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Philip Chen |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1861781049 PECOS PAC ID: 0648585158 Enrollment ID: I20150812008832 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lauren Coyne |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1063724979 PECOS PAC ID: 3375794316 Enrollment ID: I20150813009562 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Irena Gribovskaja-rupp |
---|---|
Provider Type | Practitioner - Colorectal Surgery (proctology) |
Provider Identifiers | NPI Number: 1659494482 PECOS PAC ID: 2264747609 Enrollment ID: I20150814012988 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bianca A Strack |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1124400221 PECOS PAC ID: 9537474838 Enrollment ID: I20150817000123 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sarina M Martini |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1548559701 PECOS PAC ID: 4688989726 Enrollment ID: I20150818005216 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Samuel Gallo |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1578944724 PECOS PAC ID: 3678889375 Enrollment ID: I20150826000252 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bradley W Zeithamel |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1568768752 PECOS PAC ID: 4486960119 Enrollment ID: I20150826001044 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kelly L Preuninger |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1417339755 PECOS PAC ID: 0244546984 Enrollment ID: I20150826001666 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Cody R Tigges |
---|---|
Provider Type | Practitioner - Critical Care (intensivists) |
Provider Identifiers | NPI Number: 1043474505 PECOS PAC ID: 4688844335 Enrollment ID: I20150826001700 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alina V Dumitrescu |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1942442231 PECOS PAC ID: 2365758869 Enrollment ID: I20150828001349 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | David R Sheff |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1508111402 PECOS PAC ID: 2668610338 Enrollment ID: I20150901000084 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kecia Suzanne Leary |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1902923576 PECOS PAC ID: 9335455583 Enrollment ID: I20150902001170 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Matthew J Landherr |
---|---|
Provider Type | Practitioner - Dermatology |
Provider Identifiers | NPI Number: 1033554498 PECOS PAC ID: 3870809098 Enrollment ID: I20150903000111 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Fatma Simsek-duran |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1528353208 PECOS PAC ID: 2365685294 Enrollment ID: I20150903000532 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kelly M Vinquist |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1558641753 PECOS PAC ID: 9133436835 Enrollment ID: I20150914000143 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Benjamin P Davis |
---|---|
Provider Type | Practitioner - Allergy/immunology |
Provider Identifiers | NPI Number: 1467616326 PECOS PAC ID: 1052542891 Enrollment ID: I20150914000260 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sara E Wertz |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1053756270 PECOS PAC ID: 8325355522 Enrollment ID: I20150921002704 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Tacie Clark |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1346685757 PECOS PAC ID: 0648587840 Enrollment ID: I20150921002867 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alyssa M Donahue |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1245606193 PECOS PAC ID: 6800104704 Enrollment ID: I20150925001373 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Andrew Pugely |
---|---|
Provider Type | Practitioner - Orthopedic Surgery |
Provider Identifiers | NPI Number: 1508185521 PECOS PAC ID: 3971742289 Enrollment ID: I20150928000190 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Anna M Arens |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1639470511 PECOS PAC ID: 7113235912 Enrollment ID: I20150928002585 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ina Bardhoshi |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1992106587 PECOS PAC ID: 1951521368 Enrollment ID: I20151006002358 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kimberly J Hart |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1891030557 PECOS PAC ID: 7113151333 Enrollment ID: I20151006002853 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sarah C Dailey |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1902241847 PECOS PAC ID: 7810205192 Enrollment ID: I20151006002970 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lesley J Haro |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1891808697 PECOS PAC ID: 8628214137 Enrollment ID: I20151014000332 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Cara Drew |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1699189639 PECOS PAC ID: 5294951661 Enrollment ID: I20151014002554 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Allison C Voss |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1881064665 PECOS PAC ID: 8022327881 Enrollment ID: I20151016001450 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Edgar A Samaniego |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1093771511 PECOS PAC ID: 3971776410 Enrollment ID: I20151016001915 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Dana L Lotempio |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1295104446 PECOS PAC ID: 8921317496 Enrollment ID: I20151023000254 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Eva G Schoen |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1194122127 PECOS PAC ID: 4385953850 Enrollment ID: I20151023000270 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sarah M Fees |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1104293570 PECOS PAC ID: 8820307093 Enrollment ID: I20151029001132 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lynette P Cooper |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1972973881 PECOS PAC ID: 9133438310 Enrollment ID: I20151029001412 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Emily S Rockafellow |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1477922052 PECOS PAC ID: 5294045977 Enrollment ID: I20151109001857 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alexander W Thompson |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1740380922 PECOS PAC ID: 8921005042 Enrollment ID: I20151110002267 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Susan Joy |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1629446521 PECOS PAC ID: 8729398383 Enrollment ID: I20151110003047 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Carlos H Chan |
---|---|
Provider Type | Practitioner - Surgical Oncology |
Provider Identifiers | NPI Number: 1659711661 PECOS PAC ID: 4587808696 Enrollment ID: I20151120000109 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brian J Howe |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1003945437 PECOS PAC ID: 7911207055 Enrollment ID: I20151123000645 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Shannon M Kussatz |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1255701660 PECOS PAC ID: 2961702782 Enrollment ID: I20151201001511 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sandra K Koppes |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1891167367 PECOS PAC ID: 7214237858 Enrollment ID: I20151203001353 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jamie S Hada |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1093188872 PECOS PAC ID: 2466752811 Enrollment ID: I20151208000565 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Maia H Hightower |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1770603946 PECOS PAC ID: 5294822177 Enrollment ID: I20151208001582 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Tomohiro Tanaka |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1184098667 PECOS PAC ID: 5395046353 Enrollment ID: I20151216000540 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Saima Sharif |
---|---|
Provider Type | Practitioner - Medical Oncology |
Provider Identifiers | NPI Number: 1548258940 PECOS PAC ID: 1850311366 Enrollment ID: I20151228000447 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Cynthia A Wong |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1790703882 PECOS PAC ID: 1456263722 Enrollment ID: I20151228000868 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Heidi A Rossow |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1134591829 PECOS PAC ID: 7315248903 Enrollment ID: I20151228000882 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lane Strathearn |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1487734828 PECOS PAC ID: 8729051966 Enrollment ID: I20160129002379 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mehul R Adhaduk |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1649534769 PECOS PAC ID: 7214168897 Enrollment ID: I20160201000363 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sara D Spiva |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1053727487 PECOS PAC ID: 7810115458 Enrollment ID: I20160208000370 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael S Hoffman |
---|---|
Provider Type | Practitioner - Critical Care (intensivists) |
Provider Identifiers | NPI Number: 1124310172 PECOS PAC ID: 9335365642 Enrollment ID: I20160209001402 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amber L Goodrich |
---|---|
Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
Provider Identifiers | NPI Number: 1043676166 PECOS PAC ID: 5890090658 Enrollment ID: I20160217000256 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Steven Michael Kelly |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1821178377 PECOS PAC ID: 8729383385 Enrollment ID: I20160219001910 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Danielle R Sparks |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1083935480 PECOS PAC ID: 1456657857 Enrollment ID: I20160310002383 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Teresa Hoffman |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1477578615 PECOS PAC ID: 7315952504 Enrollment ID: I20160420001174 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Stephanie M Atkinson |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1891157285 PECOS PAC ID: 1557660578 Enrollment ID: I20160426001151 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Aditya V Badheka |
---|---|
Provider Type | Practitioner - Critical Care (intensivists) |
Provider Identifiers | NPI Number: 1467712869 PECOS PAC ID: 7214176809 Enrollment ID: I20160505000997 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Haleigh M Skaggs |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1619336856 PECOS PAC ID: 6002105368 Enrollment ID: I20160510002069 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brandy M Leclere |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1932563061 PECOS PAC ID: 6800185042 Enrollment ID: I20160511002299 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Timothy W Thomsen |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1063770097 PECOS PAC ID: 7911146493 Enrollment ID: I20160512000392 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Shruti N Tewar |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1477787638 PECOS PAC ID: 8729377858 Enrollment ID: I20160512002330 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Vesselin T Tenev |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1104105139 PECOS PAC ID: 0244470342 Enrollment ID: I20160513000107 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Archit Sharma |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1174753503 PECOS PAC ID: 2163646118 Enrollment ID: I20160517001427 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nanette J Brokaw |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1790120673 PECOS PAC ID: 6800036450 Enrollment ID: I20160523002601 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ana A Cary |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1902032444 PECOS PAC ID: 7315236734 Enrollment ID: I20160525000235 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lyndsay A Harshman |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1730473315 PECOS PAC ID: 8022258284 Enrollment ID: I20160525000314 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alpheus B Appenheimer |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1083932909 PECOS PAC ID: 0547403677 Enrollment ID: I20160525001247 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Katherine D Patrick |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1649533092 PECOS PAC ID: 6800025677 Enrollment ID: I20160602001344 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rashi Khanna |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1518308840 PECOS PAC ID: 2264721026 Enrollment ID: I20160603000348 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Emily F Morton |
---|---|
Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
Provider Identifiers | NPI Number: 1598190035 PECOS PAC ID: 9830489756 Enrollment ID: I20160606002131 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Takashi S Sato |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1023245115 PECOS PAC ID: 8123266038 Enrollment ID: I20160607001800 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Dionne Fan Peacher |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1669797577 PECOS PAC ID: 0446474845 Enrollment ID: I20160608002396 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Carly A Kuehn |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1073952883 PECOS PAC ID: 1658515630 Enrollment ID: I20160609000095 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Christopher Scott Nance |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1649370065 PECOS PAC ID: 7315977931 Enrollment ID: I20160615000158 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sangil Lee |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1003022237 PECOS PAC ID: 8123143450 Enrollment ID: I20160615002301 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Christopher S Strouse |
---|---|
Provider Type | Practitioner - Hematology/oncology |
Provider Identifiers | NPI Number: 1295078533 PECOS PAC ID: 4082933312 Enrollment ID: I20160616001002 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Hanna D Zembrzuska |
---|---|
Provider Type | Practitioner - Rheumatology |
Provider Identifiers | NPI Number: 1336346352 PECOS PAC ID: 8921288069 Enrollment ID: I20160623000807 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Andrew J Feider |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1245551555 PECOS PAC ID: 9537318548 Enrollment ID: I20160705001270 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Chandrikha Chandrasekharan |
---|---|
Provider Type | Practitioner - Medical Oncology |
Provider Identifiers | NPI Number: 1780814491 PECOS PAC ID: 9436306685 Enrollment ID: I20160705001431 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nathan M Blair |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1164711511 PECOS PAC ID: 4880906932 Enrollment ID: I20160706001157 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Stephanie M Radke |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1497989784 PECOS PAC ID: 7012134224 Enrollment ID: I20160708001863 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Esperanza G Ingersoll Weng |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1477550424 PECOS PAC ID: 9335040849 Enrollment ID: I20160708001991 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brandy L Mitchell |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1295973444 PECOS PAC ID: 8022202779 Enrollment ID: I20160708002034 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joshua B Radke |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1700014453 PECOS PAC ID: 4183888456 Enrollment ID: I20160711001159 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Elayne J Gustoff |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1154779361 PECOS PAC ID: 2961794060 Enrollment ID: I20160711001834 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Justin G Wikle |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1912292152 PECOS PAC ID: 3678865631 Enrollment ID: I20160712001542 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jessica R Thomas |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1467802124 PECOS PAC ID: 1850683830 Enrollment ID: I20160712001882 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Stephanie L Stauffer |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1609160548 PECOS PAC ID: 7618110628 Enrollment ID: I20160715001620 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Melissa S Willis |
---|---|
Provider Type | Practitioner - Dermatology |
Provider Identifiers | NPI Number: 1386902682 PECOS PAC ID: 3274775457 Enrollment ID: I20160720002174 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | D Anand Rajan Kanagasabapathy |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1548540834 PECOS PAC ID: 7618260191 Enrollment ID: I20160720002436 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Aaron D Boes |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1770880387 PECOS PAC ID: 4981862349 Enrollment ID: I20160725000321 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Patrick William Mcgonagill |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1639497530 PECOS PAC ID: 1557681582 Enrollment ID: I20160725000842 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Erica M Carlisle |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1649508037 PECOS PAC ID: 1658674080 Enrollment ID: I20160728000923 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Channa Z Davenport |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1932559275 PECOS PAC ID: 0244523157 Enrollment ID: I20160728002232 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Marcelo L Correia |
---|---|
Provider Type | Practitioner - Endocrinology |
Provider Identifiers | NPI Number: 1235421140 PECOS PAC ID: 8628208964 Enrollment ID: I20160803001421 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brian T Oneill |
---|---|
Provider Type | Practitioner - Endocrinology |
Provider Identifiers | NPI Number: 1477720357 PECOS PAC ID: 3971744426 Enrollment ID: I20160803003056 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Catherina T Pinnaro |
---|---|
Provider Type | Practitioner - Endocrinology |
Provider Identifiers | NPI Number: 1487091518 PECOS PAC ID: 3476796558 Enrollment ID: I20160805001923 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Aaron R Kunz |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1609119791 PECOS PAC ID: 8921327735 Enrollment ID: I20160808000238 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joseph D Boysen |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1215959432 PECOS PAC ID: 3971897075 Enrollment ID: I20160812000639 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ian Han |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1285861187 PECOS PAC ID: 2668622028 Enrollment ID: I20160812001094 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Susan A Shea |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1356791610 PECOS PAC ID: 0840585444 Enrollment ID: I20160822001388 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ann E Killoran |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1619196565 PECOS PAC ID: 1456506997 Enrollment ID: I20160822001736 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Christina J L Michels |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1174974315 PECOS PAC ID: 2961797576 Enrollment ID: I20160822001880 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kaytee L Knoop |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1770934671 PECOS PAC ID: 8123313764 Enrollment ID: I20160822002731 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kelcee K Jarrard |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1558711465 PECOS PAC ID: 7315232584 Enrollment ID: I20160826001462 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Chiranjeev Saha |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1699921684 PECOS PAC ID: 8325234289 Enrollment ID: I20160829003243 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bijoy D Thattaliyath |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1043482912 PECOS PAC ID: 9032404090 Enrollment ID: I20160830000975 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sneha D Phadke |
---|---|
Provider Type | Practitioner - Medical Oncology |
Provider Identifiers | NPI Number: 1437460482 PECOS PAC ID: 3072803634 Enrollment ID: I20160901000415 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Megan J Greve |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1275985848 PECOS PAC ID: 0042506149 Enrollment ID: I20160915000387 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Cheryl M Byrnes |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1861844516 PECOS PAC ID: 7012203169 Enrollment ID: I20160915001874 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jessie T Koch |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1649623091 PECOS PAC ID: 7214224161 Enrollment ID: I20160921001406 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Yumi Imai |
---|---|
Provider Type | Practitioner - Endocrinology |
Provider Identifiers | NPI Number: 1376634543 PECOS PAC ID: 2860476421 Enrollment ID: I20160926001487 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lindsey K Kudej |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1891105250 PECOS PAC ID: 5193012797 Enrollment ID: I20160926001578 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kristin A Hansen |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1134539505 PECOS PAC ID: 8628365913 Enrollment ID: I20160930000691 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sara Defurio |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1205380524 PECOS PAC ID: 1951699842 Enrollment ID: I20161010000269 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kathleen L Wild |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1649248378 PECOS PAC ID: 3476841040 Enrollment ID: I20161013002294 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Shandi A Peters |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1437569894 PECOS PAC ID: 9638467210 Enrollment ID: I20161014000033 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Christine M Harlander |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1205380110 PECOS PAC ID: 1456649037 Enrollment ID: I20161014000034 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brady J Thomas |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1306158456 PECOS PAC ID: 7113165325 Enrollment ID: I20161017002044 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Katherine Hadlandsmyth |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1003363227 PECOS PAC ID: 7618265091 Enrollment ID: I20161018002189 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael H Tomasson |
---|---|
Provider Type | Practitioner - Hematology |
Provider Identifiers | NPI Number: 1841216157 PECOS PAC ID: 2163556713 Enrollment ID: I20161018002427 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rachael M Stadlen |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1306296959 PECOS PAC ID: 9638457880 Enrollment ID: I20161024001203 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joyce L Chouinard |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1770033888 PECOS PAC ID: 8224316112 Enrollment ID: I20161027001550 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Hong Chen |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1760593669 PECOS PAC ID: 0345255527 Enrollment ID: I20161027001655 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Emily M Garcia |
---|---|
Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
Provider Identifiers | NPI Number: 1497205470 PECOS PAC ID: 5799063491 Enrollment ID: I20161101001105 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael Hajdu |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1912955683 PECOS PAC ID: 5496740169 Enrollment ID: I20161101002521 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joel Geerling |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1578706628 PECOS PAC ID: 3971739723 Enrollment ID: I20161102000399 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jenna M Nielsen |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1649723446 PECOS PAC ID: 2668750225 Enrollment ID: I20161102000478 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kristen Caraher |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1336697085 PECOS PAC ID: 6709164247 Enrollment ID: I20161103000840 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jin Zhou |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1902356330 PECOS PAC ID: 2567741481 Enrollment ID: I20161117001028 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jane K Rosen |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1558628495 PECOS PAC ID: 5890075865 Enrollment ID: I20161208001236 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Gena R Ghearing |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1154307114 PECOS PAC ID: 3870692106 Enrollment ID: I20161212002052 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Haley D Stoll |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1174862148 PECOS PAC ID: 7911287735 Enrollment ID: I20161213000426 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Samuel D Andrews |
---|---|
Provider Type | Practitioner - Radiation Oncology |
Provider Identifiers | NPI Number: 1851508337 PECOS PAC ID: 5496940181 Enrollment ID: I20170112000946 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mary Jean Haas |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1255779054 PECOS PAC ID: 3577794536 Enrollment ID: I20170118002096 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Matthew J Obrien |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1871805838 PECOS PAC ID: 1153603527 Enrollment ID: I20170119000663 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mahi L Ashwath |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1235154154 PECOS PAC ID: 0840263943 Enrollment ID: I20170120000513 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brian L Harlan |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1760579585 PECOS PAC ID: 4284656216 Enrollment ID: I20170202002619 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ali Jabbari |
---|---|
Provider Type | Practitioner - Dermatology |
Provider Identifiers | NPI Number: 1427258367 PECOS PAC ID: 6507050903 Enrollment ID: I20170203001312 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alindsey J Kramer |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1386095297 PECOS PAC ID: 0547543944 Enrollment ID: I20170209000648 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Linda Mcdermott |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1841297629 PECOS PAC ID: 6608159900 Enrollment ID: I20170213000315 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Megan G Heesch |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1982076295 PECOS PAC ID: 7416230727 Enrollment ID: I20170213000348 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amy M Hammerstrom |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1003103169 PECOS PAC ID: 5496039281 Enrollment ID: I20170222001564 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Emily E Morse |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1619394715 PECOS PAC ID: 3577789411 Enrollment ID: I20170227001254 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Julie C Lensing |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1588108138 PECOS PAC ID: 5193009348 Enrollment ID: I20170307001072 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Suzanne M Hennings |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1952308348 PECOS PAC ID: 2163481417 Enrollment ID: I20170307001195 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Marcia Campos |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1245699875 PECOS PAC ID: 1052696879 Enrollment ID: I20170317001485 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joseph A Buckwalter |
---|---|
Provider Type | Practitioner - Orthopedic Surgery |
Provider Identifiers | NPI Number: 1952693129 PECOS PAC ID: 1759521057 Enrollment ID: I20170324000324 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Robert W Westermann |
---|---|
Provider Type | Practitioner - Orthopedic Surgery |
Provider Identifiers | NPI Number: 1841585239 PECOS PAC ID: 4981844271 Enrollment ID: I20170324000341 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ann-marie H Berg |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1790769552 PECOS PAC ID: 6800171182 Enrollment ID: I20170329001017 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Karen I Hammes |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1154868149 PECOS PAC ID: 7517243256 Enrollment ID: I20170413000125 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jimmy J Windsor |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1255380523 PECOS PAC ID: 9436142205 Enrollment ID: I20170426001457 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joseph T Kowalski |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1487975918 PECOS PAC ID: 8628218799 Enrollment ID: I20170509001152 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Shannon L Findlay |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1578975645 PECOS PAC ID: 0749406171 Enrollment ID: I20170509001261 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Grerk Sutamtewagul |
---|---|
Provider Type | Practitioner - Hematology |
Provider Identifiers | NPI Number: 1003103383 PECOS PAC ID: 4789961376 Enrollment ID: I20170509001389 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sudeepta Dandapat |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1073801882 PECOS PAC ID: 8527206044 Enrollment ID: I20170511000077 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kunatum Prasidthrathsint |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1417268244 PECOS PAC ID: 3870735632 Enrollment ID: I20170511001664 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Scott T Larson |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1639516685 PECOS PAC ID: 7911137229 Enrollment ID: I20170517002460 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brooks J Obr |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1528479060 PECOS PAC ID: 1557587912 Enrollment ID: I20170526000171 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jaclyn M Haugsdal |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1134567498 PECOS PAC ID: 3779727771 Enrollment ID: I20170601002615 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jarrett E Walsh |
---|---|
Provider Type | Practitioner - Otolaryngology |
Provider Identifiers | NPI Number: 1104110709 PECOS PAC ID: 7315187242 Enrollment ID: I20170609000779 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Katie S Melton |
---|---|
Provider Type | Practitioner - Hospice/palliative Care |
Provider Identifiers | NPI Number: 1184982613 PECOS PAC ID: 4385913847 Enrollment ID: I20170627002199 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alejandro A Pezzulo Colmenares |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1942569355 PECOS PAC ID: 2668699158 Enrollment ID: I20170630000916 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Maria A Pawlak |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1467691477 PECOS PAC ID: 0547539801 Enrollment ID: I20170630001097 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Gina M Lockwood |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1962727750 PECOS PAC ID: 2365744968 Enrollment ID: I20170717000100 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Marco M Hefti |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1568600468 PECOS PAC ID: 6103196688 Enrollment ID: I20170717000204 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Georgina M Aldridge |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1053750802 PECOS PAC ID: 3173757788 Enrollment ID: I20170717001301 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Natasha L Madhoo Reynolds |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1811309107 PECOS PAC ID: 2769608751 Enrollment ID: I20170718001044 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Stephanie Jane Houston |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1235497090 PECOS PAC ID: 0941440069 Enrollment ID: I20170718001953 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joseph M Caster |
---|---|
Provider Type | Practitioner - Radiation Oncology |
Provider Identifiers | NPI Number: 1033470604 PECOS PAC ID: 1759505811 Enrollment ID: I20170719002166 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nathaniel C Sears |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1306103577 PECOS PAC ID: 5597055798 Enrollment ID: I20170719003139 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nicholas Thomas Trapp |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1093155400 PECOS PAC ID: 0941438972 Enrollment ID: I20170721001414 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael L Haugsdal |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1073951059 PECOS PAC ID: 1254574866 Enrollment ID: I20170721001745 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Aaron Daniel Figueroa |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1508124785 PECOS PAC ID: 9931493913 Enrollment ID: I20170727000055 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brittany A Bettendorf |
---|---|
Provider Type | Practitioner - Rheumatology |
Provider Identifiers | NPI Number: 1487943908 PECOS PAC ID: 7214256775 Enrollment ID: I20170727003098 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Paul Thomas Gellhaus |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1104113117 PECOS PAC ID: 8729223268 Enrollment ID: I20170727003165 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Yuya Hagiwara |
---|---|
Provider Type | Practitioner - Hospice/palliative Care |
Provider Identifiers | NPI Number: 1083811087 PECOS PAC ID: 8527155977 Enrollment ID: I20170727003286 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Anureet K Walia |
---|---|
Provider Type | Practitioner - Pain Management |
Provider Identifiers | NPI Number: 1376821116 PECOS PAC ID: 2163653775 Enrollment ID: I20170728001502 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Krista R Davidson |
---|---|
Provider Type | Practitioner - Qualified Speech Language Pathologist |
Provider Identifiers | NPI Number: 1699295865 PECOS PAC ID: 9638440373 Enrollment ID: I20170731000231 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lauren M Thomann |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1730609629 PECOS PAC ID: 5193096709 Enrollment ID: I20170731003539 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ashley N Evans |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1821527862 PECOS PAC ID: 3072884626 Enrollment ID: I20170801001492 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Allison M Boardman |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1700224136 PECOS PAC ID: 6507187192 Enrollment ID: I20170807001824 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael Alan Strong |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1699153098 PECOS PAC ID: 3173835071 Enrollment ID: I20170808000376 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ashley Umoren |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1437671120 PECOS PAC ID: 7315218229 Enrollment ID: I20170810000421 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Avraham D Levin |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1982096632 PECOS PAC ID: 6103197017 Enrollment ID: I20170810000606 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amalia Gedney-lose |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1245751833 PECOS PAC ID: 0840561775 Enrollment ID: I20170810001393 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Stephany L Walk |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1275055212 PECOS PAC ID: 7113298985 Enrollment ID: I20170814000336 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joseph A Kussatz |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1487175691 PECOS PAC ID: 8527339399 Enrollment ID: I20170814000516 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Douglas A Powell |
---|---|
Provider Type | Practitioner - Interventional Radiology |
Provider Identifiers | NPI Number: 1356310387 PECOS PAC ID: 5890608137 Enrollment ID: I20170816003500 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mariko Hagiwara |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1679899157 PECOS PAC ID: 6103054952 Enrollment ID: I20170824001985 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lanae D Gibson |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1720508310 PECOS PAC ID: 9436421534 Enrollment ID: I20170824002068 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kirstin M Brainard |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1669997268 PECOS PAC ID: 6709158801 Enrollment ID: I20170824002088 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lisa M Mertens |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1851830459 PECOS PAC ID: 1153693262 Enrollment ID: I20170824002119 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Valerie J Keffala |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1386781672 PECOS PAC ID: 5799057626 Enrollment ID: I20170828000682 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Carrie Mcknight |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1669576674 PECOS PAC ID: 6002189925 Enrollment ID: I20170829000304 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bilal G Rahim |
---|---|
Provider Type | Practitioner - Hematology/oncology |
Provider Identifiers | NPI Number: 1568756682 PECOS PAC ID: 8022238542 Enrollment ID: I20170905001530 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Satoshi Yamaguchi |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1730604034 PECOS PAC ID: 2860765005 Enrollment ID: I20170908002982 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alpa Sidhu |
---|---|
Provider Type | Practitioner - Medical Genetics And Genomics |
Provider Identifiers | NPI Number: 1700015864 PECOS PAC ID: 6204159957 Enrollment ID: I20170908003119 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jun Xu |
---|---|
Provider Type | Practitioner - Vascular Surgery |
Provider Identifiers | NPI Number: 1144541681 PECOS PAC ID: 6507139649 Enrollment ID: I20170912000710 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Laura E Langholdt |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1053832626 PECOS PAC ID: 1951675800 Enrollment ID: I20170915003131 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sima M Tran |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1336665751 PECOS PAC ID: 9931473881 Enrollment ID: I20170915003197 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Trang L Duong |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1073033619 PECOS PAC ID: 4486928330 Enrollment ID: I20170915003206 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Breanne M Orr |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1821515602 PECOS PAC ID: 5294009148 Enrollment ID: I20170915003239 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Anne K Nielsen |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1558883769 PECOS PAC ID: 9739453689 Enrollment ID: I20170915003263 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bharat Kumar |
---|---|
Provider Type | Practitioner - Rheumatology |
Provider Identifiers | NPI Number: 1952694309 PECOS PAC ID: 6901022607 Enrollment ID: I20170915003265 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nabeel Y Hamzeh |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1437193745 PECOS PAC ID: 3779507512 Enrollment ID: I20170915003292 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Scott R Owen |
---|---|
Provider Type | Practitioner - Plastic And Reconstructive Surgery |
Provider Identifiers | NPI Number: 1255626685 PECOS PAC ID: 5890935753 Enrollment ID: I20170915003303 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Abey Eapen |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1437675550 PECOS PAC ID: 3072887942 Enrollment ID: I20170918000043 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Natalie E Brodersen |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1467430983 PECOS PAC ID: 8123392941 Enrollment ID: I20170918002339 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brendan C Patterson |
---|---|
Provider Type | Practitioner - Orthopedic Surgery |
Provider Identifiers | NPI Number: 1912226929 PECOS PAC ID: 3971897943 Enrollment ID: I20170921000655 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Anita Joseph Chazhikattu |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1104184126 PECOS PAC ID: 8729229596 Enrollment ID: I20170921002018 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jennifer Hutchinson |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1538699806 PECOS PAC ID: 6305110651 Enrollment ID: I20170925003478 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Tinu Bastian |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1790226629 PECOS PAC ID: 3779857867 Enrollment ID: I20170928002012 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Andrew C Potts |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1942725593 PECOS PAC ID: 9537434626 Enrollment ID: I20170928002329 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jennifer G Powers |
---|---|
Provider Type | Practitioner - Dermatology |
Provider Identifiers | NPI Number: 1831355627 PECOS PAC ID: 5698922219 Enrollment ID: I20171004001857 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Christopher Wolf |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1396195970 PECOS PAC ID: 6608162011 Enrollment ID: I20171009000684 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Cassandra K Palasiewicz |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1871017657 PECOS PAC ID: 1153697305 Enrollment ID: I20171017000192 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Aislinn J Williams |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1235440249 PECOS PAC ID: 8628381068 Enrollment ID: I20171017002532 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alycia L Elkins |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1952810178 PECOS PAC ID: 5496011728 Enrollment ID: I20171102001019 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Josiah An |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1053791517 PECOS PAC ID: 6406168145 Enrollment ID: I20171109003039 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brittany C Pechous |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1902317688 PECOS PAC ID: 8224394952 Enrollment ID: I20171113000871 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Marcio Leyser |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1811406838 PECOS PAC ID: 2769748490 Enrollment ID: I20171113000946 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Melanie A Wellington |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1619908191 PECOS PAC ID: 9032293816 Enrollment ID: I20171113001058 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Juanita M Buks |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1396260204 PECOS PAC ID: 6901162635 Enrollment ID: I20171113001150 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kyle J Ewald |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1538408638 PECOS PAC ID: 5597088344 Enrollment ID: I20171113001178 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Melissa L Swee |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1184919375 PECOS PAC ID: 3375760564 Enrollment ID: I20171113001362 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lauren A Garvin |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1407368780 PECOS PAC ID: 5799041489 Enrollment ID: I20171114000360 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lawrence D Horwitz |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1669562336 PECOS PAC ID: 4688651748 Enrollment ID: I20171115003580 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Fabricio B Teixeira |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1588788756 PECOS PAC ID: 1850574070 Enrollment ID: I20171122002346 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Chou-long Huang |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1396704425 PECOS PAC ID: 2668517798 Enrollment ID: I20171127000656 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Eleanor A Lingo |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1720597800 PECOS PAC ID: 1557628773 Enrollment ID: I20171127000903 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kristen J Eastlund |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1285143438 PECOS PAC ID: 3274890496 Enrollment ID: I20171127000940 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Diana Ibrahim Jalal |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1033142096 PECOS PAC ID: 0042266140 Enrollment ID: I20171127001863 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lauren Elizabeth Jensen |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1629484613 PECOS PAC ID: 6608133772 Enrollment ID: I20171127003235 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alisa Kindig |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1124440102 PECOS PAC ID: 0345545844 Enrollment ID: I20171204000118 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Damian J Krysan |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1942237763 PECOS PAC ID: 9335167634 Enrollment ID: I20171214000387 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Shirley K Johnson |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1336129816 PECOS PAC ID: 4688736523 Enrollment ID: I20171214000407 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Julie A Wieland |
---|---|
Provider Type | Practitioner - Qualified Audiologist |
Provider Identifiers | NPI Number: 1720594252 PECOS PAC ID: 5698033322 Enrollment ID: I20171229000416 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Shea L Becker |
---|---|
Provider Type | Practitioner - Qualified Audiologist |
Provider Identifiers | NPI Number: 1881100329 PECOS PAC ID: 5597023226 Enrollment ID: I20171229000461 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lynette M Rice |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1548770084 PECOS PAC ID: 3870851579 Enrollment ID: I20180102001132 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Maen S Aboul Hosn |
---|---|
Provider Type | Practitioner - Vascular Surgery |
Provider Identifiers | NPI Number: 1578962189 PECOS PAC ID: 6103045067 Enrollment ID: I20180103003070 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Diane L Eastman |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1699760314 PECOS PAC ID: 9638438252 Enrollment ID: I20180104001988 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jodie L Grout |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1063657369 PECOS PAC ID: 5799849618 Enrollment ID: I20180124002883 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Chaitra Mukundan |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1013265990 PECOS PAC ID: 9133488869 Enrollment ID: I20180125001515 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Martha O Herbst |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1659632230 PECOS PAC ID: 6507098381 Enrollment ID: I20180131000705 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kyle R Duchman |
---|---|
Provider Type | Practitioner - Orthopedic Surgery |
Provider Identifiers | NPI Number: 1609133107 PECOS PAC ID: 9133369424 Enrollment ID: I20180205000138 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mary P Greteman |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1053547471 PECOS PAC ID: 0143358473 Enrollment ID: I20180214002871 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sharon G Berkowitz |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1225065238 PECOS PAC ID: 9931137874 Enrollment ID: I20180215000166 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Robert J Blount |
---|---|
Provider Type | Practitioner - Critical Care (intensivists) |
Provider Identifiers | NPI Number: 1023154242 PECOS PAC ID: 9537053384 Enrollment ID: I20180215000286 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Hao P Tran |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1679664726 PECOS PAC ID: 2466347679 Enrollment ID: I20180216000248 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Miranda Kelly Maday |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1841590544 PECOS PAC ID: 5597026237 Enrollment ID: I20180221000599 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Thomas K Nickl-jockschat |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1740789734 PECOS PAC ID: 7517229370 Enrollment ID: I20180315001081 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Hildegard Janouschek |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1942702501 PECOS PAC ID: 9234491093 Enrollment ID: I20180315001133 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jessie L Baker |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1770091266 PECOS PAC ID: 3577825256 Enrollment ID: I20180316000067 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Abigail A Bartolo Costello |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1548666274 PECOS PAC ID: 4981962446 Enrollment ID: I20180320003151 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Megan M Dietzel |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1538676150 PECOS PAC ID: 4880956036 Enrollment ID: I20180328000090 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Umang Gupta |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1336346782 PECOS PAC ID: 1153592746 Enrollment ID: I20180328000098 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bruno Cavalcanti |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1023400132 PECOS PAC ID: 2860707759 Enrollment ID: I20180419001908 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Peter K Georgakakos |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1932588225 PECOS PAC ID: 7315259413 Enrollment ID: I20180420001946 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alka C Walter |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1831503564 PECOS PAC ID: 1951528488 Enrollment ID: I20180423001393 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mark Niciu |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1659534865 PECOS PAC ID: 7012271133 Enrollment ID: I20180425002276 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Matthew H Hogue |
---|---|
Provider Type | Practitioner - Orthopedic Surgery |
Provider Identifiers | NPI Number: 1619235561 PECOS PAC ID: 1052550530 Enrollment ID: I20180504000693 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brooke A Harrison |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1386145530 PECOS PAC ID: 3577827773 Enrollment ID: I20180515001783 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Elizabeth A Hynek |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1992208938 PECOS PAC ID: 6305100512 Enrollment ID: I20180515002233 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Heidi R Fincham |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1013414820 PECOS PAC ID: 8921362153 Enrollment ID: I20180515002866 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lisa M Harmon |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1629400122 PECOS PAC ID: 7315171055 Enrollment ID: I20180516000262 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jinha Park |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1811036619 PECOS PAC ID: 2365546934 Enrollment ID: I20180518001891 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jay Brooks Jackson |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1972542652 PECOS PAC ID: 5092848945 Enrollment ID: I20180518001906 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joshua B Holt |
---|---|
Provider Type | Practitioner - Orthopedic Surgery |
Provider Identifiers | NPI Number: 1073870572 PECOS PAC ID: 6507006665 Enrollment ID: I20180521000471 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Prompom Suksaranjit |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1154632982 PECOS PAC ID: 0143452805 Enrollment ID: I20180521002078 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nicole M Fleege |
---|---|
Provider Type | Practitioner - Hematology/oncology |
Provider Identifiers | NPI Number: 1609255991 PECOS PAC ID: 7416260807 Enrollment ID: I20180521002150 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rohit Unni Nair |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1912425943 PECOS PAC ID: 2264797273 Enrollment ID: I20180522002160 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Megan E Mcdonald |
---|---|
Provider Type | Practitioner - Gynecological Oncology |
Provider Identifiers | NPI Number: 1043505852 PECOS PAC ID: 4183863269 Enrollment ID: I20180523002766 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Carly Anne Theiler |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1114284775 PECOS PAC ID: 2961704713 Enrollment ID: I20180530001487 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Paul F Mazzocco |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1629199237 PECOS PAC ID: 4486842705 Enrollment ID: I20180604000821 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Christopher L Groth |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1447516083 PECOS PAC ID: 0042449621 Enrollment ID: I20180604002208 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Piriya Boonsiriphant |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1386012847 PECOS PAC ID: 7618232000 Enrollment ID: I20180606002087 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Richard Bruce Wagner |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1629014485 PECOS PAC ID: 0648535047 Enrollment ID: I20180606002527 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Heidi M Harmon |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1356541684 PECOS PAC ID: 8123115466 Enrollment ID: I20180607003182 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ion Syrbu |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1942610696 PECOS PAC ID: 5597010793 Enrollment ID: I20180612000537 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Xi Chen |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1194971879 PECOS PAC ID: 2668727868 Enrollment ID: I20180612000632 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kelly M Schieltz |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1811488943 PECOS PAC ID: 4385999549 Enrollment ID: I20180612003191 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sandra Guzmon-armstrong |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1386748036 PECOS PAC ID: 5496000523 Enrollment ID: I20180613002965 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Julie Christine Reynolds |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1073896536 PECOS PAC ID: 8022363167 Enrollment ID: I20180614000034 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kari E Maas |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1285792770 PECOS PAC ID: 2668727660 Enrollment ID: I20180614002791 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amy Barbara Lesch |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1639557028 PECOS PAC ID: 1759636541 Enrollment ID: I20180619002618 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Maria Marcela Hernandez |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1235233925 PECOS PAC ID: 4789939414 Enrollment ID: I20180620001059 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kevin C Tseng |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1215100144 PECOS PAC ID: 6204181936 Enrollment ID: I20180620001165 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mary Kay Hill |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1730477167 PECOS PAC ID: 9739434465 Enrollment ID: I20180620001225 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Marcos A Vargas |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1235233230 PECOS PAC ID: 6901151661 Enrollment ID: I20180620002123 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Josalyn Leah Olsen Cho |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1679554331 PECOS PAC ID: 4880617851 Enrollment ID: I20180627000673 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Erica C Teixeira |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1124395108 PECOS PAC ID: 7315293743 Enrollment ID: I20180627002285 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Zeina Al Salihi |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1376838524 PECOS PAC ID: 7719292895 Enrollment ID: I20180627002287 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Aubrey C Chan |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1700223971 PECOS PAC ID: 5193969152 Enrollment ID: I20180629002118 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mohammad Amarneh |
---|---|
Provider Type | Practitioner - Interventional Radiology |
Provider Identifiers | NPI Number: 1134437726 PECOS PAC ID: 4082854294 Enrollment ID: I20180630000024 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bashar H.h. Abuqayas |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1710474259 PECOS PAC ID: 3375899354 Enrollment ID: I20180705000833 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ana M Diaz-arnold |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1346344348 PECOS PAC ID: 5698021293 Enrollment ID: I20180712001640 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | David A Claassen |
---|---|
Provider Type | Practitioner - Hematology/oncology |
Provider Identifiers | NPI Number: 1871892455 PECOS PAC ID: 7618196205 Enrollment ID: I20180716002565 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Megan M Rohlf |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1275890709 PECOS PAC ID: 2264672369 Enrollment ID: I20180716002644 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Keely E Pelzel |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1417117219 PECOS PAC ID: 9931456407 Enrollment ID: I20180716002717 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Patrick J Mcnamara |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1558851766 PECOS PAC ID: 7618224098 Enrollment ID: I20180716003296 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Erin A Boese |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1821431651 PECOS PAC ID: 8729205984 Enrollment ID: I20180717000040 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Julianne S Torres |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1831570951 PECOS PAC ID: 9931413267 Enrollment ID: I20180718001101 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kristen E Sandgren |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1720466113 PECOS PAC ID: 8921312109 Enrollment ID: I20180720001655 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kari A Wellnitz |
---|---|
Provider Type | Practitioner - Critical Care (intensivists) |
Provider Identifiers | NPI Number: 1952690828 PECOS PAC ID: 6901037050 Enrollment ID: I20180725000601 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lauren A Kanner |
---|---|
Provider Type | Practitioner - Endocrinology |
Provider Identifiers | NPI Number: 1972879625 PECOS PAC ID: 8022327386 Enrollment ID: I20180725000858 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kristin A Plichta |
---|---|
Provider Type | Practitioner - Radiation Oncology |
Provider Identifiers | NPI Number: 1326305038 PECOS PAC ID: 4284850637 Enrollment ID: I20180727000638 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Adam L Brown |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1649246083 PECOS PAC ID: 9234487760 Enrollment ID: I20180731002895 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kati A Carpenter |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1619461357 PECOS PAC ID: 3476801838 Enrollment ID: I20180801003997 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Salahaldeen M Abuhammoud |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1083083943 PECOS PAC ID: 9830447143 Enrollment ID: I20180802002235 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Qiang Zhang |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1083027403 PECOS PAC ID: 6709001423 Enrollment ID: I20180807001912 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kimberly A Kenne |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1407168305 PECOS PAC ID: 3678725199 Enrollment ID: I20180813001419 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mikhail P Shkiryak |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1750867248 PECOS PAC ID: 5597013268 Enrollment ID: I20180813002036 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Cassie J Wagner |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1134523269 PECOS PAC ID: 0941558613 Enrollment ID: I20180813002055 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Natalie Sofia Weger |
---|---|
Provider Type | Practitioner - Vascular Surgery |
Provider Identifiers | NPI Number: 1205090339 PECOS PAC ID: 7214086610 Enrollment ID: I20180813002178 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kristin L Rood |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1922590132 PECOS PAC ID: 0648529354 Enrollment ID: I20180814000524 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | James Muse Davis |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1194042382 PECOS PAC ID: 8123250701 Enrollment ID: I20180827002735 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Tracey A Cho |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1992787915 PECOS PAC ID: 6709977309 Enrollment ID: I20180827003434 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alexandra B Iannone |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1760775233 PECOS PAC ID: 3274772736 Enrollment ID: I20180912001076 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Erin Marie Brown |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1871803312 PECOS PAC ID: 0547510539 Enrollment ID: I20180913000063 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Carolina Cucco |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1568813780 PECOS PAC ID: 3375894215 Enrollment ID: I20180917000934 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alberto Gasparoni |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1508960501 PECOS PAC ID: 7911258678 Enrollment ID: I20180920000116 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sarah Elizabeth Cyr |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1932639713 PECOS PAC ID: 6305197930 Enrollment ID: I20180920003060 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lisa M Woodroffe |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1578976155 PECOS PAC ID: 2264659754 Enrollment ID: I20180924000048 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michelle Renee Mcquistan |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1942304951 PECOS PAC ID: 7113278631 Enrollment ID: I20180924000055 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Satheesh Elangovan |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1962660274 PECOS PAC ID: 0244581635 Enrollment ID: I20180925000436 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Cristina De Mattos Pimenta Vidal |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1659817872 PECOS PAC ID: 7012268436 Enrollment ID: I20180925001604 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Aditi Jain |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1871924530 PECOS PAC ID: 5496006827 Enrollment ID: I20180925002021 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ashley A Wilkens |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1780062299 PECOS PAC ID: 5193033009 Enrollment ID: I20180926002747 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | David A Axelrod |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1477574820 PECOS PAC ID: 1355379132 Enrollment ID: I20181002001421 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Megumi Aita Williamson |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1205212792 PECOS PAC ID: 0345592275 Enrollment ID: I20181004000539 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Galen Belmont Schneider |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1487740270 PECOS PAC ID: 0345592150 Enrollment ID: I20181005001235 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Matthew Nels Negaard |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1265881569 PECOS PAC ID: 4284926601 Enrollment ID: I20181005002072 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Madhuradhar Mbbs Chegondi |
---|---|
Provider Type | Practitioner - Critical Care (intensivists) |
Provider Identifiers | NPI Number: 1104173103 PECOS PAC ID: 8123308285 Enrollment ID: I20181010002383 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Claire E Harapat |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1942670781 PECOS PAC ID: 7517265002 Enrollment ID: I20181010002549 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Beth L Dinoff |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1760425839 PECOS PAC ID: 9537133988 Enrollment ID: I20181010002600 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Peter Cosimo Damiano |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1871697870 PECOS PAC ID: 5799037222 Enrollment ID: I20181011001626 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael James Kanellis |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1518061209 PECOS PAC ID: 0547512907 Enrollment ID: I20181012000239 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | David Charles Holmes |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1952405649 PECOS PAC ID: 0446502819 Enrollment ID: I20181012000663 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Shaoping Zhang |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1346723475 PECOS PAC ID: 6608128822 Enrollment ID: I20181016001706 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Justine Lane Kolker |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1396849089 PECOS PAC ID: 6800148982 Enrollment ID: I20181018001040 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Gregory Adam Farris |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1306392253 PECOS PAC ID: 3577816636 Enrollment ID: I20181019001386 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Katie R Hasler |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1144716986 PECOS PAC ID: 5597018580 Enrollment ID: I20181020000724 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Melissa D Mohling |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1285128033 PECOS PAC ID: 9739432568 Enrollment ID: I20181025000276 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brittany M Mcgraw |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1033697586 PECOS PAC ID: 1153674817 Enrollment ID: I20181025001931 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Natalia Restrepo-kennedy |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1053627786 PECOS PAC ID: 6709139397 Enrollment ID: I20181029002495 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Cassie M Doolady |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1497241293 PECOS PAC ID: 2163775628 Enrollment ID: I20181030002543 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kyungsup Shin |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1023446853 PECOS PAC ID: 6406109727 Enrollment ID: I20181101003391 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Christopher Andrew Barwacz |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1912163957 PECOS PAC ID: 9830238997 Enrollment ID: I20181102000700 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Tarek K El-kerdani |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1629378807 PECOS PAC ID: 2062765308 Enrollment ID: I20181102000766 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Olivia Marie Croskey |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1801373808 PECOS PAC ID: 9234482514 Enrollment ID: I20181102002137 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Terry J Lindquist |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1114021128 PECOS PAC ID: 8224381520 Enrollment ID: I20181105000229 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sven W Steen |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1952716714 PECOS PAC ID: 3577856368 Enrollment ID: I20181105002466 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Abimbola Olayinka |
---|---|
Provider Type | Practitioner - Hospice/palliative Care |
Provider Identifiers | NPI Number: 1851705099 PECOS PAC ID: 1850518648 Enrollment ID: I20181105002688 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Katie A Halbmaier |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1669958922 PECOS PAC ID: 3072867654 Enrollment ID: I20181117000481 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sara J Downes |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1578850038 PECOS PAC ID: 8820266521 Enrollment ID: I20181119000038 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Shannon M Edwards |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1205316775 PECOS PAC ID: 7012261605 Enrollment ID: I20181119000195 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ikami Sasa |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1619460201 PECOS PAC ID: 4789928318 Enrollment ID: I20181207001020 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ily Kristine T Yumul |
---|---|
Provider Type | Practitioner - Advanced Heart Failure And Transplant Cardiology |
Provider Identifiers | NPI Number: 1598077307 PECOS PAC ID: 4284861857 Enrollment ID: I20181210001585 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Priya D Larson |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1346699808 PECOS PAC ID: 0840583910 Enrollment ID: I20181210003203 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joyce E Goins-fernandez |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1326422650 PECOS PAC ID: 3779828090 Enrollment ID: I20181214000915 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Natalie M Petersen |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1982183836 PECOS PAC ID: 5294070561 Enrollment ID: I20181214002990 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sophia M Chung |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1336169762 PECOS PAC ID: 3779628623 Enrollment ID: I20181214003027 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Erin Elizabeth Hayward |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1598004392 PECOS PAC ID: 6901195056 Enrollment ID: I20181215000207 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | David S Dickens |
---|---|
Provider Type | Practitioner - Hematology/oncology |
Provider Identifiers | NPI Number: 1720058092 PECOS PAC ID: 7012184641 Enrollment ID: I20181215000249 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Martha Lydia Carvour |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1619235553 PECOS PAC ID: 0749421253 Enrollment ID: I20181219001679 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ryan Keegan Lehmann |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1508072190 PECOS PAC ID: 8426342817 Enrollment ID: I20190110000187 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Taylor J Hull |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1104399146 PECOS PAC ID: 4688910755 Enrollment ID: I20190110000546 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nicole J Schneider |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1871064345 PECOS PAC ID: 7416293543 Enrollment ID: I20190110002922 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joseph C Glykys |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1629204136 PECOS PAC ID: 6800057027 Enrollment ID: I20190117002698 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Tyler Paul Rasmussen |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1265880454 PECOS PAC ID: 1052604659 Enrollment ID: I20190118000752 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Pixie Plummer |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1972603793 PECOS PAC ID: 4486745445 Enrollment ID: I20190121000472 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Christina R Kopp |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1164894432 PECOS PAC ID: 0941507032 Enrollment ID: I20190131002626 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joan Marie Tuberty |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1285074310 PECOS PAC ID: 8426396532 Enrollment ID: I20190215000855 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rachel Mcquade Leach |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1073959961 PECOS PAC ID: 1951543420 Enrollment ID: I20190219002746 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Shankar Rengasamy Venugopalan |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1831486356 PECOS PAC ID: 1557600137 Enrollment ID: I20190226000928 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Laurie L Mclaughlin |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1194280438 PECOS PAC ID: 9739428335 Enrollment ID: I20190226001411 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Hatem I El-shanti |
---|---|
Provider Type | Practitioner - Medical Genetics And Genomics |
Provider Identifiers | NPI Number: 1801881685 PECOS PAC ID: 1153660568 Enrollment ID: I20190301001864 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sarah L Averill |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1003137522 PECOS PAC ID: 1658512504 Enrollment ID: I20190312000534 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jonathan Michael Nizar |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1104083815 PECOS PAC ID: 1658557483 Enrollment ID: I20190314000269 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Edward M Powers |
---|---|
Provider Type | Practitioner - Cardiac Electrophysiology |
Provider Identifiers | NPI Number: 1184019895 PECOS PAC ID: 6608146899 Enrollment ID: I20190402000673 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Harmony Genelle Tamboura |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1033674981 PECOS PAC ID: 8123369501 Enrollment ID: I20190411002582 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kristen Elizabeth Harring |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1881952356 PECOS PAC ID: 2264657378 Enrollment ID: I20190416002109 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Steven Brooks Mobley |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1316424930 PECOS PAC ID: 8325380918 Enrollment ID: I20190501000990 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Prashob Porayette |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1851551428 PECOS PAC ID: 4486934601 Enrollment ID: I20190513000593 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ashley N Greiner |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1194183756 PECOS PAC ID: 8527301639 Enrollment ID: I20190513001338 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jhanvi Desai |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1073090213 PECOS PAC ID: 6204179179 Enrollment ID: I20190516000138 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Chandni Desai |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1770838880 PECOS PAC ID: 8325381205 Enrollment ID: I20190516000404 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kellsie A Busho |
---|---|
Provider Type | Practitioner - Qualified Audiologist |
Provider Identifiers | NPI Number: 1255831525 PECOS PAC ID: 7012259898 Enrollment ID: I20190607000100 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Arun K Singhal |
---|---|
Provider Type | Practitioner - Thoracic Surgery |
Provider Identifiers | NPI Number: 1578551446 PECOS PAC ID: 1052217148 Enrollment ID: I20190613000195 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jacob Matthias Elkins |
---|---|
Provider Type | Practitioner - Orthopedic Surgery |
Provider Identifiers | NPI Number: 1194163972 PECOS PAC ID: 1052553344 Enrollment ID: I20190702002126 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Eun Kyung Jeon |
---|---|
Provider Type | Practitioner - Qualified Audiologist |
Provider Identifiers | NPI Number: 1417516980 PECOS PAC ID: 8022343581 Enrollment ID: I20190706000058 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jaron D Lassen |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1144887944 PECOS PAC ID: 2163757626 Enrollment ID: I20190706000184 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Corrie J Swartzentruber |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1275984783 PECOS PAC ID: 5597090951 Enrollment ID: I20190709000170 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Anna H Schmitz |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1093132086 PECOS PAC ID: 6103105846 Enrollment ID: I20190709002906 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sreenath Thati Ganganna |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1609131770 PECOS PAC ID: 3678878105 Enrollment ID: I20190709002933 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lemuel Benedict R Non |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1013205285 PECOS PAC ID: 3375764012 Enrollment ID: I20190709002986 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rebecca Larie Weiner |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1295091510 PECOS PAC ID: 0143509935 Enrollment ID: I20190710003176 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amir Shaban |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1740695865 PECOS PAC ID: 0648495457 Enrollment ID: I20190710003361 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Shannon Jans |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1053845677 PECOS PAC ID: 2860761822 Enrollment ID: I20190711000515 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sangini Punia |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1396151353 PECOS PAC ID: 1355568692 Enrollment ID: I20190711003138 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mohammad S Ansari |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1902257405 PECOS PAC ID: 2466745153 Enrollment ID: I20190712000667 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Daniel Joseph Mccabe |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1366888356 PECOS PAC ID: 3375836430 Enrollment ID: I20190712000750 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ayotunde O Dokun |
---|---|
Provider Type | Practitioner - Endocrinology |
Provider Identifiers | NPI Number: 1548463078 PECOS PAC ID: 7113019464 Enrollment ID: I20190712000772 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bryan P Koestner |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1043669393 PECOS PAC ID: 1951692813 Enrollment ID: I20190712000837 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Holly Marie Van Den Beldt |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1881072247 PECOS PAC ID: 0042522807 Enrollment ID: I20190712000857 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lukasz Dobromir Weiner |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1205271954 PECOS PAC ID: 4284938317 Enrollment ID: I20190712000859 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ernesto Anibal Ruiz Duque |
---|---|
Provider Type | Practitioner - Advanced Heart Failure And Transplant Cardiology |
Provider Identifiers | NPI Number: 1215439708 PECOS PAC ID: 1254681489 Enrollment ID: I20190712000900 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | James C Willey |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1134579774 PECOS PAC ID: 2567754252 Enrollment ID: I20190712000992 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Devin L Shrock |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1619358876 PECOS PAC ID: 8426363938 Enrollment ID: I20190712001004 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Samuel K Shultz |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1629459417 PECOS PAC ID: 6800108713 Enrollment ID: I20190712001021 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Andrew D Bryant |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1902268972 PECOS PAC ID: 5890087696 Enrollment ID: I20190715000830 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joshua Kevin Stopak |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1093133779 PECOS PAC ID: 0648571968 Enrollment ID: I20190715003224 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Aric W Aldrich |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1821400102 PECOS PAC ID: 0446576904 Enrollment ID: I20190715003458 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Donna Ann Cheung |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1144662123 PECOS PAC ID: 1254666019 Enrollment ID: I20190716002182 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Robert Paul Bertellotti |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1013120740 PECOS PAC ID: 9234282898 Enrollment ID: I20190716002265 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mohsen Karimi |
---|---|
Provider Type | Practitioner - Cardiac Surgery |
Provider Identifiers | NPI Number: 1366400129 PECOS PAC ID: 6608808902 Enrollment ID: I20190716003292 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Anthony L. Panos |
---|---|
Provider Type | Practitioner - Cardiac Surgery |
Provider Identifiers | NPI Number: 1538123393 PECOS PAC ID: 2163315706 Enrollment ID: I20190718001760 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Timothy Michael Boyce |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1962880393 PECOS PAC ID: 2769778109 Enrollment ID: I20190718002918 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Cody R. Gremore |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1164810727 PECOS PAC ID: 5991031478 Enrollment ID: I20190722000547 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Benjamin R Griffin |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1568726529 PECOS PAC ID: 5496991242 Enrollment ID: I20190724000091 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Marisa Rae Buchakjian |
---|---|
Provider Type | Practitioner - Otolaryngology |
Provider Identifiers | NPI Number: 1699068122 PECOS PAC ID: 1658511589 Enrollment ID: I20190724000195 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Francisco Donato Junior |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1356878425 PECOS PAC ID: 6406182856 Enrollment ID: I20190724000213 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Aprajita Singh |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1528333473 PECOS PAC ID: 9830471390 Enrollment ID: I20190725001633 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sukirth Murthy Ganesan |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1437531795 PECOS PAC ID: 2365716693 Enrollment ID: I20190726001281 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Paul C Pierson |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1649686890 PECOS PAC ID: 4880810860 Enrollment ID: I20190727000386 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rupesh Kshetri |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1871926444 PECOS PAC ID: 2264710656 Enrollment ID: I20190729002396 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jessica Mary Rockafellow |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1063860690 PECOS PAC ID: 6103118526 Enrollment ID: I20190731001425 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kathryn Joyce Huber-keener |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1457764730 PECOS PAC ID: 2961629001 Enrollment ID: I20190801000922 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Miriam Esther Weiner Murray |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1326433038 PECOS PAC ID: 6305172008 Enrollment ID: I20190801000931 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael Wayne Klein |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1790133288 PECOS PAC ID: 6406149194 Enrollment ID: I20190801001717 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amanda Lee Hoffman |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1336597525 PECOS PAC ID: 4981996675 Enrollment ID: I20190801001885 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Malesse B Waje |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1790138451 PECOS PAC ID: 6800140682 Enrollment ID: I20190802001089 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kathleen Elizabeth Dlouhy |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1801182977 PECOS PAC ID: 8628207818 Enrollment ID: I20190809002508 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Christine M Gill |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1255743928 PECOS PAC ID: 7113142928 Enrollment ID: I20190812000070 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Emily R Welder |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1538517024 PECOS PAC ID: 5294027595 Enrollment ID: I20190812002164 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Marcus Richard Noyes |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1093206096 PECOS PAC ID: 9739416637 Enrollment ID: I20190815001987 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Pantip Henprasert |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1013463660 PECOS PAC ID: 7618205444 Enrollment ID: I20190819000454 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | William Andrew Zeitler |
---|---|
Provider Type | Practitioner - Hematology/oncology |
Provider Identifiers | NPI Number: 1013356096 PECOS PAC ID: 0648414649 Enrollment ID: I20190819002715 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jennifer Leah Miksanek Strouse |
---|---|
Provider Type | Practitioner - Rheumatology |
Provider Identifiers | NPI Number: 1750739868 PECOS PAC ID: 0840583530 Enrollment ID: I20190819003213 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rakesh Sondekoppam Vijayashankar |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1083269187 PECOS PAC ID: 9638407331 Enrollment ID: I20190819003665 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jessica Rose Parkhurst |
---|---|
Provider Type | Practitioner - Radiation Oncology |
Provider Identifiers | NPI Number: 1699188664 PECOS PAC ID: 2567687346 Enrollment ID: I20190820001424 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Allyson L Wolcott |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1639737596 PECOS PAC ID: 3870821515 Enrollment ID: I20190820001636 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | James R Kinney |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1942852454 PECOS PAC ID: 5799013306 Enrollment ID: I20190821000256 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Pascale F Doresca |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1023678042 PECOS PAC ID: 9234467846 Enrollment ID: I20190821000270 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nichole M Harklau |
---|---|
Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
Provider Identifiers | NPI Number: 1093360323 PECOS PAC ID: 5799013108 Enrollment ID: I20190822004314 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kendra L Tracy |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1912476177 PECOS PAC ID: 2264761931 Enrollment ID: I20190905000135 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rebecca A Schafer |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1306493630 PECOS PAC ID: 3971832650 Enrollment ID: I20190905000681 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kristen G. Berrebi |
---|---|
Provider Type | Practitioner - Dermatology |
Provider Identifiers | NPI Number: 1740608280 PECOS PAC ID: 6507174976 Enrollment ID: I20190905001407 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Katie Lynn Lutz |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1356753859 PECOS PAC ID: 3870719909 Enrollment ID: I20190916000508 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Theresa M Czech |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1386938447 PECOS PAC ID: 6608105796 Enrollment ID: I20190916001834 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Adam John Arendt |
---|---|
Provider Type | Practitioner - Podiatry |
Provider Identifiers | NPI Number: 1497072987 PECOS PAC ID: 0446491310 Enrollment ID: I20190916001882 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Shannon Jo Schroetter |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1982025680 PECOS PAC ID: 8527296342 Enrollment ID: I20190916002030 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lisa E Koonce |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1184270506 PECOS PAC ID: 5294064200 Enrollment ID: I20190916003442 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lindsay Marie Brown Crandall |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1588196422 PECOS PAC ID: 9032448089 Enrollment ID: I20190917001145 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Johanna Theresa Clark |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1750942892 PECOS PAC ID: 8729317771 Enrollment ID: I20190917001352 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Whitney Ks Kaefring |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1548619349 PECOS PAC ID: 1456643873 Enrollment ID: I20190917001845 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alyssa K Miller |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1679129530 PECOS PAC ID: 1355671389 Enrollment ID: I20190918000637 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Connie M Moffit |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1093368425 PECOS PAC ID: 4688904923 Enrollment ID: I20190930000479 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Scott Kevin Sherman |
---|---|
Provider Type | Practitioner - Surgical Oncology |
Provider Identifiers | NPI Number: 1942521265 PECOS PAC ID: 2567735442 Enrollment ID: I20191002002677 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Elizabeth Mary Highland-fonder |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1083089189 PECOS PAC ID: 3072891233 Enrollment ID: I20191003001492 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Emily Lu Struble |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1104473172 PECOS PAC ID: 1850622952 Enrollment ID: I20191003001645 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Masaaki Yamada |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1962766139 PECOS PAC ID: 0840590139 Enrollment ID: I20191003002772 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brandon C Dozier |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1730731977 PECOS PAC ID: 4486551090 Enrollment ID: I20191014001236 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brooke Marie Hewer |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1821642646 PECOS PAC ID: 0941531149 Enrollment ID: I20191018000474 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ryan C Kruse |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1588000798 PECOS PAC ID: 1153541453 Enrollment ID: I20191018000640 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Danielle Rae Rios |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1225394042 PECOS PAC ID: 2668636317 Enrollment ID: I20191018000665 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alan W Hemming |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1073529426 PECOS PAC ID: 4082753561 Enrollment ID: I20191018001820 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michelle Margaret Manternach |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1356824072 PECOS PAC ID: 9931430170 Enrollment ID: I20191018001899 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rebekah A Siegert |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1447805320 PECOS PAC ID: 6709118870 Enrollment ID: I20191023001924 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Katharine A Robb |
---|---|
Provider Type | Practitioner - Critical Care (intensivists) |
Provider Identifiers | NPI Number: 1083970925 PECOS PAC ID: 9234379405 Enrollment ID: I20191029000443 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Emily M Schultz |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1376193342 PECOS PAC ID: 9830421437 Enrollment ID: I20191031001990 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Yousef Ismael |
---|---|
Provider Type | Practitioner - Radiation Oncology |
Provider Identifiers | NPI Number: 1922657337 PECOS PAC ID: 8729410733 Enrollment ID: I20191113001274 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Aleksander Lenert |
---|---|
Provider Type | Practitioner - Rheumatology |
Provider Identifiers | NPI Number: 1770716193 PECOS PAC ID: 0547488488 Enrollment ID: I20191113002678 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Carissa Marie Brown |
---|---|
Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
Provider Identifiers | NPI Number: 1861036840 PECOS PAC ID: 8628400371 Enrollment ID: I20191118002166 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Audrey L Watkins |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1992355895 PECOS PAC ID: 0446682140 Enrollment ID: I20191119001176 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Tami Lynn Miller |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1669015640 PECOS PAC ID: 6709219702 Enrollment ID: I20191205001068 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Paul A Dicamillo |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1831341007 PECOS PAC ID: 2860767639 Enrollment ID: I20191211000318 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Anne M Daggett |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1548692585 PECOS PAC ID: 1355636598 Enrollment ID: I20191216001895 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Loreen R Curley |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1992340863 PECOS PAC ID: 7810321189 Enrollment ID: I20191218003145 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Stephanie Catherine Sands |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1740823079 PECOS PAC ID: 4789018946 Enrollment ID: I20191220000610 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mallory Ann Lukan |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1467996041 PECOS PAC ID: 9638452899 Enrollment ID: I20191230000252 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kara Wood |
---|---|
Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
Provider Identifiers | NPI Number: 1518504547 PECOS PAC ID: 7315371325 Enrollment ID: I20191230000338 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Darrick Jonathan Zirker |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1205031986 PECOS PAC ID: 0547695868 Enrollment ID: I20200115000588 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jessica Marie Becker |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1700422854 PECOS PAC ID: 2365877511 Enrollment ID: I20200115002541 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amy Sue Bader Takes |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1457994360 PECOS PAC ID: 2769817691 Enrollment ID: I20200122002389 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Eden Ariel Oconnor |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1831738749 PECOS PAC ID: 8325473010 Enrollment ID: I20200128000751 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brooke M Salter |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1184265738 PECOS PAC ID: 1951737634 Enrollment ID: I20200129001768 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Anna Elyse Spykerman |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1902444284 PECOS PAC ID: 2567898828 Enrollment ID: I20200204002434 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Adrianna N Vanduyne |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1396388302 PECOS PAC ID: 4789010190 Enrollment ID: I20200214001950 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Carissa R Gehl |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1780872374 PECOS PAC ID: 3971930553 Enrollment ID: I20200220000103 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | April Lynn Haven |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1528609070 PECOS PAC ID: 7810324449 Enrollment ID: I20200220002349 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jamie L Duffy |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1356981518 PECOS PAC ID: 0840627352 Enrollment ID: I20200224000088 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kristin Nicole Bermeo |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1780092312 PECOS PAC ID: 7517289465 Enrollment ID: I20200228001581 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mark P Atcher |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1205473808 PECOS PAC ID: 7416384342 Enrollment ID: I20200305000680 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Hiroyuki Suzuki |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1891223665 PECOS PAC ID: 7911277454 Enrollment ID: I20200305001562 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Gina M Rottinghaus |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1396225041 PECOS PAC ID: 8224360169 Enrollment ID: I20200309000367 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Delores S Fitton |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1184702235 PECOS PAC ID: 9537169966 Enrollment ID: I20200311001622 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Pilar G. Fleshman |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1477986479 PECOS PAC ID: 0244468742 Enrollment ID: I20200311002050 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alexandra M Telford |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1528698966 PECOS PAC ID: 4486082013 Enrollment ID: I20200313002137 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Allison M Donovan |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1306486030 PECOS PAC ID: 3274961545 Enrollment ID: I20200319002299 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kathryn L Crawford |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1497388243 PECOS PAC ID: 2860820859 Enrollment ID: I20200325003542 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nataliya Grandt |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1538799903 PECOS PAC ID: 5799114021 Enrollment ID: I20200407002074 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Hela Kotob |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1831500230 PECOS PAC ID: 9436427580 Enrollment ID: I20200408003969 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Cathy J Hostettler |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1174504310 PECOS PAC ID: 5698794691 Enrollment ID: I20200409003572 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Cory Allen Wittrock |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1720255409 PECOS PAC ID: 4486708377 Enrollment ID: I20200411000713 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Katherine Y Ignacio |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1134215270 PECOS PAC ID: 5496752032 Enrollment ID: I20200414000469 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alysha Reese |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1447800685 PECOS PAC ID: 6901236553 Enrollment ID: I20200422000394 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jyoti Mago |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1841714920 PECOS PAC ID: 9436424009 Enrollment ID: I20200427000126 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael A Callan |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1124385448 PECOS PAC ID: 6800226259 Enrollment ID: I20200427000143 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sung H Kim |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1649653577 PECOS PAC ID: 7719293414 Enrollment ID: I20200429002643 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Silvia Villagomez |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1124418678 PECOS PAC ID: 7012236078 Enrollment ID: I20200430000555 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mark Pedersen |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1275948283 PECOS PAC ID: 9032336409 Enrollment ID: I20200505000070 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sally M Roushdy |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1073029591 PECOS PAC ID: 4486085354 Enrollment ID: I20200508000774 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Laura M Fisher |
---|---|
Provider Type | Practitioner - Qualified Speech Language Pathologist |
Provider Identifiers | NPI Number: 1548556830 PECOS PAC ID: 3678904414 Enrollment ID: I20200512002451 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Paige Burden |
---|---|
Provider Type | Practitioner - Qualified Speech Language Pathologist |
Provider Identifiers | NPI Number: 1669637450 PECOS PAC ID: 0648601484 Enrollment ID: I20200512002574 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Debora Downey |
---|---|
Provider Type | Practitioner - Qualified Speech Language Pathologist |
Provider Identifiers | NPI Number: 1043475767 PECOS PAC ID: 9537590278 Enrollment ID: I20200512002685 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Pena Lynn V Lubrica |
---|---|
Provider Type | Practitioner - Qualified Speech Language Pathologist |
Provider Identifiers | NPI Number: 1811152564 PECOS PAC ID: 3971934613 Enrollment ID: I20200512002780 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Gwen Elise Mcnatt |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1134610140 PECOS PAC ID: 2062843691 Enrollment ID: I20200514000176 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ramon L Ignacio |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1043405814 PECOS PAC ID: 5193918605 Enrollment ID: I20200526001955 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Gregory J Beiermann |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1386838506 PECOS PAC ID: 9133212954 Enrollment ID: I20200527002057 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Barbara Jean Kane |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1538187760 PECOS PAC ID: 4789645805 Enrollment ID: I20200601001813 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Erika B Detweiler |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1437498698 PECOS PAC ID: 6507088176 Enrollment ID: I20200610000418 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jonathan J Davick |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1932595295 PECOS PAC ID: 6800219395 Enrollment ID: I20200630001848 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Junjie Liu |
---|---|
Provider Type | Practitioner - Sleep Medicine |
Provider Identifiers | NPI Number: 1619356383 PECOS PAC ID: 4284947482 Enrollment ID: I20200630001950 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Tyler G Slayman |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1336501402 PECOS PAC ID: 9234465899 Enrollment ID: I20200706000813 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Abigail C Mancuso |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1376980524 PECOS PAC ID: 8224271820 Enrollment ID: I20200706000975 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Meenakshi Sambharia |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1346623055 PECOS PAC ID: 4880997261 Enrollment ID: I20200706001004 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jessica Ann Odendahl Zimmerman |
---|---|
Provider Type | Practitioner - Hematology/oncology |
Provider Identifiers | NPI Number: 1730591975 PECOS PAC ID: 6800013392 Enrollment ID: I20200706001049 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Gerard P Clancy |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1346210747 PECOS PAC ID: 7911928833 Enrollment ID: I20200707002049 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michelle Ouyang |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1255726329 PECOS PAC ID: 4688976012 Enrollment ID: I20200709001547 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mitchell A Luangrath |
---|---|
Provider Type | Practitioner - Critical Care (intensivists) |
Provider Identifiers | NPI Number: 1568881027 PECOS PAC ID: 3274843164 Enrollment ID: I20200714001069 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Matthew D Soltys |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1013441773 PECOS PAC ID: 2163791849 Enrollment ID: I20200714002838 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Katherine Lynn Schroeder |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1487271102 PECOS PAC ID: 5193149714 Enrollment ID: I20200715002861 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Carolyn Verna Kay-buckelew |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1699391441 PECOS PAC ID: 8325462963 Enrollment ID: I20200716000110 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brandon S Janss |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1508363177 PECOS PAC ID: 5991129579 Enrollment ID: I20200716001573 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Adeyinka A Taiwo |
---|---|
Provider Type | Practitioner - Endocrinology |
Provider Identifiers | NPI Number: 1841398278 PECOS PAC ID: 4688560139 Enrollment ID: I20200716002519 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Leon B Jons |
---|---|
Provider Type | Practitioner - Endocrinology |
Provider Identifiers | NPI Number: 1821109224 PECOS PAC ID: 9234172933 Enrollment ID: I20200717000627 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Courtney Jo Reinsmoen |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1164058863 PECOS PAC ID: 8022432434 Enrollment ID: I20200717002332 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Stephanie Si-tang Lee |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1427324334 PECOS PAC ID: 7911321328 Enrollment ID: I20200717002408 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Samuel W Wong |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1598059198 PECOS PAC ID: 2961628151 Enrollment ID: I20200721000293 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Richard W Russillo |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1740630938 PECOS PAC ID: 0941593255 Enrollment ID: I20200721000697 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Austin K Blay |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1518464163 PECOS PAC ID: 1658795851 Enrollment ID: I20200721002831 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lindsay Mcconnell De Andrade |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1386055895 PECOS PAC ID: 6103043203 Enrollment ID: I20200723001132 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Andrew E Pouw |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1497139075 PECOS PAC ID: 8527352384 Enrollment ID: I20200728002724 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael L Santucci |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1003031477 PECOS PAC ID: 3870813082 Enrollment ID: I20200729003385 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Elias B Hanna |
---|---|
Provider Type | Practitioner - Interventional Cardiology |
Provider Identifiers | NPI Number: 1124215173 PECOS PAC ID: 9032303599 Enrollment ID: I20200731000354 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mark L Marz |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1184772238 PECOS PAC ID: 2769666858 Enrollment ID: I20200803002390 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Chad O Paisley |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1972669729 PECOS PAC ID: 7719954411 Enrollment ID: I20200806000451 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ryan Lawrence Steinberg |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1598021545 PECOS PAC ID: 9133366032 Enrollment ID: I20200806003351 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Akhila Ramakrishna |
---|---|
Provider Type | Practitioner - Endocrinology |
Provider Identifiers | NPI Number: 1427464379 PECOS PAC ID: 4082905609 Enrollment ID: I20200810001785 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Adrianne Rahde Bischoff |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1447808340 PECOS PAC ID: 7315277639 Enrollment ID: I20200810002004 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mark Edwards |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1710508130 PECOS PAC ID: 6002231909 Enrollment ID: I20200810002325 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Maria Tessa Witt |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1528683638 PECOS PAC ID: 0042635864 Enrollment ID: I20200810003204 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | David Villanueva |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1578060240 PECOS PAC ID: 6901221746 Enrollment ID: I20200810003656 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jane Fischer |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1457889149 PECOS PAC ID: 2769751726 Enrollment ID: I20200811000181 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Laura C Johnston |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1093212607 PECOS PAC ID: 2163848946 Enrollment ID: I20200812000135 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Victoria J Tann |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1467832238 PECOS PAC ID: 1254639636 Enrollment ID: I20200812002363 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Valery L Tran |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1861050262 PECOS PAC ID: 5799019295 Enrollment ID: I20200813000663 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bassel Mohammad Nijres |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1083011613 PECOS PAC ID: 4688968142 Enrollment ID: I20200814001414 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Xiaoyang Hua |
---|---|
Provider Type | Practitioner - Otolaryngology |
Provider Identifiers | NPI Number: 1780942946 PECOS PAC ID: 9032359955 Enrollment ID: I20200814002145 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Christopher S Sales |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1790005064 PECOS PAC ID: 1557588225 Enrollment ID: I20200817000708 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Pollyanne Iben |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1164504726 PECOS PAC ID: 6305262791 Enrollment ID: I20200817000800 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Emily Frances Lambrecht |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1356969612 PECOS PAC ID: 0042636342 Enrollment ID: I20200818000471 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Andrea H Gjerde Rohl |
---|---|
Provider Type | Practitioner - Qualified Speech Language Pathologist |
Provider Identifiers | NPI Number: 1164989836 PECOS PAC ID: 9537585799 Enrollment ID: I20200818003101 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Aliza Scarlett Barkdoll |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1841800091 PECOS PAC ID: 5395161434 Enrollment ID: I20200819002476 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Eirene Georgia Alexandrou |
---|---|
Provider Type | Practitioner - Endocrinology |
Provider Identifiers | NPI Number: 1619382942 PECOS PAC ID: 0345666400 Enrollment ID: I20200819003109 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jennifer K Paternostro |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1811398266 PECOS PAC ID: 5991058133 Enrollment ID: I20200820002991 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Vaishali S Lafita |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1053583633 PECOS PAC ID: 3476626847 Enrollment ID: I20200821000950 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Asad Javed |
---|---|
Provider Type | Practitioner - Medical Oncology |
Provider Identifiers | NPI Number: 1427339928 PECOS PAC ID: 5799058178 Enrollment ID: I20200821000979 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brianne R Benjamin |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1164049680 PECOS PAC ID: 6305263229 Enrollment ID: I20200824002392 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Chau Pham |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1447693692 PECOS PAC ID: 5193954626 Enrollment ID: I20200826002374 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kristina Linnea Guyton |
---|---|
Provider Type | Practitioner - Colorectal Surgery (proctology) |
Provider Identifiers | NPI Number: 1356605125 PECOS PAC ID: 8921300708 Enrollment ID: I20200826003188 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Allison Judge |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1326679937 PECOS PAC ID: 9638596216 Enrollment ID: I20200827001160 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jennifer R Bermick |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1790988517 PECOS PAC ID: 5799929121 Enrollment ID: I20200827003702 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Angelena Brittany Edwards |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1073856860 PECOS PAC ID: 6709203045 Enrollment ID: I20200901000766 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Quanhathai Kaewpoowat |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1780995506 PECOS PAC ID: 4880011055 Enrollment ID: I20200902001772 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Courtney E Fahrer |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1801393244 PECOS PAC ID: 8426475500 Enrollment ID: I20200903002320 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kimberly Jean Gregorich |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1033746896 PECOS PAC ID: 9335566314 Enrollment ID: I20200908000237 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ashley A Hui |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1356728778 PECOS PAC ID: 2961772835 Enrollment ID: I20200908002720 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jeffrey Duane Quinlan |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1710967138 PECOS PAC ID: 0244462513 Enrollment ID: I20200911000147 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | James Pereira De Andrade |
---|---|
Provider Type | Practitioner - Surgical Oncology |
Provider Identifiers | NPI Number: 1780979468 PECOS PAC ID: 6305070178 Enrollment ID: I20200911000288 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Stephanie King Steffen |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1740802305 PECOS PAC ID: 9830517143 Enrollment ID: I20200918001521 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Hua Sun |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1487065934 PECOS PAC ID: 8426274325 Enrollment ID: I20200921001332 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kevin D Sanchez |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1992233324 PECOS PAC ID: 9133490717 Enrollment ID: I20200921001830 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Megan Rae Hansen |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1295347490 PECOS PAC ID: 9739508771 Enrollment ID: I20200924002579 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kelly Danielle Ledbetter |
---|---|
Provider Type | Practitioner - Plastic And Reconstructive Surgery |
Provider Identifiers | NPI Number: 1073855128 PECOS PAC ID: 3971810227 Enrollment ID: I20200928002765 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Skyler L Rathkamp |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1457842882 PECOS PAC ID: 0446670533 Enrollment ID: I20201010000097 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Tera L Noard |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1023393311 PECOS PAC ID: 3173786795 Enrollment ID: I20201012001761 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jasmine J Kayvani |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1548767106 PECOS PAC ID: 2062832009 Enrollment ID: I20201013003602 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kara Morningstar |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1124497219 PECOS PAC ID: 5092024620 Enrollment ID: I20201014003377 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Logan West Sardzinski |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1902419070 PECOS PAC ID: 7810317443 Enrollment ID: I20201020001018 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nicole Pauline Safina |
---|---|
Provider Type | Practitioner - Medical Genetics And Genomics |
Provider Identifiers | NPI Number: 1144308156 PECOS PAC ID: 8325108079 Enrollment ID: I20201022003669 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jillian Rae Reiher |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1558849174 PECOS PAC ID: 9436579729 Enrollment ID: I20201027000959 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Allison Sara Wampler |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1508359753 PECOS PAC ID: 1355751629 Enrollment ID: I20201028001593 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rebecca Ann Mischel |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1649897190 PECOS PAC ID: 8123438363 Enrollment ID: I20201029001487 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jolene M Mcadam |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1679187108 PECOS PAC ID: 8921418740 Enrollment ID: I20201106001333 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lindy Mae Pelzer |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1972101533 PECOS PAC ID: 3375953045 Enrollment ID: I20201109001009 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jannet S Eastman |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1144821794 PECOS PAC ID: 9537579909 Enrollment ID: I20201113002286 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Christopher A Iverson |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1366970097 PECOS PAC ID: 5890064570 Enrollment ID: I20201117001045 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joan Marie Sieren |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1972119071 PECOS PAC ID: 9537570817 Enrollment ID: I20201117001060 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kathleen M Vonderhaar |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1679991038 PECOS PAC ID: 0648575183 Enrollment ID: I20201123000249 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Chantal J Rozmus |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1477045797 PECOS PAC ID: 2567718182 Enrollment ID: I20201125001274 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Shea Marie Jorgensen |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1396272233 PECOS PAC ID: 7214206275 Enrollment ID: I20201130002124 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nina C Pletcher |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1679176218 PECOS PAC ID: 3870905235 Enrollment ID: I20201209002054 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jennifer Renee Manternach |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1205437951 PECOS PAC ID: 1759793110 Enrollment ID: I20201209002195 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Steven M Udelhofen |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1457581308 PECOS PAC ID: 2961799796 Enrollment ID: I20201214001897 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Erin C Maetzold |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1518378488 PECOS PAC ID: 0446597892 Enrollment ID: I20201217001113 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alexandra Ann Lacarte |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1871198382 PECOS PAC ID: 5193137800 Enrollment ID: I20201221002267 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Giovanni E Lorenz |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1114196185 PECOS PAC ID: 7719258904 Enrollment ID: I20201222001178 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Katelin Hildreth |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1811591498 PECOS PAC ID: 0749693331 Enrollment ID: I20201228000877 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Keatyn Renee Mcvietty |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1669019964 PECOS PAC ID: 0749617629 Enrollment ID: I20210107000959 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Masaaki Kurahashi |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1568058329 PECOS PAC ID: 1759794803 Enrollment ID: I20210108001453 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Eric Yu Mou |
---|---|
Provider Type | Practitioner - Hematology/oncology |
Provider Identifiers | NPI Number: 1184044398 PECOS PAC ID: 3577976638 Enrollment ID: I20210108002014 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amr A Mourad |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1588763635 PECOS PAC ID: 7012348147 Enrollment ID: I20210112003064 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alpana Garg |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1922530682 PECOS PAC ID: 2466720453 Enrollment ID: I20210121002594 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Hope E Breitbach |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1568075331 PECOS PAC ID: 1052725553 Enrollment ID: I20210125000995 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Erin S Cullen |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1821684564 PECOS PAC ID: 5294149704 Enrollment ID: I20210125001185 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sarah Jorgensen |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1073593703 PECOS PAC ID: 4587762356 Enrollment ID: I20210129000537 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael J Dimarco |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1265878193 PECOS PAC ID: 6800197088 Enrollment ID: I20210208002775 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Daniel J Crawford |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1609158930 PECOS PAC ID: 3971779919 Enrollment ID: I20210218000992 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amarjit S Virdi |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1669541702 PECOS PAC ID: 2860544848 Enrollment ID: I20210222002478 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Yashant Aswani |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1194387225 PECOS PAC ID: 8921439365 Enrollment ID: I20210225000668 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amy Louise Pinkerton |
---|---|
Provider Type | Practitioner - Qualified Speech Language Pathologist |
Provider Identifiers | NPI Number: 1053854968 PECOS PAC ID: 3779863899 Enrollment ID: I20210226000586 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Robert Bowers |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1659724656 PECOS PAC ID: 1951717636 Enrollment ID: I20210303002460 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ariene Arcas Leme-kraus |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1831793744 PECOS PAC ID: 8325454580 Enrollment ID: I20210312001247 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | James Marlow Blum |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1497874762 PECOS PAC ID: 8426116955 Enrollment ID: I20210316000539 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Julia Catalina Parra |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1942899869 PECOS PAC ID: 1355758236 Enrollment ID: I20210319000690 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amanda R Karanikolas |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1184209314 PECOS PAC ID: 9436567500 Enrollment ID: I20210412000185 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Roy R Zhou |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1689068116 PECOS PAC ID: 5799034542 Enrollment ID: I20210414001523 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Justin Ganz |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1073909313 PECOS PAC ID: 6608110622 Enrollment ID: I20210503000876 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Erin Cline |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1972197929 PECOS PAC ID: 0244649317 Enrollment ID: I20210503001484 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nabil Jose Khoury |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1881272946 PECOS PAC ID: 8527477124 Enrollment ID: I20210512000880 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Marika R Raff |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1093168775 PECOS PAC ID: 7618262387 Enrollment ID: I20210514000121 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rachel L Becker |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1912531369 PECOS PAC ID: 8325447675 Enrollment ID: I20210519000954 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Eric Thomas Barnes |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1104415140 PECOS PAC ID: 4789083924 Enrollment ID: I20210520001951 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Anece Hong Adam |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1346814779 PECOS PAC ID: 4688073695 Enrollment ID: I20210525000903 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Dustin Eli Bosch |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1952797177 PECOS PAC ID: 3274846670 Enrollment ID: I20210525000973 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bryan Stephen Brindeiro |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1871727578 PECOS PAC ID: 3476784729 Enrollment ID: I20210602000659 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mohammad A Kotob |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1538726617 PECOS PAC ID: 4284969395 Enrollment ID: I20210603000841 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Steven D Marshall |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1063737237 PECOS PAC ID: 4486053972 Enrollment ID: I20210603002218 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Meaghan E Foody |
---|---|
Provider Type | Practitioner - Qualified Speech Language Pathologist |
Provider Identifiers | NPI Number: 1619358520 PECOS PAC ID: 1153630652 Enrollment ID: I20210607000805 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Steven Baxter Means |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1871660282 PECOS PAC ID: 2466731849 Enrollment ID: I20210610001896 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jason Edward Allen |
---|---|
Provider Type | Practitioner - Interventional Cardiology |
Provider Identifiers | NPI Number: 1225471816 PECOS PAC ID: 8224350558 Enrollment ID: I20210616002320 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Justin Jensen |
---|---|
Provider Type | Practitioner - Qualified Audiologist |
Provider Identifiers | NPI Number: 1356918353 PECOS PAC ID: 1557762267 Enrollment ID: I20210701000300 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Elyse Nicole Brock |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1851659403 PECOS PAC ID: 4880833003 Enrollment ID: I20210712000322 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Keely Ulmer |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1942720875 PECOS PAC ID: 5092086777 Enrollment ID: I20210712000459 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Hannah Roeder |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1982067013 PECOS PAC ID: 2961804174 Enrollment ID: I20210712000554 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Munish Ashat |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1649687831 PECOS PAC ID: 2264738327 Enrollment ID: I20210712000848 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amy Hc Stanford |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1457764391 PECOS PAC ID: 5193943702 Enrollment ID: I20210712000932 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ashlee Lafontaine Enzinger |
---|---|
Provider Type | Practitioner - Sports Medicine |
Provider Identifiers | NPI Number: 1992141907 PECOS PAC ID: 3375782766 Enrollment ID: I20210712000959 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kaila Ann Pomeranz |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1962930115 PECOS PAC ID: 7517236276 Enrollment ID: I20210712000999 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Anthony Purgianto |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1891236212 PECOS PAC ID: 6800165846 Enrollment ID: I20210712001612 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jacob Taylor Hodges |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1215162110 PECOS PAC ID: 8022255504 Enrollment ID: I20210712004076 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Angela R Wild |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1497106348 PECOS PAC ID: 4587959325 Enrollment ID: I20210713001140 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lindsey Knake |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1376930271 PECOS PAC ID: 6002218138 Enrollment ID: I20210713001303 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Matthew Christopher Hanewich |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1437649795 PECOS PAC ID: 9537561568 Enrollment ID: I20210713001387 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | David Patrick Shaha |
---|---|
Provider Type | Practitioner - Sleep Medicine |
Provider Identifiers | NPI Number: 1679912778 PECOS PAC ID: 5698900819 Enrollment ID: I20210713001516 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sarv Priya |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1538612056 PECOS PAC ID: 8325326770 Enrollment ID: I20210713003202 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ashmita Banerjee |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1023462843 PECOS PAC ID: 9234423542 Enrollment ID: I20210714001110 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | James Donald Byrne |
---|---|
Provider Type | Practitioner - Radiation Oncology |
Provider Identifiers | NPI Number: 1386091148 PECOS PAC ID: 1850683483 Enrollment ID: I20210714001331 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Akimasa Tsujimoto |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1376113407 PECOS PAC ID: 5395147243 Enrollment ID: I20210714002595 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Aimee Carswell |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1619156635 PECOS PAC ID: 4981755279 Enrollment ID: I20210714003374 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Yacoub Sallam |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1407333065 PECOS PAC ID: 6901142231 Enrollment ID: I20210714003517 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jackie Kaye Morgan |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1831789882 PECOS PAC ID: 8224430087 Enrollment ID: I20210715003352 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mary K Gallagher |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1972094837 PECOS PAC ID: 0143576769 Enrollment ID: I20210715003406 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amie Ogunsakin |
---|---|
Provider Type | Practitioner - Endocrinology |
Provider Identifiers | NPI Number: 1952533580 PECOS PAC ID: 2163661729 Enrollment ID: I20210715003523 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Edward Fort Linton |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1144754946 PECOS PAC ID: 2466854245 Enrollment ID: I20210715004026 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Majekodunmi V Olaleye |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1528556644 PECOS PAC ID: 0042563330 Enrollment ID: I20210719001779 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bethany M Bryant |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1992980098 PECOS PAC ID: 6406093400 Enrollment ID: I20210719002520 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Danielle Renee' Howsare |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1699269431 PECOS PAC ID: 1850647066 Enrollment ID: I20210720002966 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Melika Farshad |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1215545959 PECOS PAC ID: 3779986252 Enrollment ID: I20210721001335 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jie Xin Tang |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1073967311 PECOS PAC ID: 2860784279 Enrollment ID: I20210722000800 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ji Yang Kim |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1174194583 PECOS PAC ID: 9830592260 Enrollment ID: I20210722003568 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Elizabeth Cusick |
---|---|
Provider Type | Practitioner - Dermatology |
Provider Identifiers | NPI Number: 1033641196 PECOS PAC ID: 7719389527 Enrollment ID: I20210726001217 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Naomi Fei |
---|---|
Provider Type | Practitioner - Medical Oncology |
Provider Identifiers | NPI Number: 1760878755 PECOS PAC ID: 0244532802 Enrollment ID: I20210726001982 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Fabiola P Kestelman |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1780256586 PECOS PAC ID: 6800299942 Enrollment ID: I20210727000906 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jonathan Foster Russell |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1013301910 PECOS PAC ID: 1254668577 Enrollment ID: I20210727000958 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Taraz Imani Ramos |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1700382090 PECOS PAC ID: 1850794991 Enrollment ID: I20210727001077 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mikhael Sebaaly |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1851877112 PECOS PAC ID: 4486902723 Enrollment ID: I20210727001165 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Annah Jean Vollstedt |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1942629274 PECOS PAC ID: 5294093829 Enrollment ID: I20210729001017 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Christopher Terrence Hogden |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1275099756 PECOS PAC ID: 1951704857 Enrollment ID: I20210729003457 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brian T Andrews |
---|---|
Provider Type | Practitioner - Otolaryngology |
Provider Identifiers | NPI Number: 1245449701 PECOS PAC ID: 4789717364 Enrollment ID: I20210802001224 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joel K Bricker |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1629427711 PECOS PAC ID: 7618260902 Enrollment ID: I20210802001368 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Margaret Mcginn Byrne |
---|---|
Provider Type | Practitioner - Medical Oncology |
Provider Identifiers | NPI Number: 1295027696 PECOS PAC ID: 6305064767 Enrollment ID: I20210803001431 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jennifer L Streeter |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1811379118 PECOS PAC ID: 5193038677 Enrollment ID: I20210804003938 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Karissa L Soltys |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1891286811 PECOS PAC ID: 5597010082 Enrollment ID: I20210805000445 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | John H Wilde |
---|---|
Provider Type | Practitioner - Hospice/palliative Care |
Provider Identifiers | NPI Number: 1932620630 PECOS PAC ID: 6507260080 Enrollment ID: I20210805000550 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Yiqin Xiong |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1912369125 PECOS PAC ID: 3476844374 Enrollment ID: I20210806001811 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joseph G Curtis |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1912133414 PECOS PAC ID: 6204118631 Enrollment ID: I20210806002239 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Aniket Mittal |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1427554351 PECOS PAC ID: 9739583147 Enrollment ID: I20210806002540 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sayed Tauseef Ahmad Jan |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1578050142 PECOS PAC ID: 0446654743 Enrollment ID: I20210809003285 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nanmeng Yu |
---|---|
Provider Type | Practitioner - Hematology/oncology |
Provider Identifiers | NPI Number: 1265813612 PECOS PAC ID: 7810200391 Enrollment ID: I20210810003158 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Elizabeth R Bowen |
---|---|
Provider Type | Practitioner - Endocrinology |
Provider Identifiers | NPI Number: 1003264185 PECOS PAC ID: 8426341116 Enrollment ID: I20210811001021 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jennifer Lynn Franzwa |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1063083269 PECOS PAC ID: 1850795980 Enrollment ID: I20210811001119 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Prajwal Dhakal |
---|---|
Provider Type | Practitioner - Hematology |
Provider Identifiers | NPI Number: 1578946406 PECOS PAC ID: 4183974330 Enrollment ID: I20210811001246 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Katie Ann Sander |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1073180998 PECOS PAC ID: 7113321258 Enrollment ID: I20210811001609 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Dawn Dillman |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1861437212 PECOS PAC ID: 1355240631 Enrollment ID: I20210811001718 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jordyn I Schaper |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1972170611 PECOS PAC ID: 8921402074 Enrollment ID: I20210811001719 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Allister E Wilton |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1437538931 PECOS PAC ID: 3375856750 Enrollment ID: I20210811003933 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lama Abdel Wahed |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1861927204 PECOS PAC ID: 2961771654 Enrollment ID: I20210812001273 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | I-ching Wang |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1184216756 PECOS PAC ID: 2466856406 Enrollment ID: I20210812001398 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Paula Kyungjung Lee |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1972985596 PECOS PAC ID: 9032405998 Enrollment ID: I20210812001923 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Carlos-andres Garaicoa-pazmino |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1962929497 PECOS PAC ID: 2961806807 Enrollment ID: I20210813002392 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brandon James Rogers |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1124339031 PECOS PAC ID: 4880099456 Enrollment ID: I20210819001296 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Allison Leigh Aird |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1043875396 PECOS PAC ID: 9335544956 Enrollment ID: I20210819003714 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Paige Owen |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1497150106 PECOS PAC ID: 7517281728 Enrollment ID: I20210820000321 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mary Terese Whipple |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1215399506 PECOS PAC ID: 2163704453 Enrollment ID: I20210824001489 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Minjeong Seo |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1205509924 PECOS PAC ID: 8820493158 Enrollment ID: I20210824002474 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kelly Lynne Ferroni |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1659799914 PECOS PAC ID: 3274883418 Enrollment ID: I20210827000626 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Karen I Cyndari |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1598243636 PECOS PAC ID: 7719212828 Enrollment ID: I20210831000463 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kaley Samantha Boress |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1992378400 PECOS PAC ID: 6800292830 Enrollment ID: I20210831000868 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Meaghan Elaine Peters |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1831470244 PECOS PAC ID: 0042616021 Enrollment ID: I20210831002793 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Upneet Kaur Nijjar |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1396947107 PECOS PAC ID: 5991980955 Enrollment ID: I20210901000757 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Catherine Renee Olinger |
---|---|
Provider Type | Practitioner - Orthopedic Surgery |
Provider Identifiers | NPI Number: 1417342536 PECOS PAC ID: 0244550739 Enrollment ID: I20210901000832 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Than Pham |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1316327778 PECOS PAC ID: 3375833734 Enrollment ID: I20210903001554 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Adeola T Odugbesi |
---|---|
Provider Type | Practitioner - Vascular Surgery |
Provider Identifiers | NPI Number: 1275983801 PECOS PAC ID: 7719270446 Enrollment ID: I20210903001732 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Chih-jen Cheng |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1073281705 PECOS PAC ID: 7113323841 Enrollment ID: I20210904000016 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kevin Huang |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1255751087 PECOS PAC ID: 9234483678 Enrollment ID: I20210908001028 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Hao Mckenna |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1093388225 PECOS PAC ID: 2365848835 Enrollment ID: I20210908002924 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Angela L Smith |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1982890240 PECOS PAC ID: 6204232721 Enrollment ID: I20210909000782 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Dennis M Kivlighan |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1922771708 PECOS PAC ID: 7618373135 Enrollment ID: I20210909000938 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael Halyko |
---|---|
Provider Type | Practitioner - Hematology/oncology |
Provider Identifiers | NPI Number: 1134501745 PECOS PAC ID: 6002121936 Enrollment ID: I20210913000584 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | William Joseph Welsh |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1639736234 PECOS PAC ID: 2163757261 Enrollment ID: I20210916001602 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sreedevi K Jenigiri |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1598930257 PECOS PAC ID: 2365680451 Enrollment ID: I20210917000638 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mckenzie D Woodyard |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1104590686 PECOS PAC ID: 5294132254 Enrollment ID: I20210920000366 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kylie Loretta Costello |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1891469342 PECOS PAC ID: 8022415876 Enrollment ID: I20210922001035 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Gina M Cetta |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1689345670 PECOS PAC ID: 0446657985 Enrollment ID: I20210924002609 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Danielle N Hodge |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1285309484 PECOS PAC ID: 0446657886 Enrollment ID: I20210927003374 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Melissa B Ludgate |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1336590140 PECOS PAC ID: 2264724954 Enrollment ID: I20210928002076 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mohammed O Ali |
---|---|
Provider Type | Practitioner - Interventional Cardiology |
Provider Identifiers | NPI Number: 1144532409 PECOS PAC ID: 0749581312 Enrollment ID: I20210929002073 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Gabrielle Turner |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1659045441 PECOS PAC ID: 4385042555 Enrollment ID: I20211004000391 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nicole Ann Alsaker |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1992479679 PECOS PAC ID: 8022416593 Enrollment ID: I20211013003169 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Abdullah Sohail |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1124518600 PECOS PAC ID: 0446501837 Enrollment ID: I20211020002870 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Dimah Nayef Saade |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1114214541 PECOS PAC ID: 0648410191 Enrollment ID: I20211025000956 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rajat Sharma |
---|---|
Provider Type | Practitioner - Hematology/oncology |
Provider Identifiers | NPI Number: 1043972763 PECOS PAC ID: 1557759552 Enrollment ID: I20211025001285 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lauren Kirkpatrick |
---|---|
Provider Type | Practitioner - Hospice/palliative Care |
Provider Identifiers | NPI Number: 1174028898 PECOS PAC ID: 9739512948 Enrollment ID: I20211027002394 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | David A Hamon |
---|---|
Provider Type | Practitioner - Cardiac Electrophysiology |
Provider Identifiers | NPI Number: 1487317061 PECOS PAC ID: 7810385507 Enrollment ID: I20211029000917 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jenna L Marlow |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1215699814 PECOS PAC ID: 8022407204 Enrollment ID: I20211109001759 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Evan Gattey |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1366104358 PECOS PAC ID: 4486043643 Enrollment ID: I20211110001530 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Emmarie Febe Poolman |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1467123315 PECOS PAC ID: 2163811753 Enrollment ID: I20211122000573 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Marina Del Rios |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1689615585 PECOS PAC ID: 7113025602 Enrollment ID: I20211122000860 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Helen Prathiba Gnanapragasam |
---|---|
Provider Type | Practitioner - Endocrinology |
Provider Identifiers | NPI Number: 1750738654 PECOS PAC ID: 2860729118 Enrollment ID: I20211122001901 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Andrea G. Lamphiear |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1982892220 PECOS PAC ID: 2264602853 Enrollment ID: I20211122002048 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ahmad Shariftabrizi |
---|---|
Provider Type | Practitioner - Nuclear Medicine |
Provider Identifiers | NPI Number: 1053727313 PECOS PAC ID: 5092085928 Enrollment ID: I20211122002279 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Simon Vinarsky |
---|---|
Provider Type | Practitioner - Hematology/oncology |
Provider Identifiers | NPI Number: 1245268838 PECOS PAC ID: 5890786792 Enrollment ID: I20211124002092 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kristen Caviness Sihler |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1023194990 PECOS PAC ID: 8921008699 Enrollment ID: I20211207000945 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Shareef Mansour |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1063068732 PECOS PAC ID: 8628489390 Enrollment ID: I20211207000952 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rahul M Bijlani |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1528441078 PECOS PAC ID: 9234540592 Enrollment ID: I20211208003396 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Elena Garrido |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1669067641 PECOS PAC ID: 2567853195 Enrollment ID: I20211215001637 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Blake A. Stephenson |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1588040356 PECOS PAC ID: 5890186183 Enrollment ID: I20211221001206 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Stephanie K Rayner |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1558020289 PECOS PAC ID: 6800287111 Enrollment ID: I20211221002110 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Tarun Patel |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1912285255 PECOS PAC ID: 9739307968 Enrollment ID: I20211222000706 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nadia Naz |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1215333091 PECOS PAC ID: 7911398110 Enrollment ID: I20211223000420 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Cassie J Limoges |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1679761431 PECOS PAC ID: 3375625361 Enrollment ID: I20211227000367 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kacy Leigh Carew |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1811656333 PECOS PAC ID: 9739570789 Enrollment ID: I20211229001649 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Shanna Spies |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1013679703 PECOS PAC ID: 0840681847 Enrollment ID: I20211230001166 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lillian M Lai |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1477866614 PECOS PAC ID: 5799929790 Enrollment ID: I20220104000653 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nicole C Stein |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1407529563 PECOS PAC ID: 8921499658 Enrollment ID: I20220106001305 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Guiling Tong |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1760093504 PECOS PAC ID: 1456743186 Enrollment ID: I20220110000666 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Caroline J Mcmahon |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1811657133 PECOS PAC ID: 5395137418 Enrollment ID: I20220124001627 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jennifer L Kuhle |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1003576042 PECOS PAC ID: 2062804867 Enrollment ID: I20220127001115 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Heidi Marie Steinkamp |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1699174391 PECOS PAC ID: 4486047081 Enrollment ID: I20220203000195 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Melanie Sue Rock |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1730849647 PECOS PAC ID: 3173916608 Enrollment ID: I20220207000265 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Claire Ann Goeke |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1376183582 PECOS PAC ID: 6709215932 Enrollment ID: I20220207001415 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jeffrey H Goldman |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1316942212 PECOS PAC ID: 1254234297 Enrollment ID: I20220210001505 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Victoria Elnora Grandinetti |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1801555859 PECOS PAC ID: 4486047479 Enrollment ID: I20220216000668 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Megan C Sprecher |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1689334880 PECOS PAC ID: 3476947177 Enrollment ID: I20220223000303 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Stephanie Scheffler James |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1043586076 PECOS PAC ID: 2769793223 Enrollment ID: I20220223000824 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Megan E Drey |
---|---|
Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
Provider Identifiers | NPI Number: 1336892660 PECOS PAC ID: 1456745181 Enrollment ID: I20220223001633 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ronit Sternberg |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1457510323 PECOS PAC ID: 3870837784 Enrollment ID: I20220223002852 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Thu A Hoang |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1558891408 PECOS PAC ID: 6305116302 Enrollment ID: I20220307000358 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Andrina Mary Timmins |
---|---|
Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
Provider Identifiers | NPI Number: 1124620216 PECOS PAC ID: 1153734520 Enrollment ID: I20220307001723 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kelly N Marine |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1508281619 PECOS PAC ID: 5597172577 Enrollment ID: I20220309000488 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mary Colleen Burton |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1346910502 PECOS PAC ID: 1355736323 Enrollment ID: I20220310001099 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jacqueline Jo Klossing |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1790262822 PECOS PAC ID: 5193110781 Enrollment ID: I20220317001227 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alea A Meyer |
---|---|
Provider Type | Practitioner - Qualified Audiologist |
Provider Identifiers | NPI Number: 1508476771 PECOS PAC ID: 2365868874 Enrollment ID: I20220318001279 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Theresa Whalen |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1861153017 PECOS PAC ID: 3678968187 Enrollment ID: I20220321000756 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kayla Lynn Frazier |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1649931973 PECOS PAC ID: 3779978846 Enrollment ID: I20220328002097 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kathleen M Adams |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1518574730 PECOS PAC ID: 5991191058 Enrollment ID: I20220330000866 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rachel Anne Dawson |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1265188346 PECOS PAC ID: 8426444886 Enrollment ID: I20220412000715 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Gary S Beasley |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1669764106 PECOS PAC ID: 1557502952 Enrollment ID: I20220412001657 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Antonio S Zafred Marcelino |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1245972843 PECOS PAC ID: 1355737644 Enrollment ID: I20220414000615 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rodrigo Moreira Bello |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1326780826 PECOS PAC ID: 8325434582 Enrollment ID: I20220415001033 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ogechukwu Obiano |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1891222840 PECOS PAC ID: 2264701028 Enrollment ID: I20220419001705 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jesse M Branscomb |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1255097820 PECOS PAC ID: 5294122347 Enrollment ID: I20220420001728 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amy L Lemke |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1396488227 PECOS PAC ID: 1153718036 Enrollment ID: I20220422001638 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Elvis Kasi |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1972000438 PECOS PAC ID: 4789007774 Enrollment ID: I20220427001147 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Cara L Christianson |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1629712500 PECOS PAC ID: 5092102400 Enrollment ID: I20220503000921 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amy E Galecio |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1326404120 PECOS PAC ID: 1557748886 Enrollment ID: I20220506000800 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sarah Lynn Jones |
---|---|
Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
Provider Identifiers | NPI Number: 1104051523 PECOS PAC ID: 9931251337 Enrollment ID: I20220506001515 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Yair Rubin |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1043969272 PECOS PAC ID: 4880071984 Enrollment ID: I20220511000566 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nicole Y Ito |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1134863608 PECOS PAC ID: 5799162897 Enrollment ID: I20220511000570 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Megan Nicole Weems Wubben |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1447741129 PECOS PAC ID: 4284981366 Enrollment ID: I20220512000608 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | William J Mohr |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1407822463 PECOS PAC ID: 1951590421 Enrollment ID: I20220517000702 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lauren L Bodilly |
---|---|
Provider Type | Practitioner - Critical Care (intensivists) |
Provider Identifiers | NPI Number: 1508251745 PECOS PAC ID: 2860879418 Enrollment ID: I20220519002301 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mary Zaye Elliott |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1164174058 PECOS PAC ID: 8729465208 Enrollment ID: I20220523002023 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nicole Ann Payne |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1194469486 PECOS PAC ID: 3072990555 Enrollment ID: I20220523002109 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jaime P. Murphy |
---|---|
Provider Type | Practitioner - Critical Care (intensivists) |
Provider Identifiers | NPI Number: 1659340016 PECOS PAC ID: 1658384698 Enrollment ID: I20220527000359 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Tiffany Bee |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1811953607 PECOS PAC ID: 8628102001 Enrollment ID: I20220527001784 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Laura T Brown |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1770744823 PECOS PAC ID: 4183889504 Enrollment ID: I20220607000877 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jenna Marie Gedminas |
---|---|
Provider Type | Practitioner - Hematology/oncology |
Provider Identifiers | NPI Number: 1639516768 PECOS PAC ID: 5294031597 Enrollment ID: I20220609002429 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Elyana R Wohl |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1194454892 PECOS PAC ID: 3577941160 Enrollment ID: I20220610000801 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alexander Dale Claussen |
---|---|
Provider Type | Practitioner - Otolaryngology |
Provider Identifiers | NPI Number: 1659719235 PECOS PAC ID: 8921486499 Enrollment ID: I20220613001122 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alison Uhl |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1326368952 PECOS PAC ID: 1557667722 Enrollment ID: I20220615001622 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Karen Blanton Brust |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1558568717 PECOS PAC ID: 5799876504 Enrollment ID: I20220616001027 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Osorio Lopes Abath Neto |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1134668635 PECOS PAC ID: 9931589124 Enrollment ID: I20220706000943 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kathryn Lynne Eschbacher |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1669867693 PECOS PAC ID: 3577810126 Enrollment ID: I20220706003818 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joanna Bomkamp Gebhardt |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1730467549 PECOS PAC ID: 5799931127 Enrollment ID: I20220707000627 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jarrod K Bang |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1275064701 PECOS PAC ID: 8426328071 Enrollment ID: I20220707002069 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ashley Paige Patrick |
---|---|
Provider Type | Practitioner - Dermatology |
Provider Identifiers | NPI Number: 1245737097 PECOS PAC ID: 9234487208 Enrollment ID: I20220707002873 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Matthew T Fleege |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1710428123 PECOS PAC ID: 7719219492 Enrollment ID: I20220707003025 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Emily K Ford |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1598384786 PECOS PAC ID: 6901286830 Enrollment ID: I20220708001853 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Matthew R. Hoffman |
---|---|
Provider Type | Practitioner - Otolaryngology |
Provider Identifiers | NPI Number: 1992106355 PECOS PAC ID: 5294048708 Enrollment ID: I20220711000967 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Andrew P Groves |
---|---|
Provider Type | Practitioner - Hematology/oncology |
Provider Identifiers | NPI Number: 1891158275 PECOS PAC ID: 1052791894 Enrollment ID: I20220711001135 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kathleen M Robinson |
---|---|
Provider Type | Practitioner - Endocrinology |
Provider Identifiers | NPI Number: 1215385596 PECOS PAC ID: 6608169305 Enrollment ID: I20220711001919 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Linda J Cooper-brown |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1770690646 PECOS PAC ID: 9234519976 Enrollment ID: I20220712001097 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Quentin E Adams |
---|---|
Provider Type | Practitioner - Radiation Oncology |
Provider Identifiers | NPI Number: 1679923270 PECOS PAC ID: 9335431220 Enrollment ID: I20220712001350 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kyle A Merrill |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1437506342 PECOS PAC ID: 4880984517 Enrollment ID: I20220713000396 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Peter Kim |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1154989291 PECOS PAC ID: 2264761014 Enrollment ID: I20220713000509 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Molly L Dahm |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1083343453 PECOS PAC ID: 4688055346 Enrollment ID: I20220713001389 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rupak K Bhuyan |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1609363829 PECOS PAC ID: 8729319041 Enrollment ID: I20220713002927 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Anthony M Swatek |
---|---|
Provider Type | Practitioner - Thoracic Surgery |
Provider Identifiers | NPI Number: 1457641789 PECOS PAC ID: 1355575705 Enrollment ID: I20220714000489 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Arsenije Kojadinovic |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1871155994 PECOS PAC ID: 5193106748 Enrollment ID: I20220714000549 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nathaniel A Justice |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1366646846 PECOS PAC ID: 1153565528 Enrollment ID: I20220714003758 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jessica Jasper |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1760001358 PECOS PAC ID: 8921489469 Enrollment ID: I20220715000252 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Emma Cook |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1144858655 PECOS PAC ID: 0345621702 Enrollment ID: I20220715001153 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Erin Grace Steinbach |
---|---|
Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
Provider Identifiers | NPI Number: 1780316810 PECOS PAC ID: 9335520717 Enrollment ID: I20220715002170 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Allison Barrale |
---|---|
Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
Provider Identifiers | NPI Number: 1487295291 PECOS PAC ID: 5092147009 Enrollment ID: I20220715002204 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kaitlyn Erin Schrader |
---|---|
Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
Provider Identifiers | NPI Number: 1750013876 PECOS PAC ID: 7012398407 Enrollment ID: I20220715002407 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Paul F Mester |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1215464847 PECOS PAC ID: 6800168535 Enrollment ID: I20220715002483 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Taylor Cox |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1619590213 PECOS PAC ID: 4082038567 Enrollment ID: I20220718003528 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Marielle Alyssa Brenner |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1508398124 PECOS PAC ID: 6103150859 Enrollment ID: I20220719002401 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Chetana Daniels |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1649948605 PECOS PAC ID: 6800277971 Enrollment ID: I20220720002775 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Takaaki Kobayashi |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1689060295 PECOS PAC ID: 1456608934 Enrollment ID: I20220720003063 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Matthew D Gosse |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1245722891 PECOS PAC ID: 5395094130 Enrollment ID: I20220725000313 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Samuel D Zetumer |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1588225650 PECOS PAC ID: 0244565901 Enrollment ID: I20220726001743 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alex M Hugi |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1023637857 PECOS PAC ID: 6204218092 Enrollment ID: I20220726001969 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Daniel Hinds |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1174970453 PECOS PAC ID: 7618266313 Enrollment ID: I20220726002875 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jeffrey David Karduck |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1124480454 PECOS PAC ID: 9032499769 Enrollment ID: I20220727000442 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amy E Strong |
---|---|
Provider Type | Practitioner - Nephrology |
Provider Identifiers | NPI Number: 1861840761 PECOS PAC ID: 3678867207 Enrollment ID: I20220727004106 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sarah Adalie Auerbach |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1003279423 PECOS PAC ID: 0143503128 Enrollment ID: I20220728001516 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Hannah P Lassise |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1346819216 PECOS PAC ID: 2365824943 Enrollment ID: I20220728001934 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brandon Michael Wubben |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1205327111 PECOS PAC ID: 3971912452 Enrollment ID: I20220804003724 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Caitlin R Lindaman |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1477110245 PECOS PAC ID: 5597091512 Enrollment ID: I20220805001724 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Trudy Ann Pierick |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1528055639 PECOS PAC ID: 8325420417 Enrollment ID: I20220805002270 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lauren Marie Burchette |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1972254407 PECOS PAC ID: 7911389010 Enrollment ID: I20220805002871 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Yaseen B Adam |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1932278587 PECOS PAC ID: 3577562164 Enrollment ID: I20220808002524 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rostislav Dimitrov Ranguelov |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1699744193 PECOS PAC ID: 3173557832 Enrollment ID: I20220810002220 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joshua Digennaro Trebach |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1306260799 PECOS PAC ID: 8224320007 Enrollment ID: I20220810003470 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Su Jin Kim Hsieh |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1205560745 PECOS PAC ID: 6901289719 Enrollment ID: I20220811001265 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rintaro Hashimoto |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1780318501 PECOS PAC ID: 8527441351 Enrollment ID: I20220811002213 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Farzad Jamshidi |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1235617051 PECOS PAC ID: 4789929175 Enrollment ID: I20220811002294 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sara Claire Horton |
---|---|
Provider Type | Practitioner - Hematology/oncology |
Provider Identifiers | NPI Number: 1902268592 PECOS PAC ID: 9032404660 Enrollment ID: I20220812002755 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nicole N Kamps |
---|---|
Provider Type | Practitioner - Critical Care (intensivists) |
Provider Identifiers | NPI Number: 1467848184 PECOS PAC ID: 9133414204 Enrollment ID: I20220815000703 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael P Demoss |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1114546371 PECOS PAC ID: 3173906591 Enrollment ID: I20220818000662 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Allison W Lorenzen |
---|---|
Provider Type | Practitioner - Plastic And Reconstructive Surgery |
Provider Identifiers | NPI Number: 1346500485 PECOS PAC ID: 6608018155 Enrollment ID: I20220822001286 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Vishnu Raj Kumar Mani |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1174964951 PECOS PAC ID: 3476956095 Enrollment ID: I20220822002798 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jennifer Leigh Yuska |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1790455061 PECOS PAC ID: 8527441617 Enrollment ID: I20220823002303 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ratdanai Yodsuwan |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1457905564 PECOS PAC ID: 0143603241 Enrollment ID: I20220823002426 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Harrison John Gerdes |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1518462209 PECOS PAC ID: 9335496256 Enrollment ID: I20220823002493 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Eileen F O'connor |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1063919017 PECOS PAC ID: 0345598546 Enrollment ID: I20220825000567 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Taryn A Wisor |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1881202745 PECOS PAC ID: 7810371879 Enrollment ID: I20220825001878 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mariellen E Krischel |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1093055782 PECOS PAC ID: 8921247883 Enrollment ID: I20220826002166 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ahisan Ansari |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1124680566 PECOS PAC ID: 4082942347 Enrollment ID: I20220829002417 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Andrew M Schwartz |
---|---|
Provider Type | Practitioner - Orthopedic Surgery |
Provider Identifiers | NPI Number: 1114380524 PECOS PAC ID: 8022301670 Enrollment ID: I20220829003475 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Julie A Gabrielson |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1407452261 PECOS PAC ID: 1658755129 Enrollment ID: I20220901000202 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Elizabeth R Hinders |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1043938814 PECOS PAC ID: 1153705587 Enrollment ID: I20220901002980 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Daniel Thomas Griffin |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1386006310 PECOS PAC ID: 9032485701 Enrollment ID: I20220903000342 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Renee I Fields-hu |
---|---|
Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
Provider Identifiers | NPI Number: 1841918224 PECOS PAC ID: 0143604397 Enrollment ID: I20220907002024 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bilal Saeed |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1548824865 PECOS PAC ID: 8527442631 Enrollment ID: I20220908000712 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brett Allan Rosauer |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1447740287 PECOS PAC ID: 5991059008 Enrollment ID: I20220909000789 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Emira Deumic Shultz |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1114454543 PECOS PAC ID: 5395014351 Enrollment ID: I20220914002109 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Laura Lorraine Steers |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1114412947 PECOS PAC ID: 7810243722 Enrollment ID: I20220916001795 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kirk Andrew Sidey |
---|---|
Provider Type | Practitioner - Dermatology |
Provider Identifiers | NPI Number: 1013446780 PECOS PAC ID: 8426327552 Enrollment ID: I20220916001908 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jerry Alan Horak |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1174295729 PECOS PAC ID: 6901281641 Enrollment ID: I20220916002149 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kumi Yuki |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1255869269 PECOS PAC ID: 8022388651 Enrollment ID: I20220917000331 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Carolina Quintana Grijalba |
---|---|
Provider Type | Practitioner - Critical Care (intensivists) |
Provider Identifiers | NPI Number: 1235549189 PECOS PAC ID: 7214257021 Enrollment ID: I20220919002617 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Hassan Aziz |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1356781363 PECOS PAC ID: 6901161082 Enrollment ID: I20220922000782 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Corbin Anne Weaver |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1841797636 PECOS PAC ID: 5092190298 Enrollment ID: I20220923000168 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Maja A Campbell |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1790410157 PECOS PAC ID: 5395120547 Enrollment ID: I20220923001899 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Christopher Michael Kepros |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1154511434 PECOS PAC ID: 4082936612 Enrollment ID: I20220926001035 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Divya Ashat |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1831504380 PECOS PAC ID: 8628295904 Enrollment ID: I20220927001006 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Anna Moldysz |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1962922500 PECOS PAC ID: 8820368442 Enrollment ID: I20220927001921 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Adeeb Oweidat |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1295347706 PECOS PAC ID: 5991181968 Enrollment ID: I20220928000761 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Evelyn J Ross-shapiro |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1053979757 PECOS PAC ID: 9739414400 Enrollment ID: I20220928000962 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Hira Ghazal Shaikh |
---|---|
Provider Type | Practitioner - Hematology |
Provider Identifiers | NPI Number: 1336591759 PECOS PAC ID: 3971891359 Enrollment ID: I20220929000752 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Leeanne P Flygt |
---|---|
Provider Type | Practitioner - Critical Care (intensivists) |
Provider Identifiers | NPI Number: 1871949552 PECOS PAC ID: 5698066652 Enrollment ID: I20220929003226 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Peter James Szachowicz |
---|---|
Provider Type | Practitioner - Critical Care (intensivists) |
Provider Identifiers | NPI Number: 1417310053 PECOS PAC ID: 7719278134 Enrollment ID: I20220930001689 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michelle M Aderhold |
---|---|
Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
Provider Identifiers | NPI Number: 1932831849 PECOS PAC ID: 0648656447 Enrollment ID: I20221003000145 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Waqas J Siddiqui |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1386061729 PECOS PAC ID: 3678977717 Enrollment ID: I20221004000599 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alexandra Dvorak |
---|---|
Provider Type | Practitioner - Qualified Speech Language Pathologist |
Provider Identifiers | NPI Number: 1336571363 PECOS PAC ID: 6709262314 Enrollment ID: I20221005002962 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Katharine Celia Ruestow |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1053076976 PECOS PAC ID: 1052797420 Enrollment ID: I20221008000297 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Maggie Diane Seblani |
---|---|
Provider Type | Practitioner - Hematology/oncology |
Provider Identifiers | NPI Number: 1699195818 PECOS PAC ID: 5991181216 Enrollment ID: I20221010002000 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Moon Ley Tung |
---|---|
Provider Type | Practitioner - Medical Genetics And Genomics |
Provider Identifiers | NPI Number: 1023625142 PECOS PAC ID: 3173933884 Enrollment ID: I20221010002185 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bharatendu Chandra |
---|---|
Provider Type | Practitioner - Medical Genetics And Genomics |
Provider Identifiers | NPI Number: 1114534237 PECOS PAC ID: 3870903594 Enrollment ID: I20221010002999 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kimberly Chantelle Diah |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1619521465 PECOS PAC ID: 4385076744 Enrollment ID: I20221011000319 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Miriam Clarke Gardner |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1124040340 PECOS PAC ID: 9032585294 Enrollment ID: I20221013001783 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michelle D Miller |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1851313076 PECOS PAC ID: 9537535703 Enrollment ID: I20221013002491 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Chelsea M Owen |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1376162578 PECOS PAC ID: 6608242631 Enrollment ID: I20221017002451 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Balarama Krishna Surapaneni |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1003311648 PECOS PAC ID: 0941676985 Enrollment ID: I20221017002580 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Katie Elizabeth Barreras |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1194746503 PECOS PAC ID: 3476877218 Enrollment ID: I20221019003221 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Helen K Neumann |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1114543683 PECOS PAC ID: 2769858406 Enrollment ID: I20221020000777 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Pierre Yves Palo |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1548825599 PECOS PAC ID: 7315270733 Enrollment ID: I20221020003015 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mahil Rao |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1700206372 PECOS PAC ID: 5890118921 Enrollment ID: I20221021001785 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Melinda Sue White |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1033855804 PECOS PAC ID: 6800262445 Enrollment ID: I20221021001839 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Justine Marie Wood |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1649927864 PECOS PAC ID: 1456727056 Enrollment ID: I20221024001379 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Annika Storey |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1174751689 PECOS PAC ID: 4082851084 Enrollment ID: I20221027001539 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ingrid Goldenstein |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1871519249 PECOS PAC ID: 2163899535 Enrollment ID: I20221028000692 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Stacey A Sokol |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1649722422 PECOS PAC ID: 6709253024 Enrollment ID: I20221029000319 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Stacy Ann Granner |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1487670840 PECOS PAC ID: 7012384209 Enrollment ID: I20221101000370 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Anna Lee Weikamp |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1063134872 PECOS PAC ID: 7517334733 Enrollment ID: I20221101001557 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rachel Alyse Posey |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1447748975 PECOS PAC ID: 4385047612 Enrollment ID: I20221101003243 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nathaniel Wise |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1871083857 PECOS PAC ID: 5597168047 Enrollment ID: I20221107000970 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alison E Seline |
---|---|
Provider Type | Practitioner - Dermatology |
Provider Identifiers | NPI Number: 1700248291 PECOS PAC ID: 7214260157 Enrollment ID: I20221108001991 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Shelly Sue Eisbach |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1396116828 PECOS PAC ID: 0749582971 Enrollment ID: I20221108002082 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Josephine Marie Thurmond |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1700501343 PECOS PAC ID: 8022485820 Enrollment ID: I20221108002200 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Caitlin E Sapp |
---|---|
Provider Type | Practitioner - Qualified Audiologist |
Provider Identifiers | NPI Number: 1760917652 PECOS PAC ID: 8224300470 Enrollment ID: I20221114001279 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Melissa S Schnackenberg |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1801503578 PECOS PAC ID: 7911375076 Enrollment ID: I20221121001714 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amanda Christine Brant |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1881199578 PECOS PAC ID: 1850649583 Enrollment ID: I20221121001907 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Juhi Raju Uttamani |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1033845359 PECOS PAC ID: 9335517333 Enrollment ID: I20221123000707 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Loredana Cornelia Militaru |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1194742841 PECOS PAC ID: 9335113083 Enrollment ID: I20221201002172 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Max J Snow |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1902366743 PECOS PAC ID: 2769850346 Enrollment ID: I20221202000230 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Steven Andrew Zehring |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1265894000 PECOS PAC ID: 9537459177 Enrollment ID: I20221205002368 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Christopher D Otteni |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1073969713 PECOS PAC ID: 2961795612 Enrollment ID: I20221205002873 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Emma J Stammeyer |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1205553690 PECOS PAC ID: 4981073459 Enrollment ID: I20221206002012 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Zagum A Bhatti |
---|---|
Provider Type | Practitioner - Interventional Radiology |
Provider Identifiers | NPI Number: 1053577890 PECOS PAC ID: 8527370998 Enrollment ID: I20221207001336 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lesley Anna Green |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1225656556 PECOS PAC ID: 0840616363 Enrollment ID: I20221207002742 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jordan S Miller |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1689175200 PECOS PAC ID: 9739436981 Enrollment ID: I20221212002796 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Hope Elise Tribbey |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1740907187 PECOS PAC ID: 7012386097 Enrollment ID: I20221214000605 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rupinderjit Singh Dhillon |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1619167483 PECOS PAC ID: 6002940822 Enrollment ID: I20221215001671 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bryan D Struck |
---|---|
Provider Type | Practitioner - Hospice/palliative Care |
Provider Identifiers | NPI Number: 1831167667 PECOS PAC ID: 3779597984 Enrollment ID: I20221221002803 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | John N Jensen |
---|---|
Provider Type | Practitioner - Plastic And Reconstructive Surgery |
Provider Identifiers | NPI Number: 1003867854 PECOS PAC ID: 6608904768 Enrollment ID: I20221224000078 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alyssa Marie Wood |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1942917836 PECOS PAC ID: 0446620629 Enrollment ID: I20230104001527 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Meredith Ann Parizek |
---|---|
Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
Provider Identifiers | NPI Number: 1548971435 PECOS PAC ID: 0345610465 Enrollment ID: I20230106001331 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Heather A Highly |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1295443067 PECOS PAC ID: 2466823281 Enrollment ID: I20230113001042 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ciara M Demings |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1255048229 PECOS PAC ID: 4385015692 Enrollment ID: I20230125000494 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Samuel J Irving |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1790309847 PECOS PAC ID: 2062835846 Enrollment ID: I20230125002383 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Christine N Ries |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1972214567 PECOS PAC ID: 7113398363 Enrollment ID: I20230125003206 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nathan Porter Schulz |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1922419811 PECOS PAC ID: 4385944321 Enrollment ID: I20230127001939 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Melvin T Donaldson |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1710509781 PECOS PAC ID: 4486077146 Enrollment ID: I20230130000100 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michaela A Meyer |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1578217857 PECOS PAC ID: 6507237468 Enrollment ID: I20230201001024 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mallory Janene Mckay Heath |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1316655939 PECOS PAC ID: 2769854454 Enrollment ID: I20230206002214 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Paari Dominic |
---|---|
Provider Type | Practitioner - Cardiac Electrophysiology |
Provider Identifiers | NPI Number: 1134328958 PECOS PAC ID: 6406076405 Enrollment ID: I20230207002483 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Stephanie Y Clark |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1255049409 PECOS PAC ID: 1557733110 Enrollment ID: I20230207003031 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Shady Neematallah Al-hayek |
---|---|
Provider Type | Practitioner - Plastic And Reconstructive Surgery |
Provider Identifiers | NPI Number: 1376736686 PECOS PAC ID: 6103298732 Enrollment ID: I20230208001955 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Chandra Miller |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1669184511 PECOS PAC ID: 3173995701 Enrollment ID: I20230208002058 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jennifer Michele Mcgee |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1548977655 PECOS PAC ID: 6103298740 Enrollment ID: I20230208002431 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Robert Wyatt Love |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1396992137 PECOS PAC ID: 8123285491 Enrollment ID: I20230213000038 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jennifer Nihei |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1740775790 PECOS PAC ID: 2567718885 Enrollment ID: I20230223000656 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Catherine E Vander Zee |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1093412694 PECOS PAC ID: 8123491040 Enrollment ID: I20230223002459 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Grant C. Bullock |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1467680223 PECOS PAC ID: 4981757853 Enrollment ID: I20230306000533 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jacquelyn M Ronnfeldt |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1912618976 PECOS PAC ID: 5294109393 Enrollment ID: I20230313000464 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Catherine A Dostal |
---|---|
Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
Provider Identifiers | NPI Number: 1427756394 PECOS PAC ID: 2567836448 Enrollment ID: I20230315002336 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kimberly Ann Tritz |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1225269574 PECOS PAC ID: 2163576935 Enrollment ID: I20230315002885 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sujana Madathil |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1508219841 PECOS PAC ID: 5193121705 Enrollment ID: I20230321002414 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Abieyuwa Eweka |
---|---|
Provider Type | Practitioner - Interventional Radiology |
Provider Identifiers | NPI Number: 1144647272 PECOS PAC ID: 2365864865 Enrollment ID: I20230404000910 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Juan Pablo Castro Cuellar |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1912600263 PECOS PAC ID: 1951776806 Enrollment ID: I20230407000731 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Megan A Mobley |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1841994704 PECOS PAC ID: 7214302819 Enrollment ID: I20230413000753 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Serhan Karvar |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1992209167 PECOS PAC ID: 9436406063 Enrollment ID: I20230413000767 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Maryn Kanter |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1326494097 PECOS PAC ID: 6901197201 Enrollment ID: I20230414001480 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rahul N Sawlani |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1790096592 PECOS PAC ID: 1456645431 Enrollment ID: I20230414002134 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Andrew Chase Williams |
---|---|
Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
Provider Identifiers | NPI Number: 1790488369 PECOS PAC ID: 6406211796 Enrollment ID: I20230419002532 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Erika R Rodriguez |
---|---|
Provider Type | Practitioner - Qualified Speech Language Pathologist |
Provider Identifiers | NPI Number: 1467710459 PECOS PAC ID: 7517322894 Enrollment ID: I20230421000273 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bruna Maria Thompson Jacinto |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1922704659 PECOS PAC ID: 9638534654 Enrollment ID: I20230426003013 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Chen S Tan |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1285898494 PECOS PAC ID: 3476621962 Enrollment ID: I20230428002459 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brittney Noel Smith |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1679235717 PECOS PAC ID: 1254796014 Enrollment ID: I20230430000076 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Audrey Lee Wood |
---|---|
Provider Type | Practitioner - Qualified Speech Language Pathologist |
Provider Identifiers | NPI Number: 1619591658 PECOS PAC ID: 3173988706 Enrollment ID: I20230503001474 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ashley J Ash |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1730874785 PECOS PAC ID: 6002271673 Enrollment ID: I20230503003478 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rachel Renae Weigel |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1760181796 PECOS PAC ID: 7517323983 Enrollment ID: I20230510002043 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rehan Zahid |
---|---|
Provider Type | Practitioner - Plastic And Reconstructive Surgery |
Provider Identifiers | NPI Number: 1144831975 PECOS PAC ID: 3476919507 Enrollment ID: I20230516002366 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Richard L Catalan |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1194771097 PECOS PAC ID: 8426047010 Enrollment ID: I20230523001044 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Crystal Lynn Shramek |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1689362410 PECOS PAC ID: 9537526801 Enrollment ID: I20230531002408 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Richard John Russell |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1861471443 PECOS PAC ID: 1052352846 Enrollment ID: I20230531003128 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Pratibha Sharma Kandel |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1770279358 PECOS PAC ID: 0143688739 Enrollment ID: I20230613003498 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Chris R Link |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1710936786 PECOS PAC ID: 6507757440 Enrollment ID: I20230613003550 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Xiaoxi Yang |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1578068375 PECOS PAC ID: 2860748480 Enrollment ID: I20230622002825 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Laura J Hanna-bergen |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1477740074 PECOS PAC ID: 0446558084 Enrollment ID: I20230625000060 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Pedro Hsieh |
---|---|
Provider Type | Practitioner - Hematology |
Provider Identifiers | NPI Number: 1700561826 PECOS PAC ID: 2668830464 Enrollment ID: I20230627001977 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Stephen J Statz |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1710544754 PECOS PAC ID: 9032445788 Enrollment ID: I20230628000784 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bemen Habashi |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1487159877 PECOS PAC ID: 4688079031 Enrollment ID: I20230703000385 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rachael M Hyland |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1831549054 PECOS PAC ID: 6002298007 Enrollment ID: I20230707000535 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alexander A Garza |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1194349522 PECOS PAC ID: 4981028461 Enrollment ID: I20230707001195 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sami Koro |
---|---|
Provider Type | Practitioner - Radiation Oncology |
Provider Identifiers | NPI Number: 1730822925 PECOS PAC ID: 8628455318 Enrollment ID: I20230707001708 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ryan J Lechtenberg |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1306402904 PECOS PAC ID: 2567797251 Enrollment ID: I20230707002380 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ram Reddy Katpally |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1316285372 PECOS PAC ID: 7315235645 Enrollment ID: I20230707002623 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Morton Malcom Machir |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1851951636 PECOS PAC ID: 9234463704 Enrollment ID: I20230707002880 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Erin Lynn Sternhagen |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1497371140 PECOS PAC ID: 0648694125 Enrollment ID: I20230708000515 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kathie Q Zhang |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1225652761 PECOS PAC ID: 4284058769 Enrollment ID: I20230708000536 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Megan R Oberbillig |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1851914485 PECOS PAC ID: 3476976531 Enrollment ID: I20230710000518 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Reed A Johnson |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1497378939 PECOS PAC ID: 3971927450 Enrollment ID: I20230710000662 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Tmothy J Boly |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1427586494 PECOS PAC ID: 9739459934 Enrollment ID: I20230710001306 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kyle M Green |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1013479427 PECOS PAC ID: 0547629438 Enrollment ID: I20230711000714 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rupin Nitin Parikh |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1336643022 PECOS PAC ID: 2860851763 Enrollment ID: I20230711000939 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lindsay Youngmi Chun |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1063972370 PECOS PAC ID: 3971838582 Enrollment ID: I20230711001260 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rahul D Gulati |
---|---|
Provider Type | Practitioner - Otolaryngology |
Provider Identifiers | NPI Number: 1427554047 PECOS PAC ID: 1850638974 Enrollment ID: I20230711001724 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Christian Andrew Mays |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1003470352 PECOS PAC ID: 5092131458 Enrollment ID: I20230711002556 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Adriana C Rodriguez Leon |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1841727211 PECOS PAC ID: 1850660549 Enrollment ID: I20230711002904 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Hanna Rafaela Ferreira Dalla Pria |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1164157731 PECOS PAC ID: 4587023346 Enrollment ID: I20230711003388 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ramandeep Singh |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1003431842 PECOS PAC ID: 5496113649 Enrollment ID: I20230711004040 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kittika Poonsombudlert |
---|---|
Provider Type | Practitioner - Hematology/oncology |
Provider Identifiers | NPI Number: 1386174217 PECOS PAC ID: 2860813904 Enrollment ID: I20230712000387 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Thomas M Panicucci |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1033735295 PECOS PAC ID: 8426469149 Enrollment ID: I20230712000523 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Aamer Imdad |
---|---|
Provider Type | Practitioner - Gastroenterology |
Provider Identifiers | NPI Number: 1922386994 PECOS PAC ID: 0547532483 Enrollment ID: I20230712001793 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nitesh Shekhrajka |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1255858577 PECOS PAC ID: 5395124879 Enrollment ID: I20230712002006 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Breethaa Janani Selvamani |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1083100226 PECOS PAC ID: 2769730894 Enrollment ID: I20230712002396 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alexandra A Flanagan |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1043833486 PECOS PAC ID: 5890117865 Enrollment ID: I20230712004244 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rebecca Anne Reynolds |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1285020446 PECOS PAC ID: 3678875507 Enrollment ID: I20230713001549 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Robert Michael Humble |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1518526284 PECOS PAC ID: 1052771631 Enrollment ID: I20230713003284 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Margaret Ruth Strampe |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1013575711 PECOS PAC ID: 0143555805 Enrollment ID: I20230714000726 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ashlyn R Smith |
---|---|
Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
Provider Identifiers | NPI Number: 1316624810 PECOS PAC ID: 3870953375 Enrollment ID: I20230715000436 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Abby Mae Kerker |
---|---|
Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
Provider Identifiers | NPI Number: 1073299707 PECOS PAC ID: 4385004829 Enrollment ID: I20230717000852 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Malik Ghannam |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1669995528 PECOS PAC ID: 9436423696 Enrollment ID: I20230717001729 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Shahana Prakash |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1548883218 PECOS PAC ID: 0143644625 Enrollment ID: I20230719002492 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alysa D Lerud |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1447819925 PECOS PAC ID: 1951761147 Enrollment ID: I20230719003353 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sriya Subramani |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1336636760 PECOS PAC ID: 4880941962 Enrollment ID: I20230720000517 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael Corbett |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1194074682 PECOS PAC ID: 6901048941 Enrollment ID: I20230720001291 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | John M Rieth |
---|---|
Provider Type | Practitioner - Medical Oncology |
Provider Identifiers | NPI Number: 1528559937 PECOS PAC ID: 3971852419 Enrollment ID: I20230720002296 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Peter D Farjo |
---|---|
Provider Type | Practitioner - Cardiac Electrophysiology |
Provider Identifiers | NPI Number: 1144615469 PECOS PAC ID: 3274835848 Enrollment ID: I20230720002674 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Marina Peskina |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1487113486 PECOS PAC ID: 2365802451 Enrollment ID: I20230720003930 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Laura Lb Schmitt |
---|---|
Provider Type | Practitioner - Qualified Speech Language Pathologist |
Provider Identifiers | NPI Number: 1700282647 PECOS PAC ID: 3476890427 Enrollment ID: I20230721001022 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mahak Saad |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1720577729 PECOS PAC ID: 8224452701 Enrollment ID: I20230725001954 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Aunum P Akhter |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1124548813 PECOS PAC ID: 1557637436 Enrollment ID: I20230725002081 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Benjamin William Hale |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1124464599 PECOS PAC ID: 7214232313 Enrollment ID: I20230726001197 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Miles David Hagner |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1619409331 PECOS PAC ID: 5890066435 Enrollment ID: I20230726003582 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Latha Yalodahalli Shankar Naik |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1487209896 PECOS PAC ID: 3870821374 Enrollment ID: I20230727001923 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sarah Elizabeth Weber |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1316522857 PECOS PAC ID: 3577924265 Enrollment ID: I20230727002111 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kartik Mani |
---|---|
Provider Type | Practitioner - Interventional Cardiology |
Provider Identifiers | NPI Number: 1689869885 PECOS PAC ID: 6901987445 Enrollment ID: I20230727003482 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Taariq Mohammed |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1275094435 PECOS PAC ID: 5496168999 Enrollment ID: I20230727003491 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Christopher E Moreau |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1609371434 PECOS PAC ID: 6507112125 Enrollment ID: I20230728002240 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nicole A Negbenebor |
---|---|
Provider Type | Practitioner - Dermatology |
Provider Identifiers | NPI Number: 1740773597 PECOS PAC ID: 4385071000 Enrollment ID: I20230731000164 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Yasameen Emad Muzahim |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1639666340 PECOS PAC ID: 6406184910 Enrollment ID: I20230731001500 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Taylor C Becker |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1154943900 PECOS PAC ID: 9537583976 Enrollment ID: I20230731003329 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jeffrey C Zavala |
---|---|
Provider Type | Practitioner - Allergy/immunology |
Provider Identifiers | NPI Number: 1023539848 PECOS PAC ID: 8820367535 Enrollment ID: I20230801000747 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Meredith G Parsons |
---|---|
Provider Type | Practitioner - Pathology |
Provider Identifiers | NPI Number: 1497247662 PECOS PAC ID: 7012267826 Enrollment ID: I20230801003275 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Daniel J Kohn |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1053850149 PECOS PAC ID: 1456696434 Enrollment ID: I20230802000949 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Hannah Lane |
---|---|
Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
Provider Identifiers | NPI Number: 1295412534 PECOS PAC ID: 1557722824 Enrollment ID: I20230802003372 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Roula Hourany |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1982389862 PECOS PAC ID: 9032570346 Enrollment ID: I20230803000397 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kenan B Ashouri |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1114417862 PECOS PAC ID: 9436403532 Enrollment ID: I20230803003316 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Krista Marie Grinde |
---|---|
Provider Type | Practitioner - Hematology/oncology |
Provider Identifiers | NPI Number: 1497106298 PECOS PAC ID: 0446585582 Enrollment ID: I20230807001201 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Natalie M Russell |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1689259111 PECOS PAC ID: 9537521588 Enrollment ID: I20230808003685 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Tatsuya Yoshimura |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1255563631 PECOS PAC ID: 7911369970 Enrollment ID: I20230808004142 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Serkan Bektur |
---|---|
Provider Type | Practitioner - Advanced Heart Failure And Transplant Cardiology |
Provider Identifiers | NPI Number: 1902548928 PECOS PAC ID: 0446634018 Enrollment ID: I20230809000805 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Elizabeth M Wikle |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1881223253 PECOS PAC ID: 2961864889 Enrollment ID: I20230809002633 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Abhishek Kantamneni |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1821521501 PECOS PAC ID: 5395092779 Enrollment ID: I20230809002770 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Tanya Aggarwal |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1487278438 PECOS PAC ID: 3072937895 Enrollment ID: I20230810000163 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Andrea Vannucci |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1033137765 PECOS PAC ID: 8628032950 Enrollment ID: I20230811002910 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Zubin Shetty |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1902399470 PECOS PAC ID: 3072868884 Enrollment ID: I20230814001516 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ananya Panda |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1912404385 PECOS PAC ID: 4183972052 Enrollment ID: I20230815002446 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Malinda R Schaefer |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1942656715 PECOS PAC ID: 0749571701 Enrollment ID: I20230818002524 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Diana M Mahbod |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1689931974 PECOS PAC ID: 6901110089 Enrollment ID: I20230821002680 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Julie Christine Gudenkauf |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1043715386 PECOS PAC ID: 4688036700 Enrollment ID: I20230821003630 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Yaqi Zhang |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1164038428 PECOS PAC ID: 0547680712 Enrollment ID: I20230822000942 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amanda K Irish |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1104387505 PECOS PAC ID: 3779813803 Enrollment ID: I20230822001733 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Aman Patel |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1013399286 PECOS PAC ID: 9234437237 Enrollment ID: I20230822004106 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Renata Correa Osorio |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1902583214 PECOS PAC ID: 8022471184 Enrollment ID: I20230823001300 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Rachel K Gage |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1669152997 PECOS PAC ID: 3870956782 Enrollment ID: I20230824004153 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Leonardo Furtado Freitas |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1801679519 PECOS PAC ID: 9830552769 Enrollment ID: I20230825000448 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Lindsey R Ricklefs |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1750062220 PECOS PAC ID: 1456714393 Enrollment ID: I20230825000926 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Crystal Nicole Rodriguez |
---|---|
Provider Type | Practitioner - Vascular Surgery |
Provider Identifiers | NPI Number: 1477047215 PECOS PAC ID: 1951658335 Enrollment ID: I20230825001577 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Georgette Richardson |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1891421004 PECOS PAC ID: 9830552611 Enrollment ID: I20230825003414 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ryan James Mcloughlin |
---|---|
Provider Type | Practitioner - Physical Medicine And Rehabilitation |
Provider Identifiers | NPI Number: 1295295731 PECOS PAC ID: 7214316298 Enrollment ID: I20230828000402 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Catherine Dory Bachur |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1669038840 PECOS PAC ID: 1456686591 Enrollment ID: I20230828001568 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jonathan D Gilmore |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1962964106 PECOS PAC ID: 6103289863 Enrollment ID: I20230828003690 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Uzma Rani |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1851898241 PECOS PAC ID: 6103162953 Enrollment ID: I20230831000224 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jeffrey Scott Marschall |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1336509397 PECOS PAC ID: 1557657988 Enrollment ID: I20230831002470 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Erin Leigh Niles |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1558946962 PECOS PAC ID: 3173986510 Enrollment ID: I20230831003459 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Vincent M Wagner |
---|---|
Provider Type | Practitioner - Gynecological Oncology |
Provider Identifiers | NPI Number: 1578913786 PECOS PAC ID: 8921391384 Enrollment ID: I20230905002230 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alix R Stalmakov |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1558041616 PECOS PAC ID: 5991169187 Enrollment ID: I20230906002087 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jing Huang Kees |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1750727244 PECOS PAC ID: 7315376464 Enrollment ID: I20230906002157 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Zhen L Deng |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1750886958 PECOS PAC ID: 7618219296 Enrollment ID: I20230908000156 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Gustavo Andrade |
---|---|
Provider Type | Practitioner - Interventional Radiology |
Provider Identifiers | NPI Number: 1528843505 PECOS PAC ID: 8729442652 Enrollment ID: I20230912000738 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Laura J Norris |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1871251819 PECOS PAC ID: 9335503267 Enrollment ID: I20230912000876 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | James Wyche Owens |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1326080409 PECOS PAC ID: 4789697731 Enrollment ID: I20230912003447 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amanda Rachel Swanton |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1396276838 PECOS PAC ID: 5991077489 Enrollment ID: I20230913004142 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bethany G Vargas |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1194210518 PECOS PAC ID: 0143684779 Enrollment ID: I20230914001506 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Alexander Neal Kurjatko |
---|---|
Provider Type | Practitioner - General Surgery |
Provider Identifiers | NPI Number: 1811277890 PECOS PAC ID: 2264708866 Enrollment ID: I20230914001872 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Matthew W Smith |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1518495241 PECOS PAC ID: 7618246307 Enrollment ID: I20230914002323 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Amber L Newland |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1659057685 PECOS PAC ID: 9032573639 Enrollment ID: I20230915000350 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Katherine M Briggie |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1255954004 PECOS PAC ID: 1052734886 Enrollment ID: I20230919001301 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bopha Chrea |
---|---|
Provider Type | Practitioner - Orthopedic Surgery |
Provider Identifiers | NPI Number: 1942611025 PECOS PAC ID: 8628394392 Enrollment ID: I20230919001410 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Penny L Heinrich |
---|---|
Provider Type | Practitioner - Medical Oncology |
Provider Identifiers | NPI Number: 1083804546 PECOS PAC ID: 3971668567 Enrollment ID: I20230919003370 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Majd S Haddad |
---|---|
Provider Type | Practitioner - Oral Surgery |
Provider Identifiers | NPI Number: 1437437449 PECOS PAC ID: 9133573215 Enrollment ID: I20230922001698 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kanwal Singh Matharu |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1649709213 PECOS PAC ID: 5799184933 Enrollment ID: I20230923000676 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Robert J Smyth |
---|---|
Provider Type | Practitioner - Pulmonary Disease |
Provider Identifiers | NPI Number: 1497245823 PECOS PAC ID: 7517218951 Enrollment ID: I20230925000119 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Chien-hsiang Chow |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1386806222 PECOS PAC ID: 0840468583 Enrollment ID: I20230925001145 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | William A Dickinson |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1073516043 PECOS PAC ID: 8729103973 Enrollment ID: I20230925002168 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Christopher D Clark |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1043669781 PECOS PAC ID: 8729374061 Enrollment ID: I20230927000281 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nagalakshmi Nagarajan |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1326576406 PECOS PAC ID: 7113296963 Enrollment ID: I20230927001814 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Deyvi J Soto |
---|---|
Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
Provider Identifiers | NPI Number: 1629653050 PECOS PAC ID: 7214381938 Enrollment ID: I20230929000835 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kimberly L Turner |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1689352668 PECOS PAC ID: 2860846482 Enrollment ID: I20230929001307 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joysree Subramanian |
---|---|
Provider Type | Practitioner - Interventional Pain Management |
Provider Identifiers | NPI Number: 1215943949 PECOS PAC ID: 7618930108 Enrollment ID: I20231002003135 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jangbo Lee |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1619658291 PECOS PAC ID: 1850745258 Enrollment ID: I20231003001870 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nuong Thu Nguyen |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1629766720 PECOS PAC ID: 4587018965 Enrollment ID: I20231004001106 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Gatr-alnada Nagib Gheriani |
---|---|
Provider Type | Practitioner - Rheumatology |
Provider Identifiers | NPI Number: 1083029979 PECOS PAC ID: 3678847092 Enrollment ID: I20231004003204 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Annemarie Juliette Gilley |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1740713031 PECOS PAC ID: 8224315841 Enrollment ID: I20231012002022 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brittany N Sprigg |
---|---|
Provider Type | Practitioner - Neurology |
Provider Identifiers | NPI Number: 1679005987 PECOS PAC ID: 1850660465 Enrollment ID: I20231012003189 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mario Zanaty |
---|---|
Provider Type | Practitioner - Neurosurgery |
Provider Identifiers | NPI Number: 1316351075 PECOS PAC ID: 9234358417 Enrollment ID: I20231012003361 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Helen Y Hougen |
---|---|
Provider Type | Practitioner - Urology |
Provider Identifiers | NPI Number: 1629439542 PECOS PAC ID: 6103114624 Enrollment ID: I20231020000835 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kristen Renee Hurst |
---|---|
Provider Type | Practitioner - Otolaryngology |
Provider Identifiers | NPI Number: 1114190915 PECOS PAC ID: 7719126812 Enrollment ID: I20231020001470 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ronald C Gildersleeve |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1437133626 PECOS PAC ID: 2365468600 Enrollment ID: I20231020003042 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Chadron J Vassar |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1962898825 PECOS PAC ID: 3274836424 Enrollment ID: I20231023000531 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Joseph Tholany |
---|---|
Provider Type | Practitioner - Infectious Disease |
Provider Identifiers | NPI Number: 1386178820 PECOS PAC ID: 8426327834 Enrollment ID: I20231024002412 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Madison T Mcilrath |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1982484093 PECOS PAC ID: 3678929882 Enrollment ID: I20231024003655 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Melinda A King |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1649287681 PECOS PAC ID: 3870586381 Enrollment ID: I20231027001108 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Christiana Brenner |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1427284736 PECOS PAC ID: 4082060009 Enrollment ID: I20231027001455 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jeffrey R Daniels |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1336778273 PECOS PAC ID: 2961824792 Enrollment ID: I20231030002227 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Erica Testani |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1326531369 PECOS PAC ID: 4385992825 Enrollment ID: I20231031000303 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Stephanie A Acosta |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1609261718 PECOS PAC ID: 0941657951 Enrollment ID: I20231114000317 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Soorih Shaikh |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1003334574 PECOS PAC ID: 5799043113 Enrollment ID: I20231114001579 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Emma Victoria James |
---|---|
Provider Type | Practitioner - Obstetrics/gynecology |
Provider Identifiers | NPI Number: 1063070597 PECOS PAC ID: 0345574943 Enrollment ID: I20231114001723 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Erin E Briggie |
---|---|
Provider Type | Practitioner - Endocrinology |
Provider Identifiers | NPI Number: 1508357203 PECOS PAC ID: 2961751490 Enrollment ID: I20231116000364 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jadyn Miller |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1790452183 PECOS PAC ID: 0244628675 Enrollment ID: I20231116001374 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Annette Elise Contrady |
---|---|
Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
Provider Identifiers | NPI Number: 1083188239 PECOS PAC ID: 3072961358 Enrollment ID: I20231127002903 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ryan C Price |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1447031752 PECOS PAC ID: 9234587536 Enrollment ID: I20231128000397 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bobbi J Jones |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1003698093 PECOS PAC ID: 3971951203 Enrollment ID: I20231128001305 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Carolina Augusta Modena Heming |
---|---|
Provider Type | Practitioner - Diagnostic Radiology |
Provider Identifiers | NPI Number: 1437925021 PECOS PAC ID: 3678921491 Enrollment ID: I20231204003015 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mark Aaron Collie |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1184185530 PECOS PAC ID: 6901135011 Enrollment ID: I20231206002159 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nancy Petrick Almasi |
---|---|
Provider Type | Practitioner - Qualified Speech Language Pathologist |
Provider Identifiers | NPI Number: 1114791944 PECOS PAC ID: 3476902065 Enrollment ID: I20231207002768 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Daniel A Flappan |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1588123657 PECOS PAC ID: 8820323678 Enrollment ID: I20231211001450 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Katie L Hepfer |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1871029322 PECOS PAC ID: 9638420433 Enrollment ID: I20231213001848 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Karla K Hemesath |
---|---|
Provider Type | Practitioner - Marriage And Family Therapist |
Provider Identifiers | NPI Number: 1619217304 PECOS PAC ID: 8729438361 Enrollment ID: I20231222002102 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jacob Bird Priest |
---|---|
Provider Type | Practitioner - Marriage And Family Therapist |
Provider Identifiers | NPI Number: 1447532015 PECOS PAC ID: 6406206903 Enrollment ID: I20231226000972 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Naomi R Polley |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1053895953 PECOS PAC ID: 0941545933 Enrollment ID: I20231228000990 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Michael E Berrebi |
---|---|
Provider Type | Practitioner - Mental Health Counselor |
Provider Identifiers | NPI Number: 1942714472 PECOS PAC ID: 7012368905 Enrollment ID: I20240104002452 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Matthew R Schettle |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1639736309 PECOS PAC ID: 0042547739 Enrollment ID: I20240111003919 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ryan John Diel |
---|---|
Provider Type | Practitioner - Ophthalmology |
Provider Identifiers | NPI Number: 1972000164 PECOS PAC ID: 9638428170 Enrollment ID: I20240113000350 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Claire M Schluensen |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1649043522 PECOS PAC ID: 0345692356 Enrollment ID: I20240116000664 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Adrienne Owens Jensen |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1184389934 PECOS PAC ID: 8022488519 Enrollment ID: I20240116001980 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Debra Sue Brockington |
---|---|
Provider Type | Practitioner - Mental Health Counselor |
Provider Identifiers | NPI Number: 1790263176 PECOS PAC ID: 9830541663 Enrollment ID: I20240117003619 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brianna K Snider |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1760140255 PECOS PAC ID: 6204289499 Enrollment ID: I20240124000901 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Anne Grady Healy |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1639566128 PECOS PAC ID: 2769798826 Enrollment ID: I20240205000414 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jamie Leann Reiter |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1841936077 PECOS PAC ID: 9133562887 Enrollment ID: I20240209000159 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jonne L Wilmore |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1558783480 PECOS PAC ID: 6507089588 Enrollment ID: I20240214002101 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Ian James Gordon |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1659143998 PECOS PAC ID: 9335583640 Enrollment ID: I20240214003233 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Laura J Hanna-bergen |
---|---|
Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
Provider Identifiers | NPI Number: 1477740074 PECOS PAC ID: 0446558084 Enrollment ID: I20240215000561 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Melinda Sue Malchow |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1275301772 PECOS PAC ID: 6901240126 Enrollment ID: I20240215002938 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Elizabeth M Whitaker |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1538841721 PECOS PAC ID: 4880038710 Enrollment ID: I20240220001192 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nicholas Joseph Wissing |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1831872191 PECOS PAC ID: 4385088848 Enrollment ID: I20240223000337 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Sarah S Shafer |
---|---|
Provider Type | Practitioner - Emergency Medicine |
Provider Identifiers | NPI Number: 1639438385 PECOS PAC ID: 7719292762 Enrollment ID: I20240223000734 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kathryn Mary Skopec |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1497771851 PECOS PAC ID: 9335584614 Enrollment ID: I20240226003749 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Mahmoud E Mohamed Elfadil |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1669907242 PECOS PAC ID: 3678841467 Enrollment ID: I20240227002578 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Bommy Hong Mershon |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1538315254 PECOS PAC ID: 9537319595 Enrollment ID: I20240301000532 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Brenda Anne Reddinger |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1205618030 PECOS PAC ID: 6608211503 Enrollment ID: I20240301001779 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Igor V Bulatov |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1912091646 PECOS PAC ID: 9436376209 Enrollment ID: I20240304002137 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Benjamin T Stevens |
---|---|
Provider Type | Practitioner - Hospitalist |
Provider Identifiers | NPI Number: 1871599787 PECOS PAC ID: 3072959238 Enrollment ID: I20240311000104 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jeffrey Wilson |
---|---|
Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
Provider Identifiers | NPI Number: 1003287079 PECOS PAC ID: 4981999893 Enrollment ID: I20240312000363 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Nathan R Brakke |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1972716470 PECOS PAC ID: 5395882765 Enrollment ID: I20240313000622 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Kathryn R Hale |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1174584684 PECOS PAC ID: 0345247037 Enrollment ID: I20240313001584 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Provider Name | Jill Frances Arthur |
---|---|
Provider Type | Practitioner - Anesthesiology |
Provider Identifiers | NPI Number: 1033224308 PECOS PAC ID: 4385660752 Enrollment ID: I20240313003523 |
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
News Archive
Intermedix Corporation, a leading provider of revenue cycle management and software solutions to the emergency healthcare industry, today announced the completion of its previously announced acquisition by Thomas H. Lee Partners, L.P. from Parthenon Capital Partners and its minority shareholders including Glenview Capital Management.
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
When emergency medical technicians (EMTs) wirelessly transmit eletrocardiograms (ECG) directly to a cardiologist's hand-held device, heart attack patients can potentially receive direct clot removal in half the usual time, according to cardiologists at Duke University Medical Center and NorthEast Medical Center, Concord, N.C.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 4 days ago
Ui Quickcare - East Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1632 Sycamore St, Iowa City, IA 52240 Phone: 319-384-8822 Fax: 319-354-1002 | |
Ui Quickcare Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 201 S Clinton St, St 168, Iowa City, IA 52240 Phone: 319-384-8877 Fax: 319-384-0603 | |
Mre Family Care Clinic Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 404 E Bloomington St, Iowa City, IA 52245 Phone: 319-351-1483 Fax: 319-351-1027 | |
Larew Internal Medicine Plc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2557 N Dodge St, Iowa City, IA 52245 Phone: 319-338-1535 Fax: 319-338-5768 | |
Uiecare Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2346 Mormon Trek Blvd, Iowa City, IA 52246 Phone: 319-337-7642 Fax: 319-339-1449 | |
Restore Family Chiropractic Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 521 Westbury Dr, Suite 1, Iowa City, IA 52245 Phone: 319-338-7002 | |
Student Health & Wellness Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 4189 Wl University Of Iowa, Iowa City, IA 52242 Phone: 319-335-8376 Fax: 319-335-7247 |